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ABSTRACT
iii
Soluble crosslinked hydroxypropyl(methacrylamide) copolymers
have been studied in the rat, both in vitro and in vivo, in 
order to assess their suitability as drug carriers in a 
targetable drug delivery system.
The lO radiolabelled copolymers used were of Mw 31,000 ->400,000, 
and their crosslinks contained oligopeptides potentially 
degradable by lysosomal enzymes.
In vitro studies included the uptake and intracellular 
degradation of copolymers of different molecular sizes by the 
rat visceral yolk sac and the everted rat jejunal sac. The 
rate of uptake of copolymer by the yolk sac decreased with 
increasing molecular size, but molecular size had no effect on 
the extent of intracellular degradation of the copolymer. The 
use of metabolic and lysosomal enzyme inhibitors demonstrated 
that uptake of copolymers was by pinocytosis and that lysosomal 
thiol-proteinases were at least partially responsible for the 
degradation observed.
Copolymers were pinocytosed and partially degraded by the rat 
intestine cultured in vitro and were also translocated to a 
small extent across the tissue. Uptake and translocation were 
both inhibited at 15°C. Accumulation of copolymer by 
intestinal tissue increased with increasing copolymer size.
Following intravenous administration to rats, larger copolymer 
fractions were retained in the circulation and did not readily 
accumulate in any tissue. Copolymer crosslinks were stable in 
plasma.
The incorporation of a galactosamine side-chain into the 
copolymer resulted in rapid clearance of copolymer from the
iii contd.
bloodstream and accumulation by the liver. Targeting of this 
copolymer to the liver was also achieved, at lower rates, 
following intraperitoneal and subcutaneous, but not following 
oral administration.
Both unmodified copolymer and copolymer containing galactosamine 
were virtually cleared from the body within 32 days.
Rat liver lysosomal enzymes were isolated and incubated with 
the different copolymers. The rate of crosslink cleavage was 
dependent on the length and/or structure of the oligopeptide
sequence.
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l.X DRUG ADMINISTRATION - THE NEED FOR IMPROVEMENT
Most low molecular weight therapeutic agents diffuse readily 
into all cell types, and are excreted rapidly from the body. 
Consequently, administration of such agents, whether orally or 
parenterally involves frequent and repeated doses in order to 
maintain plasma drug levels within the desired therapeutic 
range. A typical pattern of plasma levels as a function of 
time, following a single oral dose is shown in fig 1.1a, and is 
characterized by an initial increase in concentration, which 
is dependent upon the rate at which the drug becomes available 
to the system, and a subsequent decrease in concentration 
following cellular uptake of the drug, excretion, or other 
transport mechanisms. Fig 1.1b shows the typical blood profile 
observed following intravenous administration of a drug, where 
the whole dose is introduced directly into the bloodstream and 
subsequently distributed as before. Difficulties in 
administration can occur when there is a minimum effective 
level of drug, or a maximum safe level, or both, and careful 
consideration must be given to the regular timing and quantity 
of drug administered in order to maintain plasma levels within 
the desired therapeutic range. Patient compliance is often 
poor, and this can lead to ineffective drug therapy or increased 
risk of toxic side-effects.
Optimization of drug delivery to maximise the therapeutic 
effect and minimise side-effects of a given drug could, in 
theory, be achieved by the control of blood levels, cellular 
uptake, metabolism and distribution of the drug within the 
body. Such control would allow delivery of the drug to the 
target tissue in the correct amount at an optimal rate to
achieve the desired response.
R E L A T I O N S H I P  B E T W E E N  D R U G  C O N C E N T R A T I O N  I N  P L A S M A  
A N D  T I M E  F O L L O W I N G  a) O R A L  A D M I N I S T R A T I O N ,  A N D
b) I N T R A V E N O U S  A D M I N I S T R A T I O N
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The need to improve drug administration has become apparent 
over the last 20-30 years, and over the last few years a number 
of systems have been proposed which aim to extend the period of 
time over which a therapeutic level of drug is maintained in 
the circulation (section 1.2). Other proposed systems aim to 
concentrate drug in the target tissue by the use of a 'homing 
device' attached to the drug (section 1.3).
This project involves the use of soluble poly N-(2-hydroxy- 
propyl )methacrylamide copolymers as potential drug carriers in 
a soluble targetable drug delivery system, which aims to 
enhance drug uptake by the target tissue, prevent rapid 
excretion of the drug and to minimise non-specific side-effects 
due to uptake of the drug by normal tissue.
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1.2 CONTROLLED DRUG RELEASE SYSTEMS
A variety of systems have been developed in which drugs are 
encapsulated or embedded within structures prior to their 
administration. Once inside the body, the drug is slowly 
released from its carrier. The ultimate goal for such systems 
is to achieve sustained release of the drug, where the rate of 
drug release just equals the rate of drug removal from the body 
by all processes over the desired time period (fig 1.1a). True 
sustained release preparations are, unfortunately, very 
difficult to produce, although prolonged action dosage forms 
can be achieved and offer many advantages over conventional 
dosage forms. Such advantages include the employment of less 
total drug, reduction in local and systemic side-effects, 
increased efficiency in treatment and less inconvenience for 
the patient (Ballard 1978).
It is unfortunate that the terminology used in this field of 
research is confused and often misleading. For the purpose of 
this thesis, the term 'controlled release' will be used to 
encompass all methods used to modify the release of drugs from 
carrier systems.
Controlled drug delivery systems have been designed by a number 
of workers, and the variety of materials, methods and routes of 
administration employed is diverse. For these reasons only a 
few specific examples of the documented systems will be 
discussed.
1.2.1 Enteric Coating
Enteric coating is one of the oldest methods employed to 
improve oral drug delivery. This can be achieved by coating 
tablet, capsule or granulate dosage forms with acid-resistant
-4-
polymer films which are impermeable to gastric secretions, but 
soluble at a higher pH, thereby releasing the drug in the small 
intestine. This, in theory, protects the drug from gastric 
degradation, protects the gastric mucosa from potentially 
damaging drugs (which could cause nausea and vomiting), and 
improves bioavailability through increased drug absorption in 
the small intestine. Enteric coatings are usually composed of 
fats, fatty acids, waxes, shellac or cellulose acetate 
phthalates (Ottenbrite 1980). Unfortunately, although gastric 
protection can be achieved, drug release in the intestine is 
both retarded and erratic (Sjogren & Bogentoft 1981). Orally 
administered multiple unit dose forms have also been described, 
where the preparations disintegrate in the stomach into a 
multitude of microencapsulated crystals, pellets or granules. 
These smaller units can penetrate physical barriers more easily 
and become distributed throughout the gastrointestinal tract 
(Bechgaard 1981).
1.2.2 Diffusion-controlled Systems
Diffusion-controlled reservoir systems consist of a core of 
drug contained within membranes, capsules, microcapsules, 
liposomes or hollow fibres. The development of a number of 
membrane-enclosed reservoir devices has proved very successful 
and commercially available products include Ocusert, which is 
applied to the conjunctiva and consists of ethylene vinyl 
acetate membrane-enclosed pilocarpine for the treatment of 
glaucoma (Stewart and Novak 1978), Progestasert, a birth control 
device consisting of an ethylene vinyl acetate membrane 
containing progesterone which is implanted in the uterus and is 
effective for one year (Place and Pharriss 1974), and 
transdermally administered scopolamine for the treatment of 
motion sickness (Chandrasekaran and Shaw 1980).
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In most of these systems, diffusion of the drug through the 
polymer is the rate-limiting step« Polymers are widely used 
in this category e.g. silicone rubber, hydrogels and ethylene 
vinyl acetate copolymer, and drug diffusion takes place either 
through pores in the polymer structure, in the case of 
microporous membranes, or solution-diffusion transport in non- 
porous homogenous polymer films i.e. between the polymer chains.
Diffusion-controlled systems can also take the form of a solid 
polymeric matrix impregnated with drug. Again, drug diffusion 
through the polymer is the rate-limiting step, but in the case 
of matrices the drug is uniformly distributed throughout the 
polymer, and consequently drug release from these devices is 
not constant with time.
Advantages of matrix systems are ease of fabrication, and the 
ability to achieve the release of macromolecules. Langer et al
(1980) demonstrated release of insulin from implanted ethylene 
vinyl acetate discs in diabetic rats over a period of 24 days, 
and also studied the release of other macromolecules from 
polymer matrices in vivo, including ribonuclease A (Mw 14,000), 
bovine serum albumin (Mw 68,000) and IgG (Mw 166,000). He 
proposed that the release of macromolecules takes place via 
diffusion of the macromolecules through channels in the matrix.
Swelling controlled systems have also been developed where the 
drug is initially dissolved or dispersed in a polymer solution. 
The solvent is then evaporated, leaving the drug incorporated 
within the polymer matrix. Following implantation, fluid 
penetrates the matrix and the polymer swells into a rubbery 
state which allows the drug contained in it to diffuse outward 
(Graham and McNeill 1984).
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1.2.3 Magnetically-controlled Systems
Magnetically-controlled systems involve the dispersion of both 
drug and small magnetic beads within a matrix or emulsion. On 
exposure to an oscillating external magnetic field, drug is 
released at a much higher rate than in the absence of magnetic 
beads. Sugibayashi et al (1982) demonstrated sustained drug release 
and targeting of magnetic albumin microspheres containing 
adriamycin to the lung by magnetic means. Enhancement of 
antitumour effects of adriamycin on AH7974 lung metastasis in 
rats was observed. The mechanism responsible for the sustained 
release of drug from the microspheres is unclear, however, and 
the metabolism of systemically administered ferrite is not 
understood and requires further investigation.
1.2.4 Osmotic Pumps
Another novel system for optimizing drug levels in the body is 
the employment of osmotic pumps. Theeuwes (1980) and 
Eckenhoff (1981) have designed a number of preprogrammed 
osmotically powered pumps which contain a reservoir which can 
be filled with a drug suspension by a conventional syringe and 
filling tube. The filled pump can be implanted or administered 
orally or rectally, but when in contact with an aqueous 
environment, water moves across the membrane into the osmotic 
compartment and displaces an equivalent volume of drug 
formulation. The pumps have been shown to be precise and allow 
accurate control over the rate of release when used over 12 and 
24 hour duration for oral and rectal administration in clinical
studies
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1.2.5 Biodegradable Systems
The drug-release mechanisms discussed so far have generally 
been insoluble« non-degradable polymeric systems which are 
often used in the form of implants. Biodegradable drug 
delivery systems have the obvious advantage that surgical 
removal following implantation is not necessary since the 
soluble degradation products are absorbed by the body.
Biodegradable systems employ both natural and synthetic drug 
carriers (natural and synthetic macromolecules as biodegradable 
drug carriers are discussed in section 1.5). In the case of 
solid degradable polymeric systems, the term "bioerodible" is 
often used, and these may take the form of a monolithic matrix 
or the polymer may envelope a drug-rich reservoir, or be in the 
form of syringe-injectable microcapsules. The difference 
between non-erodible and erodible systems is that, while the 
polymer phase in non-erodible systems remains unchanged and 
drug is released by diffusion, the polymer phase in erodible 
systems decreases with time, allowing the drug to escape as the 
surrounding polymer is eroded. Heller (1980) has described 
three dissolution mechanisms in bioerodible systems and these 
are summarized in fig 1.2. The first mechanism involves the use 
of water-soluble polymers insolubilized by degradable crosslinks. 
The crosslinks are hydrolytically unstable and the matrix is 
highly hydrophilic and completely permeated by water.
Heller investigated the release of bovine serum albumin from a 
hydrogel of this type and found that the rate of release was 
dependent on crosslink concentrations. At low crosslink 
concentrations the hydrogel swelled extensively and albumin 
was released very rapidly. The reverse was true for high 
crosslinker concentrations.
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FIGURE 1.2
The second mechanism described by Heller involves water- 
insoluble polymers which become soluble as a consequence of 
hydrolysis, ionization or protonation of pendant groups. 
Because no actual cleavage of the polymeric structure takes 
place, the solubilization does not result in any significant 
changes in molecular weight of the polymer.
The third mechanism includes all water—insoluble polymers that 
undergo hydrolytic backbone cleavage and are solubilized by 
conversion to small, water-soluble molecules. This category 
includes polylactic acid or lactic/glycolic acid copolymers, 
polyorthoesters, poly(£-caprolactone) and polyamino acids 
(Pitt et al 1981).
Drug release from bioerodible systems is often complicated 
since hydrolytic erosion can occur in two different ways. 
Heterogeneous erosion is the term used to describe surface 
erosion, which is much preferred since drug release from 
devices that maintain constant geometry will be at a fairly 
constant rate. Homogeneous erosion takes place at a uniform 
rate throughout the matrix, which remains essentially intact 
until all parts reach a critical stage at which point the 
matrix dissolves. Bulk erosion of this nature may occur in 
addition to surface erosion and also diffusion, thereby making 
the prediction of drug release rates from such systems 
extremely difficult.
1.3 LYSOSOMOTROPIC DRUG DELIVERY
The drug release systems so far discussed have involved the 
controlled release of free drug into the circulation from 
various devices which are usually contained within the body.
Another approach to the problem of drug administration is by 
the use of soluble macromolecules as carriers of chemically 
bound drugs. Such systems enable the transport of the drug- 
carrier complex directly to cells following its introduction 
into the circulation.
The attachment of low molecular weight drugs to macromolecules 
prevents indiscriminate uptake of the drug into cells, since 
the complex is too large to diffuse through cell membranes. 
Cellular uptake of macroroolecules is restricted to a mechanism 
known as endocytosis. Following endocytic uptake by cells, the 
complex is delivered to lysosomes, where free active drug is 
released.
The term 'lysosomotropic' has been used by de Duve et al (1974) 
to describe all substances that are taken up selectively into 
lysosomes, irrespective of their chemical nature or mechanism 
of uptake. The attachment of a low molecular weight drug to a 
macromolecule therefore transforms the drug into a lysosomo­
tropic agent. Substances proposed as lysosomotropic drug- 
carriers include soluble synthetic polymers, nanoparticles, 
liposomes and natural macromolecules.
1.3.1 Endocvtosis
Endocytosis is a term that encompasses both phagocytosis and 
pinocytosis. Both processes are energy-dependent and involve 
the invagination and subsequent internalization of regions of
the plasma membrane of the cell to form intracellular membrane- 
bounded vesicles which contain extracellular fluid, dissolved 
solutes and substances bound to the plasma membrane at the site 
of invagination. These vesicles may ultimately fuse with 
lysosomes, which are membrane-bounded organelles containing 
acid hydrolases capable of digesting many natural macromolecules.
Phagocytosis generally refers to the adsorptive interiorization 
of particles of greater than approximately 1.0 pm in diameter 
by specialised phagocytic cells. This adsorption to the cell 
membrane may be the result of specific interaction between the 
particle and a specific receptor present on the plasma membrane, 
or it may be a non-specific phenomenon, as occurs in the binding 
of polystyrene beads (Steinman et al 1983). Phagocytosis is the 
feeding mechanism employed by many unicellular organisms e.g. 
Amoeboe, and the ability of macrophages to phagocytose invading 
micro-organisms plays an important role in animal defence 
systems.
Pinocytosis is an on-going process of membrane internalization 
and extracellular fluid uptake common to most, if not all, cell 
types, and gives rise to vesicles 0.1-1 pm in diameter. It is 
the only mechanism by which most soluble macromolecules can 
enter cells. Pinocytosis can capture solutes either in the 
fluid-phase only or by an adsorptive mechanism (fig 1.3). 
Fluid-phase pinocytosis is the terra used when molecules present 
in the extracellular fluid enter the cell with no interaction 
with the cell membrane. When a molecule interacts with the 
cell membrane, molecular uptake is said to be through 
adsorptive pinocytosis. This interaction, too, may be in a 
non-specific way, such as the cationic binding of ferritin to 
anionic sites on the cell membrane or it may be receptor-
C E L L  S U R F A C E  E V E N T S  I N  P I N O C Y T O S I S
F L U I D - P H A S E  P I N O C Y T O S I S
A D S O R P T I V E  P I N O C Y T O S I S
ft ft ❖ «7 ft
FIGURE 1.3
mediated. Receptor-mediated pinocytosis involves the inter­
action between a receptor component present on the cell membrane 
and a specific moiety present on the molecule to be internalized 
Molecules known to be taken up by receptor-mediated pinocytosis 
include lysosomal enzymes, polypeptide hormones such as 
epidermal growth factor, insulin, plasma transport proteins 
e.g. low density lipoprotein andoC2-macroglobulin (Besterman 
et al 1983).
Figure 1.4shows the membrane-bounded structures involved in the 
endocytic lysosomal pathway and also shows another membranous 
organelle, the Golgi apparatus, which is involved in primary 
lysosome formation, the formation of secretory vesicles, and 
also other intracellular vesicular pathways such as trans­
location of proteins and possibly membrane recycling.
Many molecules which bind to specific receptors at the cell 
surface prior to pinocytosis are found to be clustered within 
differentiated regions of the plasma membrane known as coated 
pits. The coat is composed of the protein clathrin (Mw 180,000) 
and is situated on the cytoplasmic side of the plasma membrane. 
Studies by Helenius et al (1980), and Anderson, Goldstein et al 
(1977) on viruses and LDL respectively, have shown that coated 
pits transform to clathrin coated vesicles of 0.1-0.2 jun in 
diameter on internalization of plasma membrane. Coated 
vesicles were first noted by Roth and Porter in oocytes (1964) 
and by Fawcett in reticulocytes (1964). In 1969 Kanaseki and 
Kadota noted that these coats, when seen in thin section, 
resemble a basket composed of hexagonal and pentagonal arrays. 
Clathrin coated vesicles have also been implicated in the 
transport of secretory products (Palade 1975 and 1982) and 
membrane proteins (Rothman, Pettegrew and Fine 1980) from the
SC HEMA TI C R E P R E S E N T A T I O N  O F  S O M E  E N D O C Y T I C  
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FIGURE 1.4
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endoplasmic reticulum to the Golgi, the transport of lysosomal 
enzymes from the Golgi to the lysosomes (Friend and Farquhar 
1967, Bainton and Farquhar 1970), the transport of membrane 
components from the Golgi to the cell surface (Rothman,
Pettegrew and Fine 1980) and the recovery of membrane from the 
cell surface and its recycling to the Golgi complex (Ottosen, 
Courtoy and Farquhar 1980). The exact function of the clathrin 
coat, which does not appear to surround fluid-phase pinocytic 
vesicles, remains unclear.
Clathrin-coated vesicles are not permanent features of 
receptor-mediated endocytic pathways, however, since within 
seconds to minutes after the formation of the vesicle, the coat 
is lost avid larger smooth surfaced vesicles are observed which 
appear to be formed by fusion of smaller pinocytic vesicles.
This fusion is also reported to occur in fluid-phase pinocytosis. 
These larger vesicles have been termed endosomes by Helenius et 
al (1983) or receptosomes by Pastan and Willingham (1983). They 
appear to be acidic, pre-lysosomal compartments, free from 
enzyme activity, less dense than lysosomes, and showing a 
greater density of ligand (endocytosed material) than the 
plasma membrane. Helenius has proposed that the acidification 
of endosomes is due to the activity of a H+-ATPase similar to 
that believed to operate in lysosomes and secretory granules, 
and that the resultant low pH would cause dissociation of the 
receptor-ligand complexes, generating free receptors for return 
to the cell surface without requiring transit through the 
perilous environment of the lysosome.
Intracellular vesicles are believed to pinch off from endosomes 
and migrate towards the perinuclear region of the cell,
13-
ultimately fusing with lysosomes. The exposure of the 
vesicular contents to lysosomal enzymes results in the 
catabolism of any degradable material. The small molecules 
produced as a result of degradation escape across the lysosomal 
membrane and are utilised or released by the cell, whereas any 
large non-biodegradable material remains trapped in the lysosome. 
This material may be released by the cell through exocytosis, 
which may be described as the reverse of endocytosis, or it may 
remain as residual bodies within the cell.
Since direct evidence for the recycling of endocytosed membrane 
was put forward by Mellraan et al 1980, and by Schneider, 
de Duve and Trouet in 1979, a considerable amount of interest 
has been taken in the vacuolar system of the cell, and a number 
of different hypotheses have been proposed by many authors to 
explain membrane recycling, cell-surface receptor recycling and 
the role of coated vesicles and endosomes.
Although the precise intracellular events leading to lysosomal
hydrolysis of pinocytosed material is at present not precisely
defined, many studies on the uptake of macromolecules by various
cell types have helped to identify some of the factors which
govern the rate at which pinocytosis takes place. The rate of
uptake of a molecule by fluid-phase pinocytosis is dependent
upon both the concentration of the extracellular material and
the rate of vesicle formation by the tissue, since there is no
interaction of the molecule with the cell membrane. The rate
of vesicle formation, however, is dependent on temperature.
Duncan and Lloyd (1978) demonstrated a substantial reduction in
125the rate of pinocytosis of I-labelled polyvinylpyrrolidone 
by rat visceral yolk sacs by lowering the temperature by only 
7°C to 30°C, and pinocytosis is completely inhibited at 4°C.
Adsorptive pinocytosis may be receptor-mediated or non-specific 
in nature. The rate of uptake of a macromolecule by receptor- 
mediated pinocytosis will be determined by the specificity of 
the receptor-ligand interaction and also the number of receptors 
present on the cell surface at any given time. Adsorption to 
the cell membrane, whether specific or not, results in a 
greater concentration of the molecule on the cell surface during 
vesicle formation and cellular uptake of that molecule will 
therefore be at a higher rate than a molecule present at the 
same concentration entering the cell by fluid-phase pinocytosis.
Various physical parameters also govern the rate at which
macromolecules can enter cells, such as charge, hydrophobicity,
and size. It is generally agreed that cationic groups, when
present on the surface of a macromolecule, bind to the
negatively charged areas of plasma membrane, giving rise to
enhanced pinocytic uptake by cells. There is, however,
conflicting evidence with regard to possible stimulation of
vesicle formation by cationic molecules. Shen and Ryser (1968, 79)
maintain that basic polyamino acids, in particular poly-L-
lysine markedly enhances the uptake of I-BSA in Sarcoma
S18011 tumour cells, and that negatively charged poly-L-
glutamic acid decreased albumin uptake. Prat ten et al (1978)
concluded that poly-L-lysine, poly—L-ornithine, poly-L-glutamic
acid and a number of dextran derivatives all failed to affect
125greatly the rate of pinocytic uptake of I-PVP by rat 
visceral yolk sacs or rat peritoneal macrophages, thereby 
indicating no change in the rate of vesicle formation, although 
they agreed that cationic molecules entered cells by 
adsorptive pinocytosis.
The hydrophobicity of a macromolecule will also affect its 
uptake by pinocytosis. Hydrophobic molecules will generally 
bind to hydrophobic groups present on the lipid cell membrane. 
The binding of formaldehyde denatured BSA to yolk sac membranes 
(Livesey and Williams 1977) is probably due to the denaturation 
process resulting in the exposure of hydrophobic groups 
normally buried within the structure of the albumin which bind 
to hydrophobic groups on the yolk sac surface. Recent work by 
Duncan et al (1984) using HPMA copolymers bearing different 
concentrations of tyrosinamide residues has shown that uptake 
of the copolymers by rat yolk sacs increased with increasing 
tyrosinamide content. This can be explained by increasing 
hydrophobicity with increasing tyrosinamide content resulting 
in increased capacity for non-specific adsorptive pinocytosis.
The size of a macromolecule will also determine its rate of 
pinocytic uptake by cells. Cells of the reticulo-endothelial 
system have been shown to pinocytose larger molecules 
preferentially. Kooistra et al (1980) cross-linked ribonuclease 
with dimethyl suberimidate to form dimers and larger polymers 
without affecting the charge of the protein, and found that 
the larger molecules were taken up at a much higher rate than 
the monomers. Ryser in 1968 also found that larger 
polyornithine macromolecules are taken up more readily than 
smaller ones (Mw range 4,000 to 200,000) in Sarcoma S180 11 
cells, although since the molecules used were basic, size 
would also determine the number of positive charges capable of 
interacting simultaneously with the cell surface, and therefore 
the effect of size cannot be separated from the effect of 
charge. More recently, Duncan et al (1981) have 
demonstrated a positive correlation between molecular size and 
pinocytic uptake of I-PVP in macrophages (cells of the RE
system), but rat visceral yolk sacs were shown to preferentially 
pinocytose the smaller molecular weight fractions.
1.3.2 Macromolecules as Drug Carriers
De Duve et al (1974) have suggested that lysosomotropic therapy 
may be beneficial in many diseases, including lysosomal 
storage diseases, silicosis, gout, bacterial infections, 
parasitoses, and also for cancer chemotherapy. If a drug is 
bound to a macromolecule in such a way that the complex is 
stable in the bloodstream, but not in the acidic, hydrolytic 
environment of the lysosome, active drug will be released in 
the lysosome, and if small enough will traverse the lysosomal 
membrane and be able to act within the cytoplasm.
Natural Macromolecules
Trouet et al (1972) pointed out that the intracellular 
concentration of drugs when attached to digestible natural 
macromolecular carriers is dependent on the pinocytic activity 
of the cells and on the digestive potential of their lysosomes, 
and given that many tumour cells have high endocytic activity, 
cancer chemotherapy could be improved by lysosomal therapy, 
providing that the drug itself was resistant to lysosomal 
inactivation. Trouet used daunorubicin, an effective 
chemotherapeutic agent, but also one which displays serious 
toxic side-effects, non-covalently bound to a polymeric DNA 
carrier, in an attempt to improve drug therapy and reduce 
general toxicity. To begin with, DNA-daunorubicin complexes 
were incubated with lysosomal extracts at pH 3.5 and pH 5.5. 
Results demonstrated dissociation of the complex at acid pH, 
the degradation of the DNA carrier and also drug activity. 
Intraperitoneal injections of the complexes into DBA/2 or NMRI
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mice showed less toxicity of daunorubicin when attached to 
DNA than when administered as free drug. When mice were 
inoculated intraperitoneally with L1210 leukaemia cells, and 
subsequently treated with either free daunorubicin or DNA- 
daunorubicin at non-lethal doses, the survival curves were 
comparable. However, since the drug-carrier complex was shown 
to be less toxic than free drug, higher doses could be 
administered, and the period of survival was increased. Trouet 
found that the route of administration of both L1210 cells and 
drug-carrier complex was of great importance. Intraperitoneal 
administration of DNA-daunorubicin following intravenous 
injection of L1210 cells was less effective than if both were 
administered via the same route. DNA was stated to be an 
unsuitable carrier because of probable antigenicity and later 
work revealed that the non-covalent linkage of daunorubicin to 
DNA was not stable in the bloodstream. Adriamycin, another 
anthracycline used in cancer chemotherapy, was shown to be much 
more stable in the bloodstream when complexed with DNA, and 
was also shown to improve survival times and reduce toxicity 
(Trouet et al 1979). Covalent linkage of drugs to macro- 
molecular carriers, giving rise to complexes completely stablein 
the bloodstream, was described by Masquelier et al (1980). This was 
achieved by linking daunorubicin or adriamycin to proteins and 
polypeptides using the aminosugar group of the anthracycline 
to obtain a peptidic linkage with carboxylic side chains of 
the carriers. Daunorubicin was coupled to bovine serum albumin 
using carbodiimide as a coupling agent, but it was found that 
in order to achieve enzymatic hydrolysis of the conjugate 
within the lysosome, a spacer sequence, composed of up to four 
aminoacids, was required. It was found, using lysosomal
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hydrolases, that the greater the length of the spacer between 
the drug and the carrier, the greater the enzymatic cleavage 
of drug from the carrier. Trouet et al (1981) have found that 
alternating sequences of alanine and leucine form suitable 
peptidic spacers for drug attachment, providing good water- 
solubility and demonstrating lysosomal hydrolysis when BSA is 
conjugated to daunorubicin. When these conjugates were 
injected intraperitoneally in mice following intraperitoneal 
inoculation with L1210 cells, results demonstrated high 
therapeutic activities with a high proportion of long-term 
survivors after 30 days.
Other lysosomotropic agents used by Trouet's group as drug 
carriers include liposomes of various sizes and composition. 
They have entrapped daunorubicin and vincristine in multi- 
lamellar, unilamellar, positively and negatively charged 
liposomes, but have found no chemotherapeutic advantage in the 
use of liposomes. The disadvantages of liposomes as drug 
carriers include blood instability and the very high uptake of 
liposomes by the liver, lung, spleen and other cells of the 
recticuloendothelial system, thus precluding the selective 
uptake of drug by other tissues and organs (Trouet et al 1980).
Chu and Whiteley (1977) also used BSA as a macromolecular 
drug carrier, but covalently bound methotrexate (MTX) using 
carbodiimide. MTX-BSA was found to be as effective as free 
MTX in the treatment of L1210 cells in mice, and a higher, 
more prolonged serum concentration and a decreased rate of 
excretion of BSA-MTX than free MTX was noted. These 
observations indicate that BSA, as might be expected of a 
serum protein, is taken up slowly by cells by fluid-phase 
pinocytosis, rather than rapidly by adsorptive pinocytosis,
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and that the size of the conjugate exceeds the renal threshold 
which is therefore retained in the bloodstream for a prolonged 
period of time.
Chu and Whiteley (1977) also covalently linked MTX to dextran 
derivatives of various molecular weights (Mw 10,000-150,000). 
The conjugates were found to remain in the circulation for 
longer, and to produce significant levels of MTX within the 
L1210 cells, but were ineffective antitumour agents. A 
possible explanation for the ineffectiveness of the dextran-MTX 
is that the drug linkage was unsuitable for intralysosomal 
enzymatic hydrolysis, and that free active drug was therefore 
not released.
Targeting of Macromolecules
The ability not only to restrict drug uptake to pinocytosis, 
but also to restrict pinocytosis largely to a particular cell 
type can be achieved by the use of known receptor recognition 
systems. Receptor-mediated pinocytosis takes place more 
rapidly than fluid-phase pinocytosis, and this leads to rapid 
clearance of the macromolecule-drug conjugate from the blood­
stream with accumulation of drug in the target tissue.
There are a limited number of such cell recognition systems 
known in which carbohydrate moieties participate. These include 
the recognition of galactose-glycoproteins by hepatocytes 
(Ashwell and Morrell 1974), mannose/acetylglucosamine 
terminating glycoproteins by Kupffer cells of the liver 
(Stahl et al 1978), and phosphomannose residues by 
fibroblasts (Natowicz et al 1979).
Fuime et al (1981) achieved hepatocyte targeting of antiviral 
drugs coupled to galactose-terminating glycoproteins
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desialylated fetuin (isolated from foetal calf serum) and 
lactosaminated serum albumin in mice. Unfortunately, naturally 
occuring glycoproteins, such as fetuin, can be obtained in only 
relatively small amounts. Furthermore, the use of lactosaroinated 
serum albumin as a drug carrier, though easily obtained in 
large amounts, is questionable because of its possible 
immunogenicity. Immunological studies on lactosaminated serum 
albumin are currently taking place.
Targeting of lysosomotropic drug carriers has been achieved by 
the use of immunoglobulin G (IgG) either as a carrier itself, 
or as a targeting moiety attached to an intermediate carrier.
In order to achieve selectivity in cancer chemotherapy, it is 
possible to raise monoclonal antibodies against a specific 
tumour receptor. Arnon (1981) and Ghose et al (1981) 
have described the production of antibodies to several tumour 
systems. The results reported by both groups indicate that 
antibodies may serve as carriers for anticancer drugs to tumour 
cells but that the main difficulty anticipated is the 
preparation of suitable antibodies which will be specific only 
for the tumour cells and will not interact with normal tissue.
The authors also point out that the antibodies used should be 
immunospecifically purified to avoid the presence of high 
amounts of irrelevant IgG molecules.
Unusual receptors are expressed by certain tumours and therefore 
allow specific antibody production (Connors 1981). However, 
these receptors are often present on the cell surface at very 
low concentrations, and in such cases it might not be possible 
to target sufficient drug to the cell to destroy it. A 
possible solution to this problem is the use of toxins rather
than conventional drugs. The conjugation of antibodies to 
various toxins has been reviewed by Edwards et al
(1981). Several groups of workers have attached extremely 
potent natural cytotoxic agents, such as diphtheria toxin, 
abrin and ricin to antibodies. The advantage conferred on such 
a complex is that a much smaller quantity of drug is necessary 
to destroy the cell, and this is particularly useful where 
receptors are present in low concentrations. Unfortunately, 
the glycoproteinous nature of such toxins can interfere with 
the targeting and binding, and hence the specificity of 
antibody conjugates to cells. Various strategies have been 
devised in order to eliminate this problem. A further 
complication of the use of antibodies as drug carriers is the 
chemistry of the conjugation procedure. The crosslinking of 
two proteins is difficult, and the exact location of the 
bound drug on the IgG molecule is often unknown. It is 
naturally desirable to ensure that binding of the drug does 
not occur on the Fab fragments of the antibody, which are 
essential for receptor recognition. Furthermore, solubility 
problems arise on direct conjugation to antibody of high levels 
of hydrophobic anticancer agents. To facilitate improved drug 
binding, and drug loading, with intralysosomal release of 
active drug, it is possible to bind the drug to the antibodyiT*
by means of an intermediate carrier.
Poznansky and Bhardwaj (1981) have described a model for 
enzyme therapy by chemically crosslinking 1,4-glucosidase, 
homologous albumin and IgG raised against isolated rat 
hepatocytes in order to lower hepatocyte glycogen content in 
Type 11 glycogenesis (Pompe*s disease). Also, dextran has been 
used as an intermediate carrier of an alkylating agent using
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ant it umour IgG (Rowland 1977) and has been shown to be 
effective in suppression of tumour growth in mice.
Trouet et al (1981) suggest that although antibodies are the 
most obvious candidates for drug targeting, there are two 
problems which could preclude their use as drug carriers. 
Firstly, the receptor-mediated uptake of antibodies might not 
lead to lysosomal hydrolysis of the conjugate and drug release, 
since it has been observed that in many tissues IgGs are 
selectively transported across the cells intact i.e. without 
fusion with lysosomes. Secondly, the reported release of some 
tumour antigens into the bloodstream would lead to antibody- 
antigen complex formation and subsequent non-specific 
endocytosis by cells of the reticuloendothelial system. 
Preliminary results by various workers using antibodies as 
drug carriers, or targeting moieties have, however, proved 
promising in many cases.
Soluble Synthetic Macromolecules
The use of soluble synthetic polymers as drug carriers offers 
some advantages over natural macromolecules. Polymers can be 
'tailor-made' for a specific purpose, the possibilities in 
design and structural variations being much greater than in 
natural macromolecules. Ringsdorf (1975) proposed a model 
which demonstrates the many chemical possibilities of design 
in synthetic polymeric carriers (fig 1.5), enabling the 
synthesis of macromolecules with the desired biological 
properties. The polymer may be degradable, or non bio­
degradable, hydrophilic or lipophilic, drugs may be attached 
permanently, or temporarily, by use of a spacer group.
Targeting residues may be specific e.g. antibodies, or non-
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specific e.g. polyelectrolytes. By careful design, therefore, 
polymer conjugates caul be synthesized with prolonged action, 
retarded excretion, reduced toxicity and resulting in the 
required body distribution of drug.
Vinyl polymers e.g. PVP, cationic e.g. poly(L-lysine) and 
anionic polymers e.g. divinylether-maleic anhydride copolymer 
(DIVEMA) and others have been proposed as potential drug 
carriers (Zaharko et al 1979). The effect of charge on 
polymeric uptake has been studied extensively by Shen and Ryser 
(1978, 1981) who found that poly-L-glutamic acid, a polyanion, 
inhibited pinocytosis, but that polycations, in particular 
poly(L-lysine), enhanced pinocytosis. When methotrexate was 
covalently linked, using a triglycine spacer, to poly(L-lysine) 
(Mw 60,000), the conjugate entered Chinese Hamster Ovary (CHO) 
cells forty times faster than the free drug. Furthermore, CHO 
cells resistant to MTX because of a genetic defect in drug 
transport, demonstrated uptake of conjugate two hundred times 
faster than the free drug, causing at least 90% inhibition of 
cell growth. Shen and Ryser (1981) have also developed a pH 
sensitive cis-aconityl spacer between daunomycin and poly(L- 
lysine), which has been shown to release free active daunomycin 
with a hydrolysis half-life of less than three hours at pH 4 
and more than ninety-six hours at pH 6 or higher.
The ability of polycations to bind cell membranes in a non­
specific way, however, may preclude their use as selective 
drug carriers in vivo.
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1.4 N-(2-HYDROXYPROPYL)METHACRYLAMIDE - A SOLUBLE SYNTHETIC 
DRUG DELIVERY SYSTEM
A number of considerations must be taken into account when 
selecting a polymer for use in drug delivery systems. Ottenbrite 
(1980) listed several criteria for polymers to be used in 
medicine. They must have*
High purity
Chemical, physical and mechanical properties to meet the
proposed function
Ease of fabrication
High stability
Sterilizability
Furthermore, tissue and blood compatibility are essential 
requirements for polymers to be used in biological systems. 
Polymers should be non-immunogenic, non-allergenic, non- 
carcinogenic, non-irritating, nor should they cause acute or 
delayed toxicity.
The hydrophilic polymer N-(2-hydroxypropyl)methacrylamide was
V  v /proposed as a blood plasma expander by Kopecek and Bazilova in 
1973. The polymer was shown to be compatible with blood and 
other living tissues. It was shown to be non-toxic, apyrogenic,
Vnot to elicit antibody formation (Kopecek et al 1973, Kop-
•j t  * tecek 1982), nor activate the lymph nodes (Korcakova et al 
1976). However, since HPMA is a synthetic polymer which is not 
degraded in the organism, the problem of possible accumulation 
of the polymer within the body was investigated. Previous 
studies, using non-degradable PVP as a blood plasma expander 
had demonstrated accumulation of the polymer in cells of the 
reticuloendothelial system, giving rise to the formation of 
'foamy' cells in the spleen, lymph nodes, bone marrow, liver, 
lungs and thymus. The consequences of such deposition have not
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been resolved. Some authors assume the condition to be 
temporary, and others regard it as irreversible, causing a 
decrease in phagocytic activity of the tissues (Ravin et al
V v1952, Spnncl et al 1976). Sprincl et al, in 1976, fractionated 
HPMA (then under the working name of Duxon), to produce samples 
of Mw 11,000-91,000. These were injected into rabbits and the 
elimination and retention of each sample investigated over a 
period of six months. It was found that polymers of a mean 
molecular weight below the renal threshold (approx. 50,000 for 
dextran) were not significantly accumulated by the animals over 
the experimental period, but were excreted predominantly by the 
kidney.
The evaluation of soluble HPMA copolymers as potential drug 
carriers has been the subject of a collaborative project between 
Professor J.B. Lloyd and Dr. R. Duncan at the University of Keele,
Vand Dr J. Kopecek and co-workers at the Czechoslovak Academy 
of Sciences in Prague, for the past six years.
The drug delivery system conforms to the model proposed by 
Ringsdorf (section 1.3 fig 1.5), and consists of a hydrophilic 
copolymeric backbone to which drugs, targeting moieties and 
other residues, if required, can be attached. The detailed 
structures of the copolymers used in this study will be 
discussed in Chapter 3, but in all cases their synthesis 
involves the reaction of i\-(2-hydroxypropyl)-
methacrylamide with p-nitrophenyl esters of N-methacryloylated 
amino acids to produce copolymers containing oligopeptide 
sidechains which can be designed to be susceptible to enzymatic 
hydrolysis. These sidechains are usually di-, tri- and 
tetrapeptides which are suitable for drug attachment and the 
binding of targeting residues.
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Where hydrolysis of a sidechain is required for drug release,
it is necessary that the degradable bond should originate in
the amino acid specific for the given enzyme« Copolymers
containing oligopeptide sidechains of different amino-acid
sequences have been synthesized using p-nitroanilides as
terminal drug analogues, and some have been shown to be
vsusceptible to hydrolysis by various enzymes. Kopecek (1981) 
demonstrated chymotrypsin catalysed hydrolysis of p-nitroanilides 
of phenylalanine and tyrosine from sidechains of HPMA copolymers 
and also noted an increase in susceptibility to chymotrypsin 
attack with an increasing spacing of the phe/tyr residue from 
the copolymer backbone. This latter observation can be 
attributed to greater spacing allowing more efficient binding 
of the substrate to the active site of the enzyme. Efficient 
binding is naturally also dependent upon specific interactions 
between the amino acids present within the substrate and 
discrete regions within the active site. Consequently both 
the amino acid sequence and the number of amino acids present 
in a given oligopeptide sidechain will determine the overall 
activity of an enzyme towards that particular substrate 
(Schechter and Berger 1967, 1968). In the case of chymotrypsin, 
the presence of L-phenylalanine, L-tyrosine or L-leucine as a 
terminal residue on the sidechain is necessary for enzymatic 
cleavage, and the rate of cleavage is a function of its spacing 
from the polymer backbone. A hydrophobic residue in the 
penultimate position has been shown to further enhance the 
rate of degradation.
Studies on twenty two HPMA copolymers, each containing a 
different, potentially degradable sidechain, were carried out 
by Duncan and Lloyd (1980) using mixed lysosomal enzymes 
derived from rat liver. Four of the sidechains were digested
by the enzymes, liberating a terminal p-nitroaniline residue. 
Further studies by Duncan et al (1982) in the presence of the 
thiol glutathione, demonstrated hydrolysis of twelve of the 
sixteen sidechains investigated, to release p-nitroaniline.
The addition of thiol-proteinase inhibitor leupeptin to the 
incubation medium caused total or partial inhibition of 
degradation in all but one case, indicating the involvement of 
lysosomal thiol-proteinases, at least in part, in the 
degradation of these sidechains.
125Duncan et al (1981) incubated four I-labelled HPMA copolymers 
(Mw 50,000) each containing a different oligopeptide sidechain 
with rat visceral yolk sacs in vitro. All copolymers were 
found to be taken up by fluid-phase pinocytosis and three of 
the substrates were hydrolysed by the tissue, resulting in the 
release of radiolabelled low molecular weight sidechain 
degradation products back into the medium. The thiol-proteinase 
inhibitor leupeptin, when added to the medium, did not affect 
the rate of pinocytosis, but inhibited the degradation of the 
copolymers to varying degrees, depending on sidechain 
composition.
Other in vitro studies on HPMA copolymers have shown that 
oligopeptide sidechains are stable in rat plasma and rat serum 
(Kopecek, 1984).
Studies are currently in progress which aim to design 
oligopeptide sidechains in HPMA copolymers which are specific 
to lysosomal enzymes (such as Cathepsin L), are stable in the 
bloodstream, and result in controlled rate of drug release 
within lysosomes.
HPMA copolymers bearing galactose residues have been targeted
to the liver following intravenous injection in rats.
Copolymers, containing both galactose residues and potentially
125degradable sidechains terminating in a I-labelled tyrosine 
residue, were cleared rapidly from the bloodstream and 69% of 
the recovered radioactivity was found to be contained within 
the liver one hour after administration (Duncan et al 1983). 
This may be attributed to receptor-mediated pinocytosis of the 
modified copolymer by liver hepatocytes (section 1.3). Five 
hours after administration, this level had dropped to 9%, 
indicating cleavage inside the liver and release of the radio- 
labelled tyrosine residue from the liver during that period of 
time.
From the experiments described, it is apparent that HPMA 
copolymers cam be taken up by cells by fluid-phase pinocytosis 
with resultant liberation of a drug amalogue, and that it is 
possible to target the copolymers to certain tissues by the 
attachment of specific moieties to the polymer backbone.
The size of the drug carrier is am importamt consideration. 
Ideally, the molecule should be of a molecular weight high 
enough to prevent rapid excretion by the kidney i.e. above the 
renal threshold, but low enough to permit pinocytic uptake by 
a range of cell types. Cells of the reticuloendothelial 
system preferentially capture larger molecules, whereas some 
epithelial cells preferentially pinocytose smaller macro­
molecules (Duncam et al 1981).
It is very desirable that the polymer is eventually excreted 
from the body. An unfortunate problem encountered with 
synthetic polymers, as previously described, is the possible 
toxic accumulation of non-degradable molecules within the
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lysosomes of cells. If a non-degradable polymer conjugate of 
molecular weight higher than the renal threshold (approx. 60,000) 
is administered, the polymer is retained within the circulation 
until it is endocytosed by cells, where it will accumulate 
following drug release. Following exocytosis or cell death, 
the polymer may again be released into the circulation, but 
will still be 'trapped' in the body unless it is eventually 
transported into the intestine via the liver.
On the other hand, if a polymer of molecular weight lower than 
the renal threshold is administered, rapid clearance of the 
conjugate from the body will occur through glomerular 
filtration, and efficient drug delivery will not be achieved.
An ingenious potential solution to this problem is the cross- 
linking (below the gel point) of relatively short polymer 
chains using oligopeptides containing enzymatically degradable 
bonds and diamines. These crosslinks, like the sidechains used 
for drug attachment, should be stable in the circulation, but 
susceptible to enzymatic hydrolysis within lysosomes following 
pinocytosis of the macromolecule. The resultant copolymer 
chains would still be too large to permit their passage across 
the lysosomal membrane, but their release back into the 
circulation would follow exocytosis or cell death. The polymer 
chains would then be of sufficiently low molecular weight to 
be excreted by the kidney.
Soluble crosslinked copolymers have been synthesized by
VKopecek et al and certain crosslinks have been shown to be 
cleaved by papain, chymotrypsin and trypsin (Rejmanova et al 
1981, Ulbrich et al 1980, 81). Again, the structure of the 
oligopeptide sequences must be chosen so as to correspond to
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that of the active site of the enzyme responsible for the 
degradation» The rate of degradation by these enzymes was 
again found to be dependent upon the number of amino-acids 
present in the oligopeptide sequence. Extension of the 
oligopeptide sequence by one amino acid residue (from 
tripeptide to tetrapeptide) was found to increase the extent 
of degradation of the crosslinks significantly. Steric factors 
which may impede degradation of crosslinks in addition to those 
described for sidechains,include the possible conformational 
changes of the oligopeptide sequences when attached to polymer 
coils at both ends» and the presence of two or more polymer 
coils impeding access of the enzyme active site to the bond to 
be cleaved. Results, however, indicate up to 100% cleavage of 
certain crosslinks containing tetrapeptidic on incubation with 
chymotrypsin (Rejmanovci et al 1981).
Preliminary in vivo experiments on soluble crosslinked 
copolymers were carried out by Kopecek et al (1981). A high 
molecular weight HPMA fraction was administered intravenously 
to rats, urine was subsequently collected and lower molecular 
weight HPMA fractions were qualitatively detected using GPC.
The average molecular weight of the copolymer detected in the 
urine was close to that of the aminolysed polymeric precursor 
of the crosslinked HPMA copolymer used.
A schematic diagram to show the cellular events involved in 
the uptake and intracellular hydrolysis of the proposed drug 
delivery system following parenteral administration is shown 
in fig 1.6.
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1.5 AIMS OF CURRENT STUDY
Soluble synthetic polymers are often both polydisperse and 
not biodegradable. The copolymers used in this study (kindly 
synthesized by P. Rejmanova and J. Kopecek) contained 
potentially degradable crosslinks, and one copolymer (code no. 
39) had been fractionated to produce five samples of known 
mean molecular weight and low polydispersity.
One of the primary aims of this project was to ascertain 
whether or not soluble crosslinked copolymers could be 
pinocytosed by cells, and if so, whether the crosslinks could 
be hydrolysed intracellularly to produce low molecular weight 
copolymer chains. Assuming that pinocytosis does take place, 
the next objective was to try to find an optimum size for the 
proposed carrier by examining the effect of molecular size on 
pinocytosis and intracellular degradation of soluble cross- 
linked copolymers both in vitro and in vivo. In vitro studies 
were to involve the use of two established organ culture 
systems, namely the rat visceral yolk sac and the everted rat 
jejunal sac. In vivo experiments were aimed to monitor the 
blood clearance and body distribution of the various molecular 
weight fractions following intravenous injection.
A further objective was to investigate the possibility of 
targeting crosslinked HPMA copolymers to the liver by the use 
of galactosamine attached to the copolymer (code no. 78) by a 
diglycyl spacer. The targeting of galactosamine containing 
macromolecules to the liver has been described previously 
(Duncan et al 1983) following intravenous administration of a 
potential carrier, but very little is known about the precise 
movement of macromolecules containing a targeting moiety when 
administration is by other routes. The possibility of targeting
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a crosslinked copolymer to the liver by intravenous, intra- 
peritoneal, subcutaneous and oral routes was therefore of 
interest, and also the comparison of body distribution with a 
control copolymer (code no. 79) of approximately the same 
molecular weight, crosslink structure and polydispersity, but 
lacking the targeting moiety.
A further aim was to demonstrate complete clearance of the 
copolymers from the bodies following administration, in order 
to prove that the partially degradable copolymers are actually 
released from the lysosomes and are able to pass through the 
kidney glomerulus and be excreted in the urine.
The involvement of lysosomal enzymes has been proposed to be 
responsible for any degradation observed. The final objective 
was to prove that crosslinks contained in the copolymers are 
actually cleaved by the incubation of crosslinked copolymers 
with lysosomal enzymes with resultant isolation of lower 
molecular weight copolymer chains.
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2.1 MATERIALS
2.1.1 Chemicals
N-(2-Hydroxypropyl) 
methacrylamide copolymers
N,N1-dityrosyl HMDA
Calibration copolymers
Kindly donated by 
Dr J Kopecek, Czechoslovak 
Academy of Sciences, 
Prague, Czechoslovakia
1 ?5I-PVP (preparation IM.33P) 
j^ 25l] iodide (preparation IMS.30)
Radiochemical Centre, 
Amersham, Bucks.
Tissue culture medium (TC 199) GIBCO, Bio-Cult Ltd, 
Paisley, Scotland
Heat inactivated calf serum 
(CS07) Wellcome Reagents, Beckenham, Kent
Bovine serum albumin 
2,4-Dinitrophenol 
L-Pheny1alany1-L-tyros ine 
Adenosine triphosphate 
Sephadex G-15-120 
Sepharose CL-4B-200 
Sepharose CL-6B-200
Sigma (London) 
Chemical Company, 
Poole, Dorset
Leupeptin Peptide Institute Inc., 
Osaka, Japan
Polin & Ciocalteu's reagent 
Chloroform
Pisons Scientific 
Apparatus, Leics.
Anaesthetic ether 
(diethyl ether)
May & Baker Ltd, 
Dagenham
Oxygen/Carbon dioxide 
(95i5)
Carbon dioxide 10096
British Oxygen Co Ltd, 
Manchester
All other chemicals, unless otherwise stated, were of 
analytical grade.
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2.1.2 Equipment 
Assay of Radioactivity
5136 Auto-Gamma Scintillation 
Spectrometer Packard Instrument Ltd, Caversham, Berks,
3ml Disposable tubes Luckhams Ltd, Burgess Hill, 
Sussex
Centrifuaes 
MSE Mistral 4L 
MSE HS 18 
MSE Superspeed 50 
MSE Bench Top
MSE Instruments, 
Crawley, Sussex
Electrophoresis Eauioment
Shandon Electrophoresis 
Apparatus Model U 77 Shandon Scientific Co., Willesden, London
Bio-Rad Power Pack 
Model 500 Bio-Rad Laboratories Ltd, Watford, Herts.
Spectrophotometer 
Cecil CE 373 Cecil Instruments Ltd, 
Milton, Cambs.
Column Chromatoaraohv
Fraction Collector 
Model 270 Chem Lab, Horn Church, Essex
Chromatography Columns 
(C-series)
Sephadex G-25-PD-10 
Prepacked disposable columns
Pharmacia Fine Chemicals, 
Uppsala, Sweden
Peristaltic Pumps LKB Instruments Ltd, 
South Croyden, Surrey
Knauer Differential 
Refractometer (51) Roth Scientific Co Ltd, Farnborough, Hants.
Chart Recorder Magnus Scientific
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2.1.2 Eauipnent 
Assay of Radioactivity
5136 Auto-Ganna Scintillation 
Spectroneter Packard Instrument Ltd, Caversham, Berks.
3nl Disposable tubes Luckhans Ltd, Burgess Hill, 
Sussex
Centrifuaes 
MSE Mistral 4L 
MSE HS 18 
MSE Superspeed 50 
MSE Bench Top
MSE Instruments, 
Crawley, Sussex
Electrophoresis Eauipnent
Shandon Electrophoresis 
Apparatus Model U 77 Shandon Scientific Co., Willesden, London
Bio-Rad Power Pack 
Model 500 Bio-Rad Laboratories Ltd, Watford, Herts.
Soectroohotoneter 
Cecil CE 373 Cecil Instruments Ltd, 
Milton, Cambs.
Colunn Chroraatoaraohv
Fraction Collector 
Model 270 Chem Lab, Horn Church, Essex
Chronatography Columns 
(C-series)
Sephadex G-25-PD-10 
Prepacked disposable colunns
Pharmacia Fine Chemicals, 
Uppsala, Sweden
Peristaltic Pumps LKB Instruments Ltd, 
South Croyden, Surrey
Knauer Differential 
Refractometer (51) Roth Scientific Co Ltd, Farnborough, Hants.
Chart Recorder Magnus Scientific
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In Vivo Equipment
Rat Metabolic Cages North Kent Plastic Cages Ltd, 
Dartford, Kent
Michel Wound Clips (7.5mm) A R Horwell, London
Potter-Elvejhem Teflon/Glass 
Homogeniser Tri-R Instruments Inc., New York
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2.2 ESTIMATION OF TISSUE PROTEIN
An estimation of the total protein content of both yolk sacs 
and jejunal sacs was carried out according to the method of 
Lowry et al. (1951). Duplicate samples (0.1ml) of tissue 
solution were pipetted into test tubes followed by 0.4ml of 
IN sodium hydroxide and 0.5ml of distilled water. A 
calibration curve was constructed by using a standard 
solution of albumin (lmg/ml). A series of six dilutions was 
set up, in triplicate, consisting of albumin concentrations 
0, 0.05, 0.10, 0.15, 0.20 and 0.25mg/ml. IN sodium hydroxide 
and distilled water were added to the tubes as described in 
Table 2.1. Folin A (5.0ml) was added to all the tubes and 20 
min later 0.5ml of Folin B was added and thoroughly mixed 
using a Whirlimixer. The colour was allowed to develop at room 
temperature for at least 45 min and then read on a Cecil CE 
373 spectrophotometer at 750nm against distilled water. A 
calibration curve was constructed and used to read off the 
protein content (mg) of the 0.1ml tissue sample. Values were 
multiplied by a factor of 50, 250 or 500 to give the total 
tissue protein.
TABLE 2.1 SODIUM HYDROXIDE AND DISTILLED WATER ADDITIONS TO 
TUBES FOR CALIBRATION CURVE IN LOWRY PROTEIN ESTIMATION
Tube
Protein
Standard (lma/ml) (ml) Distilled Water (ml)
IN Sodium 
Hydroxide (ml)
1 0 0.50 0.5
2 0.05 0.45 0.5
3 0.10 0.40 0.5
4 0.15 0.35 0.5
5 0.20 0.30 0.5
6 0.25 0.25 0.5
FOLIN REAGENTS 
FOLIN A
2% anhydrous sodium carbonate 
1® copper sulphate 
\% sodium potassium tartrate
POLIN B
Folin Ciocalteau's reagent 
Distilled water
lOOml
1.0ml
1.0ml
1.0ml
l.Oml
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1 252.3 I-LABELLING OF HPMA COPOLYMERS
All copolymers and the crosslinking agent NfN^-dityrosyl HMDA 
were labelled with^125lj iodide according to the Chloramine T 
method originally described by Hunter et al. (1963). The 
modification used by Williams et al. (1971) was followed here. 
Copolymer (20mg) was dissolved in 9.0ml phosphate buffer
(Na2HP04 J 6.804g per litre and KH2PC>412H20| 7.098g per litre)
125at pH 8.0 and placed on ice. 1 mCi of Na I (lOpl) was then 
added and the mixture stirred for 2 min. 4ml of a lmg/ml 
solution of Chloramine T was then added and after stirring 
for 8 min the reaction was stopped with sodium metabisulphite 
(3ml of a 2mg/ml solution). Solid potassium iodide (lOOmg 
approx. ) was added to displace free [125lJ iodide during the 
subsequent dialysis.
A small sample of the preparation was reserved in order to 
assess the efficiency of the labelling procedure and the 
remainder was dialysed against 1% NaCl for 72h (2 changes 
daily) to remove excess j^ 2 l^j iodide. The efficiency of 
labelling and the amount of contaminating |^125lJ iodide present 
at any time was assessed using low voltage paper electro­
phoresis (section 2.4).
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2.4 ESTIMATION OF FREE f1251] IODIDE IN RADIOLABELLED COPOLYMER 
PREPARATIONS BY LOW VOLTAGE PAPER ELECTROPHORESIS
The method described by Sargent (1969) was followed. Barbitone 
buffer, pH 8.6 was prepared (1.84g of barbitone and 10.3g of 
barbitone sodium in 1 litre of distilled water) and the 
electrophoresis tank filled to a depth of approximately 2cm. 
Whatman No. 1 paper was cut into strips 30cm in length and 
10cm wide. The central 20cm was pencil marked into 40 x 0.5cm 
strips and the fifth strip from one end was marked for the 
origin. The papers (up to four strips at any time) were then 
dipped into the barbitone buffer, blotted and placed across the 
supporting bars in the electrophoresis tank with the origin 
close to the cathode and each end submersed in the buffer 
compartment. The restraining bars were fixed into position, and 
current (400V, 2mA) passed through the strips for 15 min to 
allow equilibration.
Radiolabelled copolymers were applied to the premarked origins 
on the paper strips using 20jil microcaps. It has been found 
that when placed vertically in a solution, these microcaps fill 
to a volume of approximately 12^1 by capillary action. To 
avoid contamination of rubber bulbs with radioactive solutions, 
it was therefore decided to apply 2 x 12pl samples to each 
paper strip. A similar sample was applied to a strip 5cm x
0.5cm of Whatman No. 1 paper which was then transferred to a 
Luckhams tube, pressed to the base of the tube using a glass 
rod and sealed.
The electrophoresis was run at 400V. 2mA for 35 min. The 
papers were then removed and cut into 0.5cm strips 
sequentially at the premarked pencil lines. The small strips 
were then transferred to labelled Luckhams tubes, pressed down
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to the base of the tubes, which were then sealed and assayed 
for radioactivity. By running standards of known composition 
against the experimental solutions and plotting radioactivity 
(corrected for background) against strip number, it was 
possible to identify the composition of experimental solutions 
by comparing the position of the peaks obtained. Measurement 
of the radioactivity in each peak and comparison with the 
total radioactivity in the sample applied gave an estimate of 
the percentage of each component peak.
This technique was used routinely to estimate the percentage
preparations, and also to estimate the labelling efficiency of
of contaminating free
125copolymer samples following I-labellmg of HPMA copolymers 
using Chloramine T.
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2.5 COLUMN CHROMATOGRAPHY
Column chromatography was used for the detection of low 
molecular weight degradation products, for molecular weight
Prepacked disposable columns containing G-25 gel filtration
columns is protected by a plastic scinter which prevents the 
gel drying out, and maintains an even bed surface. Columns 
were 8cm in length, internal diameter 16mm and bed height 5cm. 
Each column was supported over a suitable receptacle and the 
gel bed equilibrated with approximately 25ml of phosphate 
buffer at pH 8.0. The sample was made up to 2.5ml final 
volume in buffer and applied to the column. The resultant 
2.5ml of buffer eluted was discarded. The high molecular 
weight components were then eluted with 3.5ml of buffer 
solution in 0.5ml fractions and assayed for radioactivity. 
Contaminating j^^lj iodide remained in the gel, and the column 
was discarded.
Sephadex G-15 gel filtration medium was normally used for the 
detection of low molecular weight degradation products (up to 
1500 Mw). The required quantity of Sephadex powder was placed 
in a beaker containing excess solvent (sodium acetate 0.02M, 
sodium azide 0.05% buffer). The process of swelling was 
achieved by placing the beaker in a boiling water bath for lh, 
which also served to deaereate the buffer. The slurry was then 
left to cool. The column was mounted on a laboratory stand and 
adjusted to a vertical position to ensure even packing. The 
outlet tubing was sealed and the column one third filled with
125determination and for the separation of I-labelled copolymer 
from contaminating free
125medium were used to separate I-labelled copolymers from
The surface of the gel contained in these
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buffer* The slurry was then agitated and poured into the
column* The outlet tubing was then opened and buffer allowed
to drip from the column into a suitable vessel. When the gel
settled, a quantity of the resultant head of clear buffer
solution was removed, the top few centimetres of gel stirred,
more gel slurry applied and allowed to settle. This was
repeated until the desired bed height was attained. The
column was then packed down by running buffer through the gel
overnight at the desired constant flow rate (usually 20ml/h)
using a peristaltic pump. Columns were kept moist and out of
direct sunlight to prevent cracking. Initially, a column of
approximate length 45cm, internal diameter 2.5cm and bed height
30cm was used. However, this chromatography column proved to
be larger than necessary to achieve a good separation of peaks,
and took up to 9h to elute, owing to the adsorption of 
125I-tyrosine molecules on the tightly crosslinked gel, which 
took longer to elute than predicted from their molecular size. 
Also, because of this adsorption, the elution volume was 
increased, and the applied sample diluted to such an extent 
that counting for radioactivity became difficult with 
copolymers that demonstrated low labelling efficiency or when 
total counts applied were low for other reasons e.g. serosal 
fluids from jejunal sacs. For these reasons, smaller G-15 
chromatography columns were subsequently used, of column 
length 20cm, internal diameter 16mm and bed height 15cm.
Before sample application, most of the buffer was removed from 
above the gel surface by suction, using a piece of flexible 
silicone rubber tubing attached to a 10ml syringe. The 
remaining buffer was allowed to drain away. Samples (usually 
lml) were then carefully layered on top of the drained bed 
surface, and allowed to drain into the bed before replacing
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2-3ml of the buffer solution. When this» too. had drained 
away, approximately 5ml of buffer solution was carefully 
layered on top of the bed surface. Care was taken to prevent 
diffusion of the sample into the buffer and to avoid 
disturbing the bed surface, which could lead to uneven 
separated bands and poor resolution. The eluate was collected 
in 1 or 2ml aliquots using Luckhams tubes mounted in a fraction 
collector, each tube accumulating fluid for 3 or 6 minutes 
respectively. The tubes were then assayed for radioactivity 
and an elution profile prepared by plotting counts obtained 
against fraction number.
For molecular weight determination, a mixture of Sepharose 4B
and Sepharose 6B (50*50) gel filtration media was used. By
mixing in this way, it is possible to increase the
fractionation range and therefore to determine molecular
weights between 1 x 104-5 x 106 (Sepharose 6B 1 x 104-1 x 106,
4 6Sepharose 4B 3 x 10 -5 x 10 ). For molecular weight
125distribution determinations of 1-labelled copolymers 
(Chapter 8) a column of internal diameter 16mm and bed height 
60-65cm was used. Sepharose CL gel is supplied pre-swollen 
as a thick slurry in distilled water, and was therefore 
diluted in buffer (0.2M Tris/HCl, 0.5M NaCl pH 8.0), placed 
in a Buchner flask, and deaereated using a suction pump.
Columns were packed and operated, and samples applied, in 
exactly the same way as described above.
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2.6 MEASUREMENT OF PINOCYTOSIS BY RAT VISCERAL YOLK SAC 
IN CULTURE
The method used for the culture of rat visceral yolk sacs was 
as described by Williams et al. (1975 a, b)• Yolk sacs were 
obtained from an inbred colony of Wistar rats in order to 
minimise genetic variation. Pairs of rats were mated overnight 
in grid cages. If a sperm plug was detected underneath the 
grid of the cage the following morning, pregnancy was timed 
from midnight on the night of mating. After 17.5 days, pregnant 
rats were asphyxiated with carbon dioxide, the uterus removed 
and placed in a Petri dish containing medium 199 (supplemented 
with 10% calf serum) that had previously been warmed to 37°C. 
Conceptuses were exposed on making a single longitudinal cut 
through the uterine wall, and each placental cap was gently 
prised free using open fine scissors. The placental caps were 
removed, the cut edge of the yolk sac enlarged by a single cut 
and the fetuses dissected free. The yolk sacs were placed in 
another Petri dish containing fresh medium, and any remaining 
amniotic tissue was carefully removed.
The yolk sacs were incubated either singly, or in groups of
6-10, in sterile, detergent-free 50ml Erlenmeyer flasks
containing 9.0ml of medium 199 supplemented with 10% heat-
inactivated calf serum which had previously been gassed with
a mixture of 95% oxygen and 5% carbon dioxide, and sealed with
a sterile silicone rubber bung. Flasks were placed in a water
bath maintained at 37°C with a shaker attachment set to a
stoke of approximately 3.4cm at a frequency of 10015 strokes
per minute. After a preincubation period of 15-45 min, 1ml
aliquots of culture medium containing a solution of 
125I-labelled substrate was added to each flask. The flasks 
were then regassed and stoppered.
S C H E MA T I C  R E P R E S E N T A T I O N  O F  T H E  D I S S E C T I O N  O F  
A 1 7 - 5 - DAY R A T  Y O L K  S A C  F O R  O R G A N  C U L T U R E  
(from W I L L I A M S  et  al 1 9 7 5 )
✓
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Yolk sacs were removed at various times over the incubation 
period (5-12h), washed three times for 2 min in up to lOOml 
ice-cold 1% sodium chloride to remove any extracellular 
substrate» and placed in either 5ml or SOml volumetric flasks, 
depending on the number of yolk sacs present in each culture 
flask. The flasks containing yolk sacs were made up to 5ml or 
50ml with IN sodium hydroxide and left to dissolve at 37°C for 
2h, mixing at half hourly intervals. Duplicate 1ml samples of 
the resultant digest were transferred to Luckhams tubes and 
assayed for radioactivity (section 2.8) and protein content 
(section 2.2) using the method of Lowry et al. (1951).
Two 1ml samples of culture medium were pipetted into 
disposable 3ml (Luckhams) tubes, stoppered and stored at 4°C 
until assayed for radioactivity (see section 2.8). When 
studying the possible degradation of a substrate, a further 
two 1ml samples of culture medium were collected in the same 
way, but stored at -20°C prior to Sephadex G-15 column 
chromatography (sections 2.5 and 2.9).
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2.7 MEASUREMENT OF PINOCYTOSIS BY RAT JEJUNAL SAC IN CULTURE
The method used for the preparation of everted intestinal 
sacs from adult rat jejunum was essentially that described by 
Wilson and Wiseman (1954), and modified by Bridges and 
Woodley (1980).
Intestinal tissue was obtained from adult male Wistar rats of 
200-30Og body weight. Animals had free access to food and 
water before all experiments. Each animal was sacrificed by 
cervical dislocation, the abdomen opened by a midline 
incision, and the jejunum removed by cutting across the region 
of the ligament of Treitz (duodenal-jejunal junction) and the 
ileo-jejunal junction, where the intestine is loosely bound 
to the posterior wall of the abdomen. The jejunum was washed 
out immediately with oxygenated medium 199 containing 10% heat- 
inactivated calf serum and IraM ATP at 4°C, delivered from a 
10ml syringe, and placed in a rectangular dissection trough 
(60cm x 3cm) containing the same incubation medium. All 
medium was gassed with a mixture of 95% 02 and 5% CX>2 prior 
to use. (The addition of 10% calf serum and ImM ATP has been 
shown to be necessary for the maintenance of tissue viability 
and structural integrity throughout the incubation period 
(Bridges 1980)). The ileal end of the jejunum was attached to 
one end of a notched glass rod (45cm x 2.0mm diam.) with a 
ligature and the jejunum was everted by rolling the proximal 
half onto the rod. The everted intestine was then slipped off 
the rod and replaced in the dissection trough. As far as 
possible, the glass everting rod was immersed in the incubation 
medium present in the trough throughout this procedure. After 
discarding the end portions, approximately 35cm of intestine 
was straightened carefully without stretching and one end was
S C H E M A T I C  R E P R E S E N T A T I O N  O F  T H E  T E C H N I Q U E  F O R  
T H E  P R E P A R A T I O N  O F  E V E R T E D  J E J U N A L  S A C S
SMOOTH 
G L A S S  ROD S E R O S A
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held in artery clamps. Oxygenated incubation medium (4ml) at 
4°C was allowed to flow into the sac at the other end from a 
gravity feed pipette, after which this end, too, was sealed 
using artery clamps. The resultant large sac was divided into 
approximately 8 x 3cm sacs by ligatures, taking care to 
exclude Peyers patches (gut associated lymphoid tissue) which 
may have interfered with uptake studies. Each sac was then 
separated and incubated singly, as described for yolk sacs 
(section 2.6), but for an incubation period of 1.5h in all 
cases and with the addition of ImM ATP to the culture medium.
Following incubation, each gut sac was removed, gently blotted, 
held vertically by forceps over a 30ml Universal container, and 
snipped at the base with fine scissors in order to collect 
incubation medium present in the serosal space. The volume of 
the serosal fluid was measured using a 1ml syringe. Any sacs 
that had leaked were discarded. Serosal fluids were 
transferred to disposable 3ml (Luckham) tubes, stoppered, 
assayed quickly for radioactivity and then stored at -20°C 
prior to column chromatography (section 2.5). Empty sacs were 
washed four times in approximately 30ml of ice-cold 1% NaCl to 
remove extracellular substrate and placed in 25ml volumetric 
flasks. Two 1ml samples of culture medium were pipetted into 
Luckhams tubes and stored at 4°C until assayed for 
radioactivity. When studying possible degradation of a 
substrate, a further three 1ml samples of medium were collected 
in the same way, but stored at -20°C until assayed. Gut sacs 
were made up to 25ml with IN sodium hydroxide and assayed for 
both radioactivity and protein in the same way as that 
described for yolk sacs (sections 2.2 and 2.6) except that 
values for 0.1ml protein were multiplied by a factor of 250 
to give total gut sac protein.
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2.8 QUANTITATION OF THE PINOCYTIC UPTAKE OF A NON-DEGRADABLE 
SUBSTRATE BY THE YOLK SAC AND JEJUNAL SAC
The following method of quantitation of pinocytic uptake was 
used for both yolk sac and gut tissues.
Following incubation« 1ml samples of tissue solution (yolk sac
or jejunum)« and the corresponding samples of culture medium
were assayed for radioactivity with a gamma counter and the
total tissue protein estimated (sections 2.2« 2.6 and 2.7).
The accumulation of substrate at each time interval was
expressed as a clearance« defined as the volume of culture
medium (pi) whose contained substrate was captured per mg of
tissue protein. The following equation was useds-
U = Y 
M x P
where U = uptake (pl/mg protein)
Y = total tissue radioactivity (counts per min 
corrected for background)
M = radioactivity per pi of culture medium (counts per 
min corrected for background)
P = protein content (mg).
This calculation was carried out using the computer programme 
shown in Appendix 1.
125With a non-degradable substrate, such as I-PVP, uptake was 
consistently found to be linear with time. A best-fit 
regression line was used to describe the relationship and a 
correlation coefficient calculated.
-48-
2.9 QUANTITATION OF THE PINOCYTIC UPTAKE OF A DEGRADABLE 
SUBSTRATE BY THE YOLK SAC AND JEJUNAL SAC
In experiments using degradable substrates, tissue uptake was 
often found to be non linear with time. In such cases, uptake/ 
time plots were prepared from a series of experiments using 
mean uptake values at each time interval, and subsequent 
experiments performed to assess the extent of degradation of 
any substrate incubated over a given time period.
Radiolabelied copolymer 74 and 39 fractions contained
125potentially degradable sequences which included I-tyrosine
, , 125residues. It was therefore possible to identify I-labelled 
low molecular weight degradation products present in the 
medium when these copolymers were incubated with either yolk 
sac or jejunal sacs, and so assess the total pinocytic uptake 
by these tissues.
This was achieved by incubating 6-10 yolk sacs in a single
flask (section 2.6) for 5h, or 2 gut sacs in a single flask
125for 1.5h (section 2.7) with I-labelled copolymers and 
estimating tissue accumulation of substrate as described in 
section 2.8. Samples of culture medium (1ml) were assayed for 
radioactivity and then applied to a Sephadex G-15 column 
(section 2.5). Elution with 0.05M sodium acetate yielded 1ml
fractions which were counted for radioactivity. Columns were
125calibrated with blue-Dextran, I-labelled HPMA copolymer, 
[125l] iodide and 3-iodo-L-tyrosine, and other radiolabelled 
molecules where deemed necessary. The extent of degradation 
was calculated from the elution profiles by expressing the 
amount of radioactivity present in peaks corresponding to low 
molecular weight degradation products as a percentage of the 
total radioactivity recovered from the column. This percentage
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was expressed in terms of pi of culture medium per mg of 
tissue protein.
The true pinocytic uptake of the degradable substrate was then 
obtained by summing the values for tissue accumulation and for 
degradation product (both in terms of pl/mg protein) over the 
period of incubation, in the case of yolk sacs i.e.
True Pinocytic Uptake = Tissue Accumulation + Degradation
across the jejunum (serosal accumulation) is discussed in
Products in 
Culture Medium
protein)
In the case of jejunal sacs
True Pinocytic Uptake = Tissue Accumulation + Serosal
Accumulation
(pl/mg protein) (pl/mg protein) (pl/mg protein)
+ Degradation Products in Culture Medium 
(pl/mg protein)
The quantitation of transport of 125I-labelled substrates
section 2.10
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2.10 QUANTITATION OF TRANSPORT OF 1251-LABELLED HPMA 
COPOLYMERS ACROSS THE RAT JEJUNUM
The transport of molecules across the rat jejunum was
calculated using the equation
U * Y 
M x P
where U = the quantity of radioactive substrate accumulated in 
the serosal fluid in a given time (pl/mg protein)
Y = the total radioactivity in the serosal fluid (counts 
per min corrected for background)
M = radioactivity per ul of culture medium (counts per 
min corrected for oackground)
P = protein content (mg)
125In experiments usxng I-PVP, a non-degradable substrate, the 
values obtained represented the transport of the intact 
macromolecule across the gut, and uptake was found to be linear 
with time. A best fit regression line was used to describe the 
relationship and a correlation coefficient calculated.
When using degradable substrates, the values obtained using the 
equation represented both transport of macromolecules and also 
transport of low molecular weight degradation products. 
Accumulation/time plots were found to be linear with time, but 
further experiments were necessary in order to identify and 
quantify the proportion of low molecular weight degradation 
products. This was achieved by Sephadex G-15 column 
chromatography (section 2.5).
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2.11 IN VIVO METHODS
2.11.1 Intravenous Injections
Male Wistar rats of 200—250g body weight were used. A rat, 
under light ether anaesthesia, was placed on its back and a 
small incision of approximately 1.5mm was made in the left 
groin. The left femoral vein was carefully exposed by removal 
of surrounding tissue. Radiolabelled substrate (O.lml) was 
injected into the vein with a sterile disposable syringe 
fitted with a 25 gauge needle. Following injection, a swab 
was held over the area to staunch any bleeding.
2.11.2 Intraperitoneal Injections
Male Wistar rats of 250-350g body weight were used for these 
experiments. Up to 0.5ml of radiolabelled substrate was 
taken into a sterile disposable syringe fitted with a 25 gauge 
needle. Each rat, under light ether anaesthesia, was placed 
on its back and injected by pinching the skin of the abdomen, 
lifting and injecting the solution through the skin into the 
peritoneal cavity. Care was taken not to penetrate the gut or 
any other organ. The animals were allowed to recover and 
placed in metabolic cages.
2.11.3 Subcutaneous Injections
Male Wistar rats of 200-250g body weight were used. Animals 
were placed under light ether anaesthesia and laid on the 
abdomen prior to injection. Radiolabelled substrate (O.lml) 
was injected subcutaneously at the back of the neck. Animals 
were then allowed to recover and placed in metabolic cages.
2.11.4 Oral Administration
Male Wistar rats of 200-250g body weight were used. Each 
animal was placed under light ether anaesthesia and laid on its
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back prior to administration of copolymer. Up to 0.5ml of 
radiolabelled substrate was taken into a sterile disposable 
l.Oml syringe fitted with narrow gauge flexible silicone 
rubber tubing. The tubing was carefully guided through the 
mouth, down the oesophagus and the substrate administered 
directly into the stomach. Animals were then allowed to 
recover and placed in metabolic cages.
2.11.5 Collection and Analysis of Blood from Experimental Rats 
Following oral administration or injection of radiolabelled 
copolymers (intraperitoneal » intravenous or subcutaneous), rats 
were held under ether anaesthesia when the collection of blood 
samples were undertaken. A small incision was made in the 
right foot pad and samples of blood were collected in two SOpl 
heparinised tubes (Hawkesley & Son Ltd., Lancing, Sussex.). 
Bleeding was quenched by a tourniquet. Further blood samples 
were taken by temporarily loosening the tourniquet. Each blood 
sample was dispersed in 1ml distilled water contained in a 3ml 
disposable Luckhams tube» stoppered» and assayed for radio­
activity.
2.11.6 Collection and Analysis of Radioactive Tissue Samples 
Following intravenous or subcutaneous injection of radio- 
labelled copolymers and the collection of blood samples» rats 
were sacrificed by cervical dislocation whilst under ether 
anaesthesia. The liver, lungs, kidneys and spleen were 
removed, quickly rinsed in 1% NaCl (approximately 20ml), 
blotted and weighed. Between 5 and 30ml of distilled water 
was added to each tissue (dependent on tissue weight) and each 
was homogenised in a Potter-Elvejhem Teflon/glass homogeniser 
(Tri-R Instruments Inc., New York) at 3,500rpm (speed setting
3.5). The final volume of each suspension was noted and 
duplicate samples (1ml) from each tissue were assayed for
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radioactivity.
At the end of the experimental period following intraperitoneal 
injections, rats were sacrificed by chloroform asphyxiation 
(since cervical dislocation or prolonged ether anaesthesia may 
cause internal bleeding) and the recovery of residual radio­
active substrate present within the peritoneal cavity was 
attempted. Each rat was placed on its back and a flap of skin 
reflected from the abdomen, taking care not to puncture the 
body wall. 10ml of 1% NaCl was injected into the peritoneal 
cavity from a sterile disposable syringe fitted with a 25 gauge 
needle, avoiding the penetration of any organs. The abdomen 
was then massaged for 1 min. The liquid was then withdrawn 
from the peritoneal cavity by penetrating the body wall at the 
side of the flap with a Pasteur pipette placed at an angle of 
about 30° to the bench. An average recovery of approximately 
7ml of the injected saline solution was made. The solution was 
then centrifuged in an MSE bench-top centrifuge for 10 min at 
1,000rpm (200G)• The supernatant was poured off and the 
remaining pellet (consisting predominantly of peritoneal 
macrophages) was resuspended to a final volume of 1ml and 
assayed for radioactivity. Two 1ml samples of the supernatant 
were transferred to Luckhams tubes and assayed for radio­
activity, and two further 1ml samples were stored at -20°C 
prior to column chromatography. Counts for both supernatant 
and cells were corrected to lOml. The collection and analysis 
of liver, lung, kidneys and spleen was essentially as 
described above, with the exception that these organs were 
washed more thoroughly (3 x 20ml X% NaCl) in order to remove 
any radioactivity that may have adsorbed to the tissues 
following injection into the peritoneal cavity. In addition to 
the organs previously mentioned, the entire small intestine was 
removed, rinsed through with 10ml \% NaCl using a plastic
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disposable syringe, washed and treated exactly as above. Gut 
washings were also retained and assayed for radioactivity.
Rats subjected to oral administration of radiolabelled 
copolymer were sacrificed by cervical dislocation following 
ether anaesthesia. Liver, lungs, kidneys, spleen and small 
intestine were removed and analysed as described above.
In all experiments where recovery following administration of 
radiolabelled copolymers was allowed, each rat was placed in a 
metabolic cage and allowed free access to food and water until 
the end of the experiment. Total urine and faeces were 
collected in all cases. The volume of urine was noted, two 1ml 
samples were assayed for radioactivity, and whenever possible 
three 1ml samples were stored at -20‘c. prior to column 
chromatography. Faeces samples were weighed, homogenised and 
duplicate 1ml samples assayed for radioactivity.
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2.12 PREPARATION OF TRITOSOMES
Tritosomes were prepared according to the method described by 
Trouet et al (1974).
Five male Wistar rats of approximately 400g body weight were 
injected intraperitoneally with Triton WR 1339 (20% w/v in 
saline - lml/lOOg rat body weight) whilst under light ether 
anaesthesia. The animals were allowed to recover and left 
for three days with free access to food and water, and were 
starved overnight on day 3-4.
On day 4 the animals were sacrificed, their livers removed 
and placed in 0.25M sucrose on ice. All following experimental 
procedures were carried out at 4°C.
The livers were washed, blotted, chopped with scissors and 
sieved. The total liver weight was noted. The tissue was 
suspended in 0.25M sucrose (5ml/g tissue) and homogenised 
(3 passes) using a teflon/glass homogeniser. The resultant 
suspension was centrifuged in an MSE 4L centrifuge for 10 min 
at 1,650 rpm. The supernatant was stored on ice, and pellets 
resuspended in 0.25M sucrose (3ml/g tissue) and centrifuged 
for 10 min at 1,400 rpm. Supernatants were pooled and 
centrifuged at 17,000 rpm for IO min in an MSE HS 18 centrifuge. 
Again, pellets were washed by resuspending in 0.25M sucrose 
(5ml/g tissue) and centrifuged at 17,000 rpm for 10 mins. 
Supernatants were this time discarded and the pellets were 
resuspended in 45% sucrose (lml/g tissue). Approximately 10ml 
of the suspension was placed in each of three centrifuge tubes, 
and approx. 7ml of 34.5% sucrose followed by approx. 4ml of 
14.3% sucrose were layered above. The tubes were balanced and 
subsequently centrifuged at 25,000 rpm for 2h in an MSE
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Super speed 50 centrifuge.
Tritosomes, visible as a turbid band of material, were 
recovered from the interface between the 34.5% and the 14.3% 
sucrose. Tritosomes were removed carefully, pooled, and 1ml 
aliquots taken and stored at -20°C. Approximately 16ml total 
volume of tritosomes were recovered.
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2.13 ESTIMATION OF CROSSLINK CLEAVAGE OF HPMA COPOLYMERS
The estimation of the amount (%) of cleaved bonds was carried 
out as described by Bohdanecky et al (1974), and is based on 
Stockmeyer's conclusions (1944). The calculation involves the 
determination of the average molecular weight and number 
average of the polymer precursor (section 3.4), of the cross- 
linked polymer, and of the polymer obtained following enzymatic 
cleavage.
The relationship between these values is as follows
(1)
(2 )
(3)
the weight average and number 
average of the polymer precursor
the weight average and number 
average of the crosslinked or 
cleaved polymer
the crosslinking index i.e. the 
number of crosslinked units per 
primary chain
the network density i.e. the molar 
fraction of the crosslinked units.
Yw and small^
(%) =
lQO _ crosslinking density of cleaved polymer____
crosslinking density of crosslinked polymer* x "
* i.e. the crosslinked copolymer before enzymatic cleavage.
Bohdanecky et al (1974) obtained a simpler relationship for 
the calculation of cleaved bonds by rearranging (4) assuming 
that
a) polymer precursors contain a small amount of comonomers 
with reactive groups (in this case approx. 7% mol).
Xn = Yn (l - X/2)
Xw = Yw (1 -*f Yw/Yn)
t = Yn.t
where Yw,Yn, respectively ■ 
Xw,Xn =
Y
S
Equation (2) holds for high 
The amount of cleaved bonds
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b) the difference between the average weight of the monomer 
unit in the precursor and the crosslinked polymer is 
negligible
c) it is therefore possible to introduce the average weight of 
the monomer unit (150).
On making these assumptions the equation can be simplified to
The % of cleaved bonds lOO -
ww aminoivsea precursor 
Mw cleaved polymer 
ftw aminolvsed precursor 
m r  crosslinked polymer
x lOO
The calculation of the average molecular weight of copolymer 
following enzymatic cleavage is described in Chapter 8.
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3.1 INTRODUCTION
This chapter describes the copolymers used in the present 
study, and reports experiments carried out to ascertain the 
suitability of the copolymers for radioiodination and their 
subsequent use in a variety of in vitro and in vivo experimental 
methods.
All soluble poly N-(2-hydroxypropyl)methacrylamide copolymers 
used in this study were synthesized and donated by Dr J Kopecek 
and Dr P Rejmanova of the Institute of Macromolecular Chemistry, 
Czechoslovak Acadamy of Sciences, Prague, Czechoslovakia. The 
synthesis, structures find characteristics of the copolymers 
used are discussed in sections 3.2 and 3.5, and the information 
presented in those sections, unless otherwise stated, was 
received from the Institute of Macromolecular Chemistry in 
Prague.
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3.2 SYNTHESIS AND STRUCTURES OF SOLUBLE CROSSLINKED HPMA 
COPOLYMERS
All the polymeric materials used in this study were derived 
from initial reactive copolymers (polymer precursors) 
synthesized by copolymerization of N-(2-hydroxypropyl) 
methacrylamide (HPMA) with p-nitrophenyl esters of either 
N-raethacryloylated oligopeptides or N-methacryloylated amino 
acids (Rejmanovâ et al 1977, Kopecek et al 1977). The content 
of the reactive groups was only several % mol. in all cases.
For example, the preparation of the polymer precursor used in 
the synthesis of copolymers 39 and 74 is by the copolymerization 
of HPMA with p-nitrophenyl ester of N-methacryloylglycylglycyl- 
phenylalanine (shown in fig 3.1).
To prepare polymers with degradable crosslinks, the copolymers 
of HPMA p-nitrophenyl ester of N-methacryloylated oligopeptides 
were reacted with hexaraethylenediamine (HMDA). This procedure 
results in the formation of crosslinks, intramolecular 
cyclization and free NH^ groups. In the case of copolymer 39 
the crosslinking agent was N,N^-dityrosyl HMDA, and the ratio 
of polymer—bound ONp groups to diamine NH^ groups was 1<1. 
Reaction conditions were chosen so that the degree of cross- 
linking did not exceed the gel point. 14.7% of the initial 
side-chains (P-Gly-Gly-Phe-ONp) were connected by intermolecular 
crosslinks (section 2.13), the rest formed intramolecular 
bridges or were aminolysed with 1—amino—2-propanol. The 
crosslinking procedure is shown in fig 3.2.
Copolymer 74 was prepared from the same polymer precursor, 
which was reacted with tyrosinearoide to form a copolymer 
with sidechain composition P-Gly-Gly-Phe-TyrNH^.
SYNTHESIS OF HPMA COPOLYMER PRECURSOR P-Glv-Glv-Phe-ONp
c h2=c -c o -n h-c h
azoinitiator
oacetone 50 C
?“ 3
-CH-CH_ + CH=C-CO-R-ONp  : | 3 2
OH
OH
C H -C -C O -N H -C H —CH-CH 3 I £ 3
CH,
CH,—C—CO-R-ONp
3 ICH. OH
I I
CH -C —CO -NH -CH —CH-CH,3 | ^ —
CH_
(R = Gly-Gly-Phe)
FIGURE 3.1
■SYNTHESIS OF CROSSLINKED COPOLYMER 39
Intramolecular cycle
Aminolysed
sidechain Crosslink
FIGURE 3.2
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The general scheme for the preparation of crosslinked copolymers 
78 and 79 is shown in fig 3.3.
Copolymer 68 is of a similar structure to copolymer 79, but 
reaction conditions were employed to give a greater density of 
crosslinks.
The structures of the crosslinks contained in copolymers 39,
68, 78 and 79 are shown in Table 3.1. The sidechain 
composition of copolymer 74 is also shown in Table 3.1.
This table is reproduced for quick reference on the last page 
of this thesis.
SYNTHESIS OF SOLUBLE CROSSLINKED COPOLYMERS 78 AND 79
HPMA+MA-Ty rNH2 +MA-G1y-G1y-ONp
x 1
\-TyrNH,
rly-GIy-ONp
1.
1. +(H Phe)2HMDA
l
HPMA a Poly N-(2-hydroxypropyl)methacrylamide
MA-TyrNH2 = N-methacryloyltyrosinamide
MA—Gly—Gly~ONp = N-methacryloylglycylglycine p-nitrophenolester
(H Phe)2HMDA = N,N^-bis(H-Phe)hexamethyldiamine
FIGURE 3.3
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3.3  RADIOLABELLING EFFICIENCIES OF COPOLYMERS USING 
CHLORAMINE T
Each copolymer was radiolabelled using Chloramine T (section 2.3) 
on several occasions. The efficiency of labelling was 
estimated on each occasion by calculating the percentage of
residues contained within the copolymer during the reaction. 
This estimate was carried out by subjecting a small amount 
(28 fx 1) of the reaction mixture to paper electrophoresis 
(section 2.4). The remainder was dialysed against 1% NaCl to
The labelling efficiencies of the copolymer preparations 
radiolabelled throughout this project are summarised in Table 
3.2. From these results it can be seen that copolymers that 
contain the tyrosine residue attached directly to the polymer 
backbone (68, 78, 79) show consistently lower labelling 
efficiencies than those where the tyrosine residue is present 
as the fourth amino acid of a crosslink (copolymer 39 fractions). 
This could be the result of steric influences during the 
labelling procedure, where the tyrosine residues present in
the total which became bound to the tyrosine
remove the excess free
the crosslinks are more accessible to the than
those close to the polymer backbone
TABLE 3.2
THE EFFICIENCY OF RADIOLABELLING COPOLYMERS USING CHLORAMINE T
LABELLING EFFICIENCY (%)
POLYMER CODE NO. 1 2 3 4 5 6 *
39 (unfractionated) 66
39a 56
39b 57
39c 56
39d 53
39e 39
74 28
68 16
78 19
79 15
N,N^-dityrosyl-HMDA 45
* Numbers 1-6 denote separate 
were radioiodinated.
43 47 45
56 45
61 27
42 40
46 56
21 41 29
28
16 12 8
17 11
25 18
96
occasions on which copolymers
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3.4 CHARACTERISTICS OF CROSSLINKED COPOLYMERS AND COPOLYMER 74
Polymers are generally composed of molecules of similar 
monomer units, but of various chain lengths. The diversity of 
molecular sizes is further increased on crosslinking polymer 
precursors. It is therefore necessary to describe polymers in 
terms of average molecular weight and to give an indication of 
the distribution of polymer sizes. The polydispersity of a 
polymer preparation caui be indicated by /fii i.e. average 
molecular weight divided by the average number of molecules.
The average molecular weight and /Mn of each copolymer used 
are shown in Table 3.3.
In order to study the possible effect of molecular size on the 
pinocytic uptake of polymers by different tissues, copolymer 
39 was fractionated, in Prague, using Sepharose 6B gel 
permeation chromatography to give five samples whose 
characteristics are shown in Table 3.3. It was not possible 
to estimate the size of copolymer 39a, which eluted largely 
in the void volume of the column used. For this reason, 
neither was it possible to estimate the polydispersity of the 
preparation.
Copolymer 74 (P-Gly-Gly-Phe-TyrNH2) was synthesized from the 
same polymeric precursor as copolymer 39 and it can be seen 
from Table 3.3 that this copolymer and copolymer 39 fractions 
b-e all show a low polydispersity, four of them giving a value 
of less than 2. This was a desirable feature for the purpose 
of the proposed study.
Copolymers 39 (unfractionated), 68, 78 and 79 all contain a 
broader range of molecular sizes, as indicated by the /Mn
values
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Radiolabel led copolymer preparations were subjected to 
Sepharose 4B/6B column chromatography (column length 60cm, 
16mm internal diameter, flow rate 20ml/h) in order to observe 
the molecular weight distribution patterns. The results are 
shown in figs 3.4-3.13. These elution profiles compared 
extremely well with those obtained in Prague for the same 
(unlabelled) compounds using Sepharose 4B/6B chromatography 
and detection with a Knauer Differential Refractometer. This 
comparison demonstrated that molecules of all sizes within a 
preparation were radiolabelled to a similar extent, and 
therefore that a true representation of the molecular weight 
distribution of all samples could be obtained using radio- 
labelled copolymer preparations.
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FIGURE 3.4
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S E P H A R O S E  A B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
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FIGURE 3.5
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FIGURE 3.6
S E P H A R O S E  4 B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  39b
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FIGURE 3.7
S E P H A R O S E  ¿ B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
1 25I - L A B E L L E D  C O P O L Y M E R  39 c
R
A
D
IO
A
C
T
IV
IT
Y
FIGURE 3.8
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FIGURE 3.9
S E P H A R O S E  4 B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  39c
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FIGURE 3.10
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FIGURE 3.11
S E P H A R O S E  A B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  68
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FIGURE 3.12
S E P H A R O S E  ¿ B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  7 8
F R A C T I O N  N U M B E R
R
A
D
IO
A
C
T
IV
IT
Y
FIGURE 3. 13
S E P H A R O S E  ¿ B / 6 B  C O L U M N  C H R O M A T O G R A P H Y  O F  
1 2 5 I - L A B E L L E D  C O P O L Y M E R  79
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3.5  THE STABILITY OF RADIOLABELLED COPOLYMER 39 PREPARATIONS 
AT 4dC
Following radioiodination, copolymer preparations were
1
125 "1 oIIiodide, and stored at 4 C
prior to use. In order to assess the stability of the label 
during storage, preparations were periodically checked for 
free [125l] iodide using paper electrophoresis. A typical 
result (copolymer 39c after 4 weeks of storage) is shown in 
fig 3.14 and all results obtained for copolymer 39 fractions 
over a six week period are summarized in Table 3.4. It can be 
seen that the free 25i] iodide levels increase by < 1% per 
week during storage. This was an acceptable amount for the 
proposed studies, although care was taken to dialyse 
preparations periodically in order to remove free £ 2 ij iodide 
prior to use following long periods of storage.
FIGURE 3.14
L O W  V O L T A G E  P A P E R  E L E C T R O P H O R E S I S  O F
1 2 5 I - L A B E L L E D  C O P O L Y M E R  39c F O L L O W I N G  
S T O R A G E  A T  4 ° C  F O R  F O U R  W E E K S
TABLE 3.4
STABILITY OF 125I-LABELLED COPOLYMER 39 FRACTIONS ON 
STORAGE AT 4°C OVER A SIX WEEK PERIOD
POLYMER 
CODE NO.
% [125l] IODIDE CONTENT OF PREPARATIONS AFTER
1 WEEK 4 WEEKS 6 WEEKS
39 (un) 0.62 1.53 1.80
39a 1.06 2.90 2.97
39b 1.07 2.62 3.66
39c 2.90 3.62 5.10
39d 2.18 3.80 5.90
39e 1.92 4.61 5.05
3.6 THE STABILITY OF RADIOLABELLED COPOLYMER PREPARATIONS IN 
TISSUE CULTURE MEDIUM (MEDIUM 199 WITH 10% CALF SERUM)
AT 37ÜC
Since almost all experiments performed using organ culture 
systems involved the incubation of copolymers at 37°C in medium 
Tcl99 containing 10% calf serum, experiments were carried out 
to test the stability of the[125ij label of the copolymer under 
those conditions. The release of [125ij iodide and/or [_125lJ 
iodotyrosine was also monitored.
All copolymers used for organ culture experiments were therefore 
assessed for free [^ 2 l^J iodide both before and after incubation 
for 5h in 10 ml of Tcl99 containing 10% calf serum (62.5 pg/ml), 
using Sephadex G-15 column chromatography. A typical elution 
profile following incubation of copolymer 39a is shown in 
fig 3.15 and results are summarized in Table 3.5.
From the results, it is apparent that a very small increase in 
free p"2 i^| iodide occurs during a 5h incubation period (2% or 
less) and that no P 54  iodotyrosine is released from the 
preparations under the experimental conditions.
Copolymer 39e was tested under the same experimental conditions 
for 12h. During this period there was an increase of 3.36% in 
total free ^ 25ij iodide, but f1251] iodotyrosine was not 
released from the preparation under the experimental conditions 
in the absence of tissue.
From these results, it was concluded that the copolymer 
preparations were suitable for use under the given experimental
conditions
S E P H A D E X  6 - 1 5  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  3 9 a  I N  M E D I U M  1 99  
( ♦ 1 0 %  C A L F  S E R U M )  F O L L O W I N G  I N C U B A T I O N  A T  
3 7 ° C  F O R  5 H
: f 2 5 l ] l O D O T Y R O S I N E
AO 60
F R A C T I O N  N U M B E R
FIGURE 3.15
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3.7  THE STABILITY OF RADIOLA BELLED COPOLYMER PREPARATIONS 
TN RAT PLASMA
It is important to establish that crosslink cleavage takes 
place only within lysosomes, and not in the circulation. Also, 
it is necessary that the radiolabel remains attached to 
125I-labelled copolymers in the bloodstream in order to 
monitor levels of radioactivity effectively.
An in vitro method was used to investigate the stability of
125copolymers to be used in in vivo studies i.e. I-labelled 
copolymers 39, 78 and 79 in plasma.
Radiolabelled copolymer (62.5 fig in 0.1 ml.05M phosphate buffer 
pH 8.0) was added to tubes containing 1 ml of rat plasma, and 
incubated for O, 1, 5 and 24h at 37°C. Following incubation, 
plasma proteins were precipitated with 0.5 ml 20% trichloro­
acetic acid (TCA), the tubes centrifuged at 2 ,000g for 20 min, 
and the resultant supernatant applied to a Sepharose 4B/6B 
column (length 60cm, I.D. 16mm, flow rate 20 ml/h).
No differences were observed in the molecular weight 
distributions of copolymers before and following incubation 
with rat plasma. A typical elution profile is shown in fig 
3.16 and results are summarized in Table 3.6.
Sepharose 4B/6B chromatography does not discriminate between
The second peak present in the elution profiles at t—0 is due
increase in the size of the second peak during the experimental
presented, it can be seen that no significant increase in the
the smaller molecules i.e £125l] iodotyrosine.
to the presence of iodide in the preparation. Any
period could be due to the release of [125lJ iodide or 
r 25lj iodotyrosine from the copolymer. From the results
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FIGURE 3.16

second peak of radioactivity is detected for polymers 78 and 79
during a 24h incubation with plasma. This indicates that 
neither [125ll iodide or [125l] iodotyrosine is released during
that period. It can therefore be concluded that administration 
of polymer containing no free iodide to rats in vivo for up to 
24h, will result in the recovery of blood radioactivity that
This copolymer may be crosslinked or may have had its crosslinks 
cleaved following pinocytosis, digestion and exocytosis by cells.
Copolymer 39, on the other hand, released small molecules 
(5.2% of the total amount of radioactivity present) within the 
first hour of incubation in rat plasma. This radioactivity 
could be free [12'*l] iodide or ^ 25lJ iodotyrosine, or both, 
since no free £*"25l] iodide was detected in the preparation at 
the beginning of the experiment. This value does not increase 
beyond the first hour of incubation. The experiment was 
performed once only because of the difficulty involved in 
obtaining large volumes of rat plasma. It is therefore 
possible that the column chromatography result given for t=0 ,
preparation, was questionable. However, since the release of 
small molecules was confined to the first hour of incubation 
with no subsequent release, and the first time-point in 
subsequent in vivo studies was lh, it could be assumed that 
increases in low molecular weight substances recovered after 
that time would be due to the degradation of copolymer 39 
crosslinks by lysosomal enzymes to yield free l125»} iodotyrosine.
represents copolymer and not
which indicated that no

CHAPTER 4
PINOCYTIC UPTAKE AND INTRACELLULAR 
DEGRADATION OF 125I-LABELLED HPMA 
COPOLYMERS BY THE RAT VISCERAL 
YOLK SAC IN VITRO
-70-
4.1 INTRODUCTION
This chapter reports experiments on the pinocytosis and 
intracellular handling of crosslinked polymers. The specific 
questions investigated are the following*
1. Are crosslinked copolymers pinocytosed by cells?
2. If so, is the mechanism responsible fluid-phase 
pinocytosis, or adsorptive pinocytosis?
3. If pinocytosis does take place, is the rate of uptake 
dependent on the size of the copolymer?
4. Are crosslinked copolymers hydrolysed within the 
lysosomes ?
5. If so, is the extent of degradation dependent on the size 
of the copolymer?
Quantitative studies on pinocytosis can be achieved by both 
in vitro and in vivo methods. In vivo methods are less 
satisfactory in that interpretation is complicated by the 
differing rates of pinocytic uptake of substrates into 
different tissues, the clearance of low molecular weight 
substrates by the kidney, and the possible metabolism of 
radiolabelled substrates over the experimental period. For 
reasons such as these, it is better to commence studies on 
pinocytosis of a given substrate using a well documented, 
reliable in vitro method.
The rat visceral yolk sac has been used extensively as an in 
vitro model system for the quantitative study of pinocytosis. 
The method, which has been described in Chapter 2, was 
published in 1975 by Williams, Lloyd and coworkers, and is 
used routinely for investigations on fluid-phase pinocytosis, 
adsorptive pinocytosis, auid intralysosomal protein
degradation
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The yolk sac is a highly pinocytic tissue which plays an 
important role in histotrophic embryonic nutrition in the rat, 
particularly during the period between implantation of the 
embryo into the uterine wall and the formation of a fully 
functional chorio-allantoic placenta (Freeman et al 1981).
Until the 16th day of gestation, the yolk sac is composed of 
parietal and visceral yolk sac tissue (fig 4.1), after which 
the parietal yolk sac membrane is shed, leaving the visceral 
yolk sac in direct contact with the uterine cavity.
The visceral yolk sac is comprised of three layers of cells 
(fig 4.2) . The outer visceral endoderm of columnar
epithelial cells demonstrate an extensive microvillous 
structure at the apical membrane, and rest on a basement 
membrane. Secondly, the mesenchymal layer, which rests on 
the serosal basement membrane, contains scattered mesenchymal 
cells interspersed with vitelline blood capillaries. Finally, 
a thin layer of mesothelial cells are present which line the 
extra-embryonic coelom.
It is the microvillous epithelial cells found on the outer 
surface of the yolk sac which are in contact with the uterine 
cavity and which are responsible for the pinocytosis of 
macromolecules derived from the uterus. These molecules are 
degraded within lysosoraes to provide smaller nutrients for 
the growing embryo.
The 17.5 day yolk sac is easy to maintain in organ culture 
for periods of time up to 12h without loss of structural 
integrity or pinocytic capacity. The yolk sac cultured in 
vitro has been used to study the pinocytic uptake of various 
proteins including 125I-labelled bovine serum albumin (BSA), 
hen egg-white lysozyme, bovine pancreatic ribonuclease A a
the d e v e l o p m e n t  of foetal m e m b r a n e s
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bovine insulin (Livesey and Williams 1977 , Forster 1982).
The rate of pinocytic uptake was different for each protein,
but all substrates demonstrated rapid uptake, indicating some
degree of adsorption of substrate to the plasma membrane prior
to vesicle formation. Williams et al (1975b) have shown that
125pinocytosis of formaldehyde-treated I-labelled BSA by yolk 
sacs is followed by intracellular digestion with the release 
of radiolabelled degradation products back into the medium, 
predominantly as [125l]iodotyrosine. There was no progressive 
accumulation of radioactivity in the tissue itself after an 
initial period of approximately 2h. This indicated an exact 
balance between the rate of uptake and the rate of degradation 
after 2h. The possibility of exocytosis of undigested protein 
was investigated by incubating the yolk sacs for 3h in medium 
with 125I-BSA, to achieve maximum tissue levels, and 
subsequently washing and re-incubating the yolk sacs in fresh 
medium without substrate. No release of undigested protein 
was found to occur. The total pinocytic uptake of the protein 
was therefore calculated by summing the tissue levels of 
labelled substrate and the quantity of radiolabelled 
degradation products released by the tissue, and was found to 
be linear with time.
125Studies using 125I-labelled polyvinylpyrrolidone ( I-PVP) 
have shown this to be a useful marker for fluid-phase 
pinocytosis in the 17.5 day rat yolk sac (Williams et al 1975a) 
125I-PVP is a non-degradable polymer which has been shown to 
accumulate within lysosomes following pinocytic uptake by cells 
(Roberts et al 1977). Uptake of this substrate is linear with 
time, and the rate shows minimal inter-experiment variation.
The rate of exocytosis of 125I-PVP is insignificant when 
compared to its rate of pinocytosis (< 1% per hour of that
pinocytosed) (Williams et al 1975a). It was therefore chosen
as a control with which to compare uptake values obtained for 
125pinocytosis of I-labelled crosslinked HPMA copolymers.
As discussed in Chapter 1, many factors govern the rate at 
which a substrate is pinocytosed by cells. These include non­
specific effects such as the size, charge and hydrophobicity 
of the molecule, and also the presence of moieties that may 
interact with cell-surface receptors, giving rise to enhanced 
uptake by receptor-mediated pinocytosis. These factors have 
been explored using synthetic polymers as substrates. HPMA 
copolymers of Mw 30,000 consisting of a single copolymer chain 
and containing oligopeptide side chains have been shown to be
pinocytosed by the rat visceral yolk sac and to enter cells
125at a rate similar to that observed with I-PVP of Mw 40,000 
(Duncan et al 1981). This finding indicates that HPMA 
copolymers of that size do not interact with the cell membrane 
but are taken up by fluid-phase pinocytosis.
Duncan et al (1981) also examined the effect of molecular size 
of 125I-PVP on its pinocytosis by rat visceral yolk sacs and 
rat peritoneal macrophages in vitro. Polymers of four mean 
molecular weights of 50,000, 84,000, 700,000 and 7,000,000 
were used, and it was shown that macrophages preferentially 
captured the very high molecular weight fractions, whereas 
yolk sacs captured the lowest molecular weight preparations 
most rapidly. From this study, it was apparent that these 
cells, at least, can specifically select substrate of a 
preferred size from a range of otherwise identical molecules 
during fluid-phase pinocytosis.
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The first experiments in the present work were to ascertain 
whether crosslinked HPMA copolymers could be pinocytosed by 
cells. Accordingly, copolymer 39 (crosslink structure 
P-Gly-Gly-Phe-Tyr-HMDA-Tyr-Phe-Gly-Gly-P) (see Fig 3.2) was 
radiolabelled and studied using the rat visceral yolk sac 
system. The possibility of the size of the molecule having 
an effect on its rate of uptake was also investigated by 
fractionating copolymer 39 (using Sepharose 6B chromatography) 
to produce five samples of Mw 34,000, 110,000, 150,000, 400,000 
and >400,000, before radioiodination and subsequent uptake 
studies.
Crosslinked copolymer 39 contains tyrosine residues within the
potentially degradable crosslink structure. Rejmanova et al
(1981) have shown that the crosslinks contained within this
copolymer are cleaved by chymotrypsin in vitro, and
preliminary in vivo experiments carried out by the same group
in 1981 indicate crosslink cleavage following intravenous
administration with resultant excretion of copolymer chains of
lower molecular weight in the urine of a test animal. From
125these findings, it would be expected that if the I-labelled
copolymer fractions were pinocytosed by the yolk sac,
intracellular hydrolysis of crosslinks might yield radio-
labelled degradation products of low molecular weight, which
could be detected in the culture medium. Experiments were
therefore carried out to detect any degradation products in
125the culture medium following incubation of I—labelled 
copolymer 39 fractions with yolk sacs.
It is necessary to demonstrate that radioactivity associated 
with tissue following culture with radiolabelled substrates 
is due to pinocytic uptake by the tissue, and not due to the
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substrate binding to the cell surface without internalization
taking place. Furthermore, it is also possible that any
degradation products detected in the culture medium could be
the result of extracellular hydrolytic events. Using
metabolic and enzyme inhibitors, Duncan et al (1981)
demonstrated pinocytic uptake of certain HPMA copolymers 
125containing I-labelled tyrosine residues in potentially
degradable oligopeptide side-chains and the release of
£125lj iodotyrosine back into the culture medium following
incubation with yolk sacs. Uptake was completely inhibited
by 2,4-dinitrophenol (50 pg/ml), a known metabolic inhibitor,
and thiol-proteinase inhibitor leupeptin (40 pg/ml) caused
varying degrees of inhibition of lysosomal hydrolysis
depending on side-chain composition. These inhibition studies
proved that both pinocytosis and intracellular hydrolysis were
taking place, and that the observed results were not due to
extracellular events. Inhibition studies of this type were
1 25carried out using I—labelled crosslinked copolymers.
Copolymer 74 (fflw 31,000) was prepared from the same polymeric 
precursor as copolymer 39, but contains side—chains (rather 
than crosslinks) of the sequence P-Gly—Gly-Phe—TyrNHg. Since 
copolymer 39e (Mw 34,000) was of similar molecular weight to 
copolymer 74, uptake studies on both substrates were carried 
out in order to compare the extent of degradation when the 
same oligopeptide sequence was present in the form of side- 
chains, rather than crosslinks or intramolecular cycles.
Copolymer 68 (Mw 171,000 - crosslink structure 
P-Gly—Gly-Phe—HMDA-Phe—Gly-Gly—P ) was designed in order to 
trace the fate of the copolymer backbone, rather than the 
potentially degradable crosslinks contained within it. Since
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the degradability of crosslinks and side-chains depends on 
both steric and structural factors, and the likelihood of 
enzymatic cleavage increases with increasing distance from 
the copolymer chain (Kopecek 1982 - see Chapter l), it 
appeared unlikely that residues in close proximity to the 
polymer chain would be released by enzymatic hydrolysis. 
Consequently, in copolymer 68, tyrosine residues are attached 
directly to the polymer chain, in the hope of preventing 
enzymatic cleavage.
The lysosomal membrane is impermeable to molecules of 
molecular weight 200-300 (Reijngoud and Tager 1977).
In view of this, any pinocytic uptake of copolymer 68 would 
result in the accumulation of radiolabel within lysosomes, 
since the copolymer chains with attached iodotyrosine
would be too large to pass through the lysosomal membrane, 
unlike free ^ 25lJ iodotyrosine released from tyrosine- 
containing degradable crosslinks or side-chains.
Copolymer 68 was subsequently radioiodinated, and pinocytic 
uptake experiments performed using the yolk sac system.
Experiments were also performed to attempt to demonstrate 
crosslink cleavage within lysosomes following pinocytic 
uptake of 125I-labelled copolymer 68. This was done by 
comparing the molecular weight distribution of the applied 
radiolabelled preparation with the distribution of radio- 
labelled material recovered from homogenised yolk sac tissue 
after incubation with the copolymer.
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4.2 RESULTS
4.2.1 Finocvtic Uptake and Degradation of Copolymer 39
Fractions bv the Yolk Sac: The Effect of Molecular Size
The accumulation of copolymer 39 fractions by the yolk sac 
was measured at various times over a 5h incubation period 
(at 37°C). Yolk sacs were incubated singly in all cases, and 
radiolabelled copolymer (2.5 ^g/ml) was added to each flask 
at the beginning of each experiment.
125Concurrent control experiments were performed using I-PVP 
as substrate.
Figures 4.3 - 4.8 show progress curves for the tissue 
accumulation of radioactivity for each copolymer fraction 
(39a-e) and the unfractionated copolymer 39. Figure 4.9 
combines 4.3 - 4.8. Results are expressed for each time 
point in jil/mg protein (Chapter 2, sections 8 and 9) as a 
mean - S.E. of the uptake values obtained from 6-14 yolk sacs.
These values represent the levels of radioactivity associated 
with the tissue at any given time. They do not necessarily 
represent the total pinocytic uptake of the substrate. If 
digestion of substrate has occurred within the tissue 
following pinocytosis, with the subsequent release of radio- 
labelled degradation products back into the medium, the true 
rates of pinocytosis will in fact be higher than are apparent 
from figs. 4.3 - 4.8.
Inspection of Figs. 4.3 -4 .8 shows that uptake is, to a first 
approximation, linear with time. Making that assumption, 
rates of uptake can be calculated and these are given in 
Table 4.1. There is clearly a marked decrease in the rate of 
accumulation with increasing molecular weight.
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Table 4.1 and fig 4.8 show that tissue accumulation of 
copolymer 39e, the fraction with the lowest Mw, is
approximately the same as that measured for the fluid-phase
125marker I-PVP in matched control experiments (Table 4.1, 
fig. 4.10). All other fractions, and the unfractioned 
copolymer 39 showed consistently lower rates of uptake.
125To investigate the possible degradation of I-labelled
copolymer 39 by yolk sacs and release of radiolabelled
digestion products from the tissue, 6-10 yolk sacs were
incubated with radiolabelled substrate (125 pg/ml) in a single
flask for 5h at 37°C. Tissue accumulation of radioactivity
was measured, and samples (1ml) of culture medium were
applied to a Sephadex G-15 column and eluted with 0.02M
125sodium acetate in order to detect any I—labelled low
molecular weight degradation products (section 2.5 and 2.9).
Results of the column chromatography are shown in fig. 4.11.
It can be seen that in all cases two further peaks eluted
after the polymer and the ^ 2^l]iodide peak; these were not
present in the culture medium before incubation (fig. 4.12)
and must therefore represent degradation products. The third
125peak was found to correspond in position to a I—tyrosine 
marker. Attempts were made to identify the smaller, fourth 
peak by applying other possible degradation products as 
markers, namely ^2“*I—labelled phenylalanine—tyrosine,
3, 5-di [125l] iodo-L-tyrosine and 125I-labelled N,N*-dityrosyl 
HMDA (the crosslinking agent used for synthesis of the 
copolymer). Fig. 4.n shows that these three compounds all 
elute in approximately the same position as the fourth peak.
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The extent of degradation was calculated from the elution 
profiles by expressing the amount of radioactivity in peaks 
3 and 4 as a percentage of the total recovered from the 
column. This value was used to calculate the total amount of 
radiolabelled digestion products released by the yolk sacs, 
which was then expressed in terms of pi of culture medium per 
mg of yolk sac protein. Tissue accumulation of radiolabelled 
substrate was also assessed and the sum of these two values 
(in pl/mg protein) gives the total pinocytic uptake of 
copolymer over the 5h period i.e.
True pinocytic uptake = Tissue accumulation 
(pl/mg protein) (pl/mg protein)
+ Degradation Products in culture medium 
(pl/rag protein)
Tables 4.2 and 4.3 and Fig. 4.13 show a summary of the data 
obtained from the degradation experiments. From these results 
it is apparent that total pinocytic uptake does increase with 
decreasing molecular weight, as indicated by the tissue 
accumulation experiments. However, despite the differences 
in uptake, molecular weight appears to have no effect on the 
extent to which the copolymers are degraded since, with all 
fractions, approximately 40% of the total uptake is degraded 
during a 5h incubation period.
Enzymatic cleavage of the crosslink P—Gly—Gly—Phe—Tyr—HMDA 
Xyr-Phe-Gly-Gly-P to produce free tyrosine residues must 
involve the hydrolysis of at least two covalent bonds. One 
of these must be the link between tyrosine and hexamethylene 
diamine. To assess the extent of tyrosine release from the 
crosslinking agent N,N'-dityrosyl HMDA, and in an attempt to 
identify the nature of the small second peak of radioactive
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degradation product, the crosslinking agent N,N'-dityrosyl
HMDA was radiolabelled and used as a substrate in the yolk
sac system. Results of uptake and degradation experiments are
125,summarized in fig 4.14. 
carried out concurrently.
Matched I-PVP controls were
Analysis of the results revealed no progressive accumulation 
of radioactivity in the yolk sac tissue, probably indicating 
that [125l]-N,N'-dityrosyl HMDA does not enter yolk sac tissue 
by pinocytosis, but simply diffuses into the tissue and is 
degraded readily, as shown in fig. 4.15. The possible 
sites of degradation within the cell have not been investigated.
The elution profile shown in fig. 4.15 shows, again, a peak 
of radioactivity which elutes after ij iodotyrosine
following incubation with yolk sacs (5h). This peak may 
either be residual undegraded I^-N,N'—dityrosyl HMDA, or it 
may represent partially degraded substrate i.e. tyrosyl HMDA.
1254.2.2 Pinocvtic Uptake and Degradation of____ I-labelled
Copolymer 74 bv Yolk Sacs
Tissue accumulation of copolymer 74 over 5h was estimated as 
described in section 4.2.1. The experiment was performed 
three times and in each case the rate decreased with time, as 
shown in fig. 4.16. Sephadex G-15 column chromatography of 
culture medium (1ml) following incubation of I-labelled 
copolymer 74 with yolk sacs for 5h revealed a peak which co­
eluted with [125l] iodotyrosine and a further peak, as 
observed with copolymer 39 fractions following incubation with 
yolk sacs. Total uptake and degradation of copolymer 74 was 
calculated as explained in 4.2.1 and results are shown in 
Table 4.4, along with values obtained for copolymer 39e, which 
are included for comparison.
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It is attractive to suppose that the unidentified peak 
observed to elute in the same position on chromatography of 
culture medium in which yolk sacs have been incubated with 
either copolymer 39, copolymer 74 or N,N'-dityrosyl HMDA are 
the same molecule. A comparison of the structures of the
the likely constituent of the peak, since copolymer 74 
(P-Gly-Gly-Phe-TyrNH2) does not contain N,N‘-dityrosyl HMDA, 
and N,N'-dityrosyl HMDA does not contain phenylalanine.
4.2.3 Pinocvtic Uptake and Degradation of Copolymer 39e 
over a 12h Incubation Period
Since the extent of degradation of all the copolymer 39 
fractions was shown to be virtually the same (40% of the 
total uptake) after 5h incubation with yolk sacs, an 
experiment was performed to follow the pinocytic uptake and 
degradation of copolymer 39 over a prolonged incubation 
period. Fraction 39e was chosen because of its comparatively 
high rate of uptake.
The maximum incubation period for yolk sacs in medium 199 
supplemented with 10% calf serum at 37°C is 12h, after which 
time the tissue begins to degenerate (Williams et al 1975a, 
Duncan et al, unpublished). The experiment was performed as 
described in the previous sections. Each flask (containing 
10 yolk sacs) was incubated with copolymer 39e (125 pg/ral),
for a different time period. Sample times of 3, 5, 8 and 12h 
were chosen, and care was taken to gas the flasks periodically 
with 95% 0_/5% CO in order to preserve the tissue for as long
three substrates would suggest that
as possible.
lml samples of culture medium from each flask were applied 
to a Sephadex G-15 column and eluted with sodium acetate 
(0.02M) as described previously. Table 4.5 and fig. 4.17 
summarize the results of this experiment. It can be seen 
from fig. 4.17 that after I2h the yolk sac is still 
pinocytosing and digesting substrate. The results also 
show that the extent of degradation of the copolymer is 
slowly increasing with time; this is a consequence of the 
fact that tissue levels of undegraded copolymer level off 
after the first 3-5h.
4.2.4 The Effect of 2.4-Dinitrophenol and Leupeptin on the
Uptake and Degradation of Copolymer 39e by the Yolk Sac
Pinocytic uptake and degradation experiments using copolymer
39e were performed with addition of 2, 4-dinitrophenol
(50 pg/ml) or leupeptin (40 pg/ml) to the incubation medium.
The experiments were carried out exactly as described in the 
previous sections. The incubation period for all experiments 
was 5h.
The results of the experiments are summarised in figs. 4.18, 
4.19 and Table 4.6. It can be seen that the addition of 
2, 4-dinitrophenol to the incubation medium at the beginning 
of the experiment results in a greatly decreased uptake and 
subsequent degradation of the substrate, demonstrating that 
tissue accumulation does represent true pinocytosis. The 
decreased level of degradation products indicates that 
degradation does not occur when pinocytosis is inhibited 
and is an intracellular event and not the result of 
degradation in the culture medium by secreted enzymes.
The results obtained using leupeptin show an undirainished
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total uptake value, but a reduced level of degradation.
This indicates that in the presence of leupeptin the yolk sac 
is capturing copolymer 39e at the normal rate and that its 
digestion in the lysosomes is inhibited.
4.2.5 Pinocvtic Uptake and Degradation of Copolymer 68 by 
the Yolk Sac
Tissue accumulation of copolymer 68 by yolk sacs over 5h was
estimated as described above. The experiment was repeated
1255 times with matched I-PVP controls and the results showed 
a linear uptake as shown in fig. 4.20.
Radiolabelied low molecular weight degradation products were 
not expected to be released from this substrate. To verify 
this, experiments to detect such products were carried out as 
described previously. After incubation, samples of the medium 
were applied to a Sephadex G—15 column, but, as shown in fig. 
4.21, no degradation products were detected.
The absence of degradation products appearing in the medium 
is not, however, an indication that crosslinks are not 
cleaved. The crosslink structure contained in copolymer 68 
(P-Gly-Gly-Phe-HMDA-Phe-Gly-Gly-P) is potentially bio­
degradable but, since the crosslink does not include a 
radiolabelled tyrosine residue, cleavage cannot be demonstrated 
by the detection of radiolabelled degradation products. The 
radio1abelied tyrosine residues remain attached to the 
copolymer backbone which is too large to traverse the 
lysosomal membrane. Crosslink cleavage might be detected, 
however, by comparing the molecular weight distribution of 
radiolabelled copolymer before and after incubation with 
yolk sacs. This requires the chromatography of polymers 
present within the yolk sac tissue and preliminary experiments
T IS S U E  A C C U M U L A T IO N  O F C O P O L Y M E R  68 B Y  R A T  
VTSCERAL Y O L K  S A C S ______________________________
FIGURE 4.20
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were necessary in order to optimize the preparation of tissue 
samples prior to chromatography.
Ten yolk sacs were incubated in a single Erlenmeyer flask 
containing 11ml medium 199 supplemented with 10% calf serum. 
1251-Labelied copolymer 68 (125 jig/ml) was added at the 
beginning of the experiment and 1ml of the medium was removed 
immediately. This was applied to a Sepharose 4B/6B column 
(section 2.5) and the molecular weight distribution of the 
copolymer in the medium determined (fig. 4.22). After 5h 
incubation at 37°C the yolk sacs were removed and homogenised 
in distilled water.
Before application of the homogenate to the Sepharose 4B/6B 
column it was necessary to centrifuge the sample. Several 
possible methods of pre-treatment of homogenate were tried 
before centrifugation to recover the maximum amount of radio­
activity from the homogenate in the supernatant!
1) No further treatment. Homogenates were made up to lOml 
with distilled water, and duplicate 1ml samples assayed 
for radioactivity.
2) TCA precipitation of protein. 0.1ml calf serum + O.Sml 
TCA was added to duplicate 1ml samples of homogenate 
before centrifugation.
3) 0.2% final concentration of Triton XlOO was added to 
duplicate 1ml samples of homogenate in order to disrupt 
lysosomal membranes before centrifugation.
4) Both treatments 2 and 3 were carried out on duplicate 
lml samples of homogenate before centrifugation.
After centrifugation, the radioactivity present in both 
supernatant and pellet was expressed as a percentage of the
-85-
original amount of radioactivity present in a 1ml sample of 
homogenate.
The same procedure was carried out with various controls at 
the same time.
1) 10 yolk sacs previously incubated for 5h in medium with
no substrate. An equivalent amount of substrate was added 
after these yolk sacs were homogenised.
2) 10 yolk sacs that had not been incubated. Substrate was 
added to the homogenate as in 1).
3) No yolk sacs. Substrate was added to 10ml water only.
Results obtained are shown in Table 4.7. It can be seen
that there is very little difference between the methods used.
was decided to use Triton X100 (0.2% final concentration)
since the percentage radioactivity remaining in the pellet
125after centrifugation in samples incubated with I—labelled
copolymer 68 was slightly lower than the other methods.
A sample of this supernatant was applied to the same Sepharose 
4B/6B column, and the molecular weight distribution of the
I-labelled copolymer recovered from the yolk sacs observed. 
Fig. 4.22 shows the distribution of radiolabelled substrate 
in the medium together with that recovered from the yolk sacs. 
The starting material has one broad peak of radioactivity 
corresponding to the distribution of the copolymer, followed 
by a sharper, smaller peak which was found to coelute with 
[125l] iodide. The radioactivity recovered from the yolk sac 
homogenate, however, shows two polymer peaks, one corresponding 
to low and one corresponding to high molecular weight material. 
There is clearly an absence of copolymer of medium range 
molecular weight. The small peak in the higher molecular
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FIGURE 4.22
weight range could possibly be due to radiolabelled material 
binding to protein still present in the homogenate supernatant, 
and the second, larger peak represents lower molecular weight 
polymer chains which could be the product of crosslink 
cleavage of larger molecules. Unfortunately, owing to the 
poor labelling efficiency of this particular copolymer, it 
was not possible to repeat this experiment.
The results do not, however, demonstrate conclusively cross­
link cleavage by lysosomal enzymes, for two reasons»
1) It is possible that the treatment of yolk sacs with Triton 
X100 after incubation could have caused crosslink cleavage. 
This possibility is eliminated by later experiments (see 
Chapters 7 and 8).
2) It is possible, in view of the uptake and degradation 
studies using the copolymer 39 fractions described 
earlier, that the molecular weight distribution of polymer 
obtained with material derived from yolk sacs represents 
preferential capture of low molecular weight material 
during pinocytosis and is not indicative of cleavage 
products.
This possibility was investigated further and is discussed 
in section 4.2.6.
4.2.6 Preferential Uptake of Lower Molecular Weight Copolymer 
39 fractions bv the Yolk Sac
The following experiment was carried out in order to observe 
whether or not yolk sacs preferentially pinocytosed material 
of a given size, when presented with a polydisperse 
preparation.
-87-
Unfractioned copolymer 39 was used, since uptake of any 
fraction could be detected by changes in the molecular weight 
distribution of copolymer in the medium and the lower 
molecular weight radiolabelled degradation products would 
elute much later.
10 yolk sacs were incubated for 12h in a single Erlenmeyer 
flask containing 11ml medium 199 supplemented with 10% calf 
serum and gassed periodically with 95% 02/5% C02« A 1ml 
sample was removed immediately after adding 62.5 pg/ml 
125I_labelled copolymer 39 at the beginning of the experiment. 
The sample was applied to a Sepharose 4B/6B column (section
2.5), and the molecular weight distribution of the medium at 
the start of incubation plotted.
A 1ml sample of the medium after 12h incubation with yolk sacs 
was applied to the same column. The results are shown in 
fig. 4.23 and Table 4.8.
There is no observable difference in the shape of the curve in 
the first 34 fractions, indicating that there is little, if 
any, uptake of higher molecular weight fraction of the copolymer
There is a 10% reduction in the total count after incubation 
of fraction nos. 35-49. This coincides almost exactly with 
the molecular weight distribution of copolymer 39e, the 
smallest fraction (Mw 34,000) as seen in fig. 4.23.
The increase in fraction nos. 50-57 is almost entirely due to 
125I-tyrosine release since the increase in percentage of 
[125l] iodide concentration over a 12h period of incubation is 
<2.00% (Chapter 3, section 6).
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TABLE 4.8
125SEPHAROSE 4B/6B CHROMATOGRAPHY OF I-LABELLED 
COPOLYMER 39 IN MEDIUM 199 ♦ 10% CALF SERUM BEFORE 
AND FOLLOWING A 12H INCUBATION WITH YOLK SACS
FRACTION NOS.
% OF TOTAL COUNT 
BEFORE INCUBATION
% OF TOTAL COUNT 
AFTER INCUBATION
16-34 39.90 40.50
35-49 52.00 42.00
50-57 7.47 15.86
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4.3 DISCUSSION
The rate of uptake of the crosslinked copolymer 39 by yolk
sac tissue was clearly dependent upon the molecular size of
the copolymer used. From fig. 4.9, it can be seen that there
is a marked decrease in rate of tissue accumulation as the
mean molecular weight of the sample increases. This result
is consistent with the findings made by Duncan et al (1981)
125on the effect of molecular size of I-PVP on its pinocytosis
by the rat visceral yolk sac. The rate of tissue accumulation
. 125
of copolymer 39e (Mw 34,000) was 84.1% of matched I-PVP
(Mw approx. 40,000) control experiments, (an accepted measure
of the rate of fluid-phase pinocytosis). Fractions with
higher mean molecular weights are taken up more slowly, the
largest, fraction 39a (Mw >400,000), only accumulating in the
125tissue at 20.6% the rate of matched control I-PVP 
experiments. Unfractioned copolymer 39 (Mw 190,000), which 
contains a large proportion of lower molecular weight 
fractions, gives a tissue accumulation value of 38.9% of a 
matched control.
Measuring the tissue radioactivity does not, however, take 
into account the possibility of copolymer uptake with 
subsequent degradation by the tissue and the release of low 
molecular weight radiolabelled degradation products back into 
the culture medium. Using each of the fractions, Sephadex 
G-15 chromatography of the culture medium after 5h incubation 
with yolk sacs demonstrated the presence of a peak of radio­
activity which co-eluted with [125l] iodotyrosine, indicating 
degradation of copolymer fractions by the yolk sac tissue 
This peak was not present in the radiolabelled preparations 
prior to use, nor did it appear if the copolymers were
-89-
incubated in the absence of yolk sacs (Chapter 3). A 
further peak, eluting after 1^25ljiodotyrosine was also noted, 
with all fractions, after incubation of copolymers with yolk 
sacs, and this was provisionally identified as [125l]~ 
diiodotyrosine rather than other possible degradation products 
such as 125I-labelled phenylalanyl-tyrosine or 125I-labelled 
dityrosyl-HMDA. It is however, possible that other 
degradation products might be partially responsible for the 
production of this small peak of radioactivity.
The detection of degradation products in the medium after 
incubation with yolk sacs means that the tissue accumulation 
plots do not represent total pinocytic uptake of copolymers 
by yolk sacs, but only the radioactivity remaining in the 
tissue at any given time. Total pinocytic uptake is given 
by summing the value obtained for accumulation by the tissue 
and the value for degradation. Exocytosis of undegraded 
copolymer following its uptake by the tissue should also be 
accounted for when calculating total uptake values, but this 
was not investigated in the present study since Williams (1975) 
found that the rate of exocytosis of both I-BSA and 
125I-PVP was negligible on incubation of these substrates with 
rat yolk sacs.
The total pinocytic uptake of copolymer 39 fractions after 
5h incubation with yolk sacs also demonstrated a size- 
dependence, with uptake increasing with decreasing mean 
molecular weight. Degradation of copolymer fractions was 
shown not to be size dependent * all copolymer fractions 
were degraded to around the same extent (Table 4.3). 
Approximately 40% of the total uptake of all copolymer 
fractions is degraded within the 5h incubation period.
H
■v
tt
Vi
da
n 
A-
J-
IS
HB
AI
NO
 3
-i
33
>:
-90-
Duncan and Kopecek (1984) suggest that the preferential
125uptake of lower molecular weight I-PVP fractions by yolk 
sac tissue can be explained by considering the ultrastructure 
of this tissue. Newly forming pinocytic residues originate 
at the base of microvilli which are present on the apical 
region of the cell. This microvillous area acts as a barrier 
or sieve which restricts the entry of molecules larger than 
approximately Mw 100,000. The results presented support this 
suggestion, since copolymer 39e (Mw 34,000) is of a smaller 
size than the proposed threshold, and enters the tissue at a 
much higher rate than the other fractions, the larger 
molecules being taken up at a rate proportional to the mean 
molecular weight of the fraction.
Although non-crosslinked copolymer 74 (Mw 31,000) is of a 
similar size as copolymer 39e, the rate of tissue accumulation 
was much lower, but experiments performed to detect 
degradation of copolymer 74 showed that approximately 70% of 
the total uptake had been degraded during the 5h incubation 
period, and that total uptake was virtually the same. These 
data indicate that degradation of copolymer sidechains is 
much more rapid than copolymer crosslinks of the same amino 
acid sequence. This is probably due to greater accessibility 
of the susceptible bond in copolymer 74 to enzymatic cleavage, 
since this is in the form of a sidechain. Also, in copolymer 
39e it is necessary that at least two bonds must be cleaved 
to release radiolabelled degradation products from crosslinks 
or intramolecular cycles. It is interesting to note that 
copolymer 74 is degraded to approximately double the extent 
of copolymer 39e.
UNIVERSITY L'lBPAP.'-
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Extended incubation of copolymer 39e with yolk sacs revealed 
that the tissue was still accumulating substrate after 12h, 
and that the rate of degradation of the copolymer was slowly 
increasing with time. This experiment indicated that tissue 
levels of undegraded copolymer were beginning to level off, 
but unfortunately it was not possible to extend the experimental 
period further, since yolk sac tissue begins to degenerate 
after 12h in vitro (Williams et al 1975). The pattern of 
uptake and degradation observed during this experiment was 
unlike that described by Williams following pinocytic studies 
formaldehyde-denatured 125I-labelled bovine serum albumin in 
rat yolk sacs, where the levels of radioactivity in the tissue 
became constant after a short initial period of approximately 
2h. Pinocytosis of 125I-labelled BSA was shown to be 
adsorptive in nature, the rate of uptake ranging from 11.1 to 
80.8 pl/mg/h, and the rate of degradation, again indicated by 
the release of [^125l] iodotyrosine was extensive (approximately 
80% of the total uptake after 5h). One obvious difference 
between these experiments is that HPMA copolymers enter the 
tissue much more slowly by fluid-phase pinocytosis, resulting 
in a total pinocytic uptake after 12h which is less than that 
observed in the first hour of uptake of membrane bound 
125I-labelled BSA. Because of these lower levels of intra­
cellular copolymers, and in view of the high rates of 
degradation achieved by lysosomal enzymes during protein 
degradation, one might expect HPMA copolymers to be degraded 
quickly. One possible reason for the slower rates of 
degradation observed might be steric hindrance due to the 
presence of non-degradable copolymer chains which might 
prevent enzymes from gaining access to the appropriate site.
nHI_E UNIVERSITY UBP/VP-
Accumulation of copolymer chains within lysosomes would be 
expected since molecules of molecular weight greater than 
approximately 220 cannot cross the lysosomal membrane 
(Reijngoud and Tager 1977 ). Release of copolymer chains
of a molecular weight low enough to be excreted by the kidney 
would take place following exocytosis or cell death.
The introduction of 2-4-dinitrophenol, a known uncoupler of 
oxidative phosphorylation, at 50 pg/ml into the culture 
medium caused considerable inhibition of uptake of copolymer 
39e by yolk sacs. The concentration used has previously been 
shown to be inhibitory and non-toxic to cells in this and 
other experimental systems (Duncan et al 1979 < Bowers 1977 s 
Cohn 1966 and Munthe-Kaas 1977). Both the accumulation of 
radioactivity by the tissue and the appearance of  ^ ij 
iodotyrosine in the medium were virtually abolished, thereby 
indicating that both uptake and degradation take place through 
pinocytosis of copolymer by the yolk sac.
Leupeptin, a peptide aldehyde that inhibits the thiol-dependent 
lysosomal proteinases (Barrett 1977), when added to the 
culture medium at a concentration of 40 pg/ml, demonstrated 
reduced degradation of copolymer 39e. Pinocytic uptake of 
copolymer 39e was approximately the same both in the presence 
and absence of inhibitor, but a proportion representing only 
18% of the total uptake was degraded in the presence of 
leupeptin, in contrast with 44% in the absence of inhibitor. 
Lysosomal thiol-proteinases are therefore partly responsible 
for the degradation of copolymer 39e observed after incubation 
with yolk sacs.
Copolymer 68 is a more densely crosslinked preparation than 
copolymer 39, and contains shorter crosslinks, which are also 
potentially degradable. The tissue accumulation of 
12^i-iabelled copolymer 68 was found to be linear with time, 
and there was no £125l] iodotyrosine released into the medium 
following incubation with yolk sacs. These data confirmed 
that it is possible to trace the fate of the copolymer chains 
in the yolk sac, since the radiolabelled tyrosine residue 
remained attached to the copolymer backbone throughout the 
experimental period. This unfractionated copolymer has a 
mean molecular weight of 171,000 and total uptake values after 
5h (11.4 pl/mg) compared with unfractionated copolymer 39 
(Mw 190,000) after 5h (8.5 pl/mg) taking into consideration 
the difference in mean molecular weights.
Sepharose 4B/6B chromatography of yolk sac tissue homogenized 
after incubation with copolymer 68 revealed that most of the 
radiolabelled copolymer contained within the tissue was in 
the form of lower molecular weight fractions of the original 
preparation. This could indicate crosslink cleavage by 
enzymes within the tissue, but the results could also be 
explained by crosslink cleavage during preparation of the 
tissue for chromatography, or by the preferential uptake of 
lower molecular weight fractions by the tissue during 
incubation.
Preferential uptake of lower molecular weight copolymer 39 
fractions by the yolk sac was demonstrated by comparing the 
molecular weight distribution of the unfractionated copolymer 
39 in medium before and after incubation with yolk sacs for 
12h. A 10% reduction in the total counts was observed in the
region of the curve corresponding to the lower molecular 
weight fraction 39e, with a corresponding increase of 8% in 
the second peak due to the release of [125lj iodotyrosine back 
into the culture medium following uptake of copolymer by the 
tissue. There was little or no change in the molecular weight 
distribution in areas of the curve corresponding to larger 
copolymer fractions, indicating little, if any, uptake of 
these molecules.
In summary, the data obtained from the experiments performed
125using the rat visceral yolk sac have shown that I-labelled 
crosslinked HPMA copolymers are captured by cells at a rate 
consistent with uptake by fluid-phase pinocytosis, and the 
rate of uptake is dependent on the mean molecular weight of 
the copolymer used. From the range of sizes presented, the 
yolk sac tissue selects against copolymers of higher molecular 
weight. Pinocytic uptake of copolymers is followed by 
degradation of oligopeptide sequences by lysosomal enzymes 
after fusion of pinocytic vesicles with lysosomes. Lysosomal 
thiol-proteinases are partly responsible for this intra­
cellular degradation of copolymers.
From the experiments performed using yolk sac tissue, it was 
not possible to prove conclusively that crosslink cleavage 
took place to yield copolymer chains of lower mean molecular 
weight, since lower molecular weight fractions were 
preferentially pinocytosed. Copolymer 39 was synthesized 
from copolymer chains containing sidechains which were 
subsequently crosslinked (Chapter 3). Only 14-% of the initial 
sidechains were connected by crosslinks, the rest formed 
intramolecular cycles or remained as sidechains. Sidechains 
contained no tyrosine residues and were therefore not radio
-95-
label led. Under the circumstances, degradation products 
detected could have, in all cases, been due to enzymatic 
hydrolysis of bonds present in intramolecular cycles contained 
within the preparations, rather than crosslinks.
96
5.1 INTRODUCTION
Various experimental systems have been used to quantitate 
endocytosis. Pratten et al (1980) have described three main 
types of cells that have been used for such studies, namely 
unicellular animals such as Amoeba and Tetrahymena) mammalian 
cells e.g. mononuclear phagocytes, fibroblasts and liver cellsi 
and vertebrate organ cultures.
Chapter 4 described, the pinocytic uptake of soluble crosslinked 
HPMA copolymers by the rat visceral yolk sac. and it was 
observed that the rate of uptake of copolymers increased with 
decreasing molecular size of the substrate, and that the 
copolymers were partially degraded within lysosomes during the 
experimental period.
Another organ which can be used to quantitate pinocytosis is 
the rat intestine. Like the rat visceral yolk sac, the 
intestinal epithelium, and in particular the jejunum, has a 
microvillous apical plasma membrane which is highly absorptive 
in nature.
In this chapter, the pinocytic uptake of crosslinked copolymers 
by the everted rat jejunal sac is described, and a comparison 
is made between the results obtained from the studies of the 
two organ culture systems i.e. the rat visceral yolk sac and 
the everted rat jejunal sac. Specifically, the questions 
investigated are the followingi-
1. Are crosslinked copolymers pinocytosed by the rat jejunal 
epithelial cells?
2. If so, does this occur by fluid-phase pinocytosis, as in 
the yolk sac, or is the uptake adsorptive in nature?
CHAPTER 5
PINOCYTIC UPTAKE, INTRACELLULAR DEGRADATION 
AND TRANSPORT OF 1251-LABELLED HPMA 
COPOLYMERS BY THE RAT JEJUNAL SAC IN VITRO
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3. If pinocytosis does take place, is the rate of uptake in 
this tissuet too, dependent on the size of the copolymer?
4. Are crosslinked copolymers transported across the jejunal 
tissue i.e. from the mucosal to the serosal surface?
5. Are crosslinked copolymers hydrolysed within the lysosomes, 
and if so, is the extent of degradation dependent on the 
size of the copolymer?
The small intestine is a much thicker tissue than the visceral 
yolk sac, consisting of a strongly muscular tube with an outer 
longitudinal muscle layer, and an inner circular muscular 
layer. Adjacent to the circular layer lies a bed of vascular 
connective tissue, the submucosa, and finally, adjacent to the 
lumen lies the intestinal mucosa. The mucosa may be divided 
into three layers (Fig. 5.1). The deepest layer, the 
muscularis mucosae, is a thin sheet of smooth muscle which 
separates the mucosa from the submucosa. The middle layer, 
the lamina propria, is a continuous sheet of connective tissue 
which, together with the epithelium, forms the villi and the 
crypts. The lamina propria provides structural support for 
the intestinal epithelium and contains a variety of cell types 
including fibroblasts, macrophages, plasma cells, lymphocytes, 
mast cells and eosinophils. Also present are blood and lymph 
vessels, nerve fibres, smooth muscle strands and non-cellular 
connective tissue elements. The third layer of the intestinal 
mucosa consists of a continuous sheet of a single layer of 
columnar epithelial cells which covers the villi and the crypts. 
Absorptive, goblet and some enterochromaffin cells cover the 
surface of the villi and goblet, enterochromaffin and Paneth 
cells line the crypts. The presence of the villi increases 
the surface area of the absorptive epithelium about eightfold. 
The epithelial cells, in turn, have a microvillous apical
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membrane which further increases the surface area available 
for absorption (Fig. 5.2). This apical membrane is often 
termed the brush border, and is known to contain a variety of 
hydrolytic enzymes (Bruce 1983).
The intestinal epithelium is a highly active tissue which 
renews itself every 2-3 days. Cell proliferation occurs in 
the crypts and the absorptive cells differentiate and mature 
during their migration from the crypts to the tips of the 
villi, from which cells are eventually shed (Trier 1967).
The rate of cell renewal and loss, and the height of the villi, 
can be affected by a number of factors, such as certain 
nutritional states, or the use of radiation or antimitotic 
drugs (Trier 1967).
With the exception of the tips of the villi, where old cells 
are shed, the epithelial cells, or enterocytes, are closely 
apposed and locked together by junctional complexes comprising 
tight junctions where membranes from adjacent cells appear to 
fuse, intermediate zones, and a number of desraosomes which are 
thickened areas beneath the cell membrane (Fig. 5.2). These 
junctional complexes are believed to be impermeable to 
macromolecules. Most studies suggest that uptake of macro- 
molecules takes place by endocytosis and innumerable E.M. 
studies using electron dense substrates such as horseradish 
peroxidase (HRP) have demonstrated the presence of pinocytic 
vesicles within the columnar epithelial cells.
Quantitative studies on pinocytosis have been undertaken using 
both the neonatal and adult mammalian intestine, and much work 
has been centred on the pinocytic uptake of lgG from the gut 
lumen and its transport across the tissue into the circulation
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in neonatal mammals, which are known to acquire passive 
immunity from the transfer of maternal antibodies present in 
colostrum (Brambell 1966, Rodewald 1980). The species studied 
by various workers include the rabbit, rat and pig. The 
mechanism of uptake of IgG in the neonatal intestine is 
believed to be receptor-mediated pinocytosis.
Increased permeability to all macromolecules coming into 
contact with intestinal mucosa has been demonstrated in 
immature individuals of many species (Walker 1981). A few 
days after birth, when immunological and nonimmunological 
host defences develop, and intestinal epithelial cells mature 
functionally and morphologically, the uptake of macromolecules 
decreases. This phenomenon is known as closure.
Comparatively few studies have been carried out on the uptake 
and transport of macromolecules across the adult intestine. 
Walker (1981) provided morphological and physiological 
evidence for pinocytosis of macromolecules by the intestine, 
using an enzyme marker, horseradish peroxidase (HRP). This 
enzyme can be detected histochemically at both light and 
electron microscopic levels and can also be radiolabelled and 
measured quantitively in very small concentrations. Following 
intraluminal injection of HRP into ligated segements of jejunum 
and ileum, the substrate was found adsorbed to the apical 
surface membranes and within membrane-bound cytoplasmic 
vesicles. Extracellular HRP was present in the intercellular 
spaces between adjacent absorptive cells (following exocytosis 
from the baso-lateral membrane), traversing the basement 
membranes and in the spaces of the lamina propria. Walker 
(1981) reported further evidence by other workers for the 
movement of macromolecules such as insulin, haptens and
-lOO-
larger antigens which were transported in sufficient quantity 
to evoke a biological response.
Most previous studies have been carried out by injection of 
substrate directly into the lumen of a ligated portion of 
intestine in situ» with subsequent removal and examination of 
the tissue. The present study» however, was carried out 
according to the method of Bridges and Woodley (section 2.7) 
using everted sacs of adult rat jejunum incubated in vitro. 
This method, improved from that of Wilson and Wiseman (1954) 
involves the use of everted segments (3-4cm) of jejunum which 
are filled with culture medium and tied off at both ends 
before total immersion in culture medium. (The use of everted 
sacs facilitates the necessary oxygenation of the intestinal 
mucosa during the experimental period.)
Previous objections to the use of everted sacs centre around 
the possibility that the sacs may leak and that differing 
degrees of distention will produce differing degrees of 
unfolding of the villous surface. A further important 
objection stems from evidence of ultrastructural and 
biochemical changes which occur in the tissue when everted 
sacs are cultured in vitro (Levine et al 1970, Plattner et al 
1970).
The method described by Bridges (1980) employs modified 
procedures which show that tissue viability and structural
integrity can be maintained over a 2h incubation period. This 
was achieved by reducing the tissue preparation time and by 
the use of complex medium TC 199 containing 10% calf serum 
and imM ATP, as opposed to the traditional basic Krebs-Henleit 
Ringer medium used by other workers. Viability studies by 
Bridges included the use of light and electron microscopy iE,M
studies, the monitoring of oxygen consumption of the tissue, 
and sacs were also monitored for the active transport of 
D-glucose and L-methionine across the tissue into the serosal 
fluid during the incubation period* Both D-glucose and 
L-methionine were accumulated against a concentration gradient, 
and the finding that these gradients could be maintained for 
up to 2h indicated both tissue viability and that no leakage 
of sacs had occurred in that period of time*
Studies by Bridges (1980) and Beahon (1981), using non- 
degradable 125I-PVP have shown this to be taken up into the 
tissue in a linear fashion by rat jejunal sacs, as in rat 
visceral yolk sacs, but at a lower rate (0.74 pl/h/mg protein 
as opposed to 1.71 pl/h/mg protein in the yolk sac). Uptake 
was proportional to substrate concentration, was temperature 
sensitive, and could be partially inhibited by inhibitors of 
glycolysis or oxidative phosphorylation. This evidence 
indicated fluid-phase pinocytosis to be the mechanism of 
uptake. 125l-PVP was therefore again chosen as a control with 
which to compare uptake values obtained for the pinocytosis of 
125I-labelled HPMA copolymers by everted jejunal sacs.
125I-PVP was also shown by Bridges (1980) to accumulate in 
the serosal fluid of the everted sac linearly with respect to 
time up to 2h at a rate of 0.12 pl/mg protein/hr. Bridges 
proposed that 125I-PVP had traversed the tissue following its 
pinocytosis by absorptive epithelial cells.
Pinocytic uptake studies using a degradable substrate were 
carried out by Bridges (1980) and Beahon (1981). Both authors 
used 125i-labelled horseradish peroxidase (HRP) as a substrate 
in the everted sac system, and found a linear accumulation of 
radioactivity with time (up to 2h) in both the tissue and the
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serosal fluid. Bridges noted that this substrate entered the
125tissue about sixteen times faster than I-PVP but that
tissue uptake increased with substrate concentration up to
50 pg/ml, after which uptake became independent of substrate
concentration. This work was stated to be of a preliminary
naturei but the author suggested that the results are
indicative of substrate undergoing adsorptive pinocytosis.
Accumulation of 125I-HRP into the serosal fluid took place at
125a similar rate to that observed for I-PVP.
Bridges (1980) also considered the possibility of substrate 
degradation. A comparison of the rate of total substrate 
disappearance and the combined rate of tissue and serosal 
accumulation of HRP revealed that the substrate disappeared at 
a greater rate than could be accounted for by the measured 
uptake values. Bridges concluded that a large proportion of 
the HRP taken into the tissue, or adsorbed onto the membrane, 
was degraded.
In order to ascertain whether crosslinked copolymers could be 
pinocytosed by this tissue, and transported to some extent 
into the serosal fluid, copolymer 39 (crosslink structure 
P-Gly-Gly-Phe-Tyr-HMDA-Tyr-Phe-Gly-Gly-P, Mw 190,000) was 
again radiolabelled and incubated with everted rat jejunal 
sacs. The possible effect of molecular size of the copolymer 
on the rate of jejunal tissue accumulation of substrate was 
also investigated using radiolabelled fractionated copolymer 
39 of mean molecular weights 34,000, 110,000, 150,000, 400,000 
and >400,000.
The potentially degradable crosslinks contained within 
125I-labelled copolymer 39 contain radiolabelled tyrosine
UNIVERSITY
residues which were shown (Chapter 4) to be liberated in the
culture medium following hydrolysis by lysosomal enzymes
present in the rat visceral yolk sac tissue. In the present
study experiments were again carried out» using column
chromatography, to detect low molecular weight radiolabelled
degradation products in both the external medium and the
125serosal fluid following incubation of I-labelled copolymer 
39 fractions with everted jejunal sacs.
In Chapter 4, inhibition studies were described which proved 
that crosslinked copolymers were pinocytosed by the rat 
visceral yolk sac and degraded intracellularly. The work 
carried out by Bridges (1980), and others previously, has 
demonstrated that complete inhibition of uptake of macro­
molecules by the small intestine using metabolic inhibitors 
has not been achieved.
125Bridges (1981) did show, however, that I-PVP uptake into
both the tissue and the serosal fluid was reduced by approx.
50% when experiments were carried out at temperatures between
10 and 30°C. Since this method of pinocytic inhibition
equalled the maximum observed by Bridges using metabolic
inhibitors, pinocytic uptake experiments on copolymer 39
fractions (a and e) were carried out at low temperature (15 C)
oto observe whether the uptake values obtained at 37 C were the 
result of an active, pinocytic process, or the binding of 
substrate to the tissue without subsequent internalization.
Copolymer 68 (Mw 171,000, crosslink structure P-Gly-Gly-Phe- 
HMDA—Phe-Gly-Gly-P) contains a tyrosine residue, which can be 
radiolabelled, close to the copolymer backbone. Unlike 
copolymer 39, this copolymer can be used to trace the fate of
the copolymer backbone following intralysosomal degradation 
of the potentially degradable crosslinks contained within it 
(Chapters 3 and 4). Copolymer 68 was therefore radiolabelled 
and used as a substrate in the present system in order to 
compare patterns of tissue accumulation of radioactivity with 
the yolk sac system and to observe the possible transport of 
macromolecular material into the serosal fluid.
The final experiment performed using the everted jejunal sac 
was an attempt to disprove the possibility of leakage of 
macromolecules across the tied ends of the sac into the 
serosal fluid. Although this possibility had been eliminated 
by Bridgesf the present experiment aimed to demonstrate that 
the experimental method was reproducible. The method employed 
involved the use of loops of intestine» the cut ends of which 
were not immersed in the culture medium. The substrate used 
for this experiment was unfractionated I—labelled copolymer 
39» and column chromatography of the serosal fluid was carried 
out at the end of the experimental period in order to identify 
the nature of the radioactivity accumulated within it.
5.2 RESULTS
5,2.1 Tissue Accumulation of Copolymer 39 Fractions by the 
Everted Jeiunal Sac i The Effect of Molecular Size
The accumulation of copolymer 39 fractions by everted jejunal
sacs was measured at various times over a 1.5h incubation
period at 37°C. Sacs were incubated singly and radiolabelled
copolymer (125 pg/ml) was added to each flask at the beginning
of each experiment. Duplicate samples were taken at each time
point for each experiment. Concurrent control experiments
125were performed using I—PVP as substrate.
Figures 5.3-5.8 show progress curves for the tissue
accumulation of radioactivity for each copolymer fraction
(39a-e) and the unfractionated copolymer 39. Fig. 5.9
combines figs. 5.3—5.8. Results for each time point are
expressed as a clearance value (pl/mg protein)| (see Chapter
2, sections 8 and 9). Each value is given as a mean - S.E. of
125the uptake values obtained from 4-8 sacs. I—PVP was used
as a fluid-phase marker in matched control experiments and 
results showed a linear uptake as shown in fig. 5.10.
Figures 5.3-5.9 show that the tissue accumulation of the 
copolymers is approximately linear with time. Rates of 
uptake were calculated for each of the copolymer fractions 
and are shown in Table 5.1.
From the results presented, there is an increase in the rate 
of accumulation of substrate within the tissue with increasing 
molecular size. 125I-PVP (Mw 40,000) enters the tissue at a 
rate similar to that observed for copolymer 39e (Mw 34,000), 
but in this tissue, the larger molecules associate with the 
tissue at a faster rate. This is clearly demonstrated by
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the values obtained for the largest fraction (Mw >400,000),
125which is taken up approximately five times faster than I-PVP.
5.2.2 Accumulation of Radioactivity in the Serosal Fluid of 
Jeiunal Sacs Incubated with Copolymer 39 Fractions
Following the 1.5h incubation period of everted jejunal sacs 
with copolymer 39 fractions (section 5.2.1), serosal fluid was 
recovered from the sacs (section 2.7), and assayed for radio­
activity. Figs. 5.11-5.16 show the progress curves for the 
accumulation of radioactivity in the serosal fluids for each 
copolymer fraction (39a-e) and the unfractionated copolymer 
39. Again, results are expressed for each time point in pi/mg 
protein as a mean - S.E. of the values obtained for 4-8 sacs.
Fig. 5.17 shows figs. 5.11-5.16 combined and the accumulation 
125of I-PVP in the serosal fluid is shown in fig. 5.18.
The figures demonstrate that radioactivity is translocated 
across the intestine and that the values obtained for the 
serosal accumulation of substrate are lower than those 
obtained for the tissue in all cases. It is also apparent 
from the figures that the rate of accumulation of radioactivity 
in the serosal fluid is not dependent upon the molecular size 
of the copolymer.
Figures 5.11-5.17 show the progressive accumulation of radio­
activity in the serosal fluid with time, but do not indicate 
the nature of the radiolabelled molecules transported. In 
order to determine whether macromolecules had been transported 
across the jejunal sacs, or if the radioactivity represented 
low molecular weight degradation products or iodide, column 
chromatography was carried out on serosal fluids following 
incubation with each of the copolymer fractions using
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disposable Sephadex G-25 PD 10 columns (section 2.5). A 
typical elution profile is shown in fig. 5.19 and the results 
are summarized in Table 5.2.
Between 40-64% of the radioactivity recovered from the serosal 
fluids was found to be present in the first peak (fig. 5.19 
and Table 5.2), indicating the movement of macromolecules 
across the intestine. The amount translocated was independent 
of the molecular size of the polymeric substrate. It was not 
possible, however, to identify the component(s) of the second 
peak of radioactivity (fig. 5.19) using Sephadex G-25 PD 10 
columns. Further chromatography experiments were therefore 
carried out using Sephadex G—15 in order to identify radio- 
labelled degradation products. Because the total radioactivity 
present in the serosal fluids was so low in all cases, G-15 
columns were prepared of bed volume 15 ml and bed height 25 cm 
in order to minimise the elution volume following application 
of serosal samples. A typical elution profile is shown in 
fig. 5.20 and from this it can be seen that two peaks elute 
after the polymer peak. The second and third peaks were 
found to co-elute with [125l] iodide and ^ 25lj-iodotyrosine 
respectively, indicating the presence of low molecular weight 
radiolabelled polymer degradation products in the serosal 
fluid. The results from duplicate experiments are shown in 
Table 5.3 and the value for each peak is expressed as a 
percentage of the total radioactivity recovered from the 
serosal fluid in each case.
m
E
On comparing Tables 5.2 and 5.3, it is apparent that the 
values presented for the proportion of polymer present in the 
serosal fluid, particularly in the case of copolymer 39b,
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TABLE 5.2
SEPHADEX G-25 COLUMN CHROMATOGRAPHY OF SEROSAL FLUID 
FOLLOWING INCUBATION OF COPOLYMER 39 FRACTIONS WITH 
EVERTED JEJUNAL SACS FOR 1.5H
POLYMER POLYMER (1ST PEAK) L.M.W. (2ND PEAK)
CODE NO. % %
39a 59 41
39b 40 60
39c 64 36
39d 50 50
39e 40 60
Results are expressed as the %  of the total counts 
recovered from the column.
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TABLE 5.3
SEPHADEX G.-15 COLUMN CHROMATOGRAPHY OF SEROSAL FLUID
FOLLOWING 1.5H INCUBATION WITH POLYMER 39 AND FRACTIONS
SEROSAL FLUID i n n i n tPOLYMER 
CODE NO. %  POLYMER % [125l] IODIDE 125% ■l" i-TYR IN MEDIUM (a)
39 60.32 15.63 18.06 2.4954.00 20.89 7.79 2.42
39a 37.04 42.63 17.51 4.8528.64 20.48 19.88 4.76
39b 11.06 74.99 17.23 11.0012.24 74.71 11.69 12.86
39c 63.78 19.68 13.93 6.9965.80 18.87 10.92 7. 12
39d 39.42 36.61 21.86 3.30
42.95 40.08 16.30 3.38
39e 40.81 25.00 30.58 6.19
30.55 39.38 25.88 5.73
Results are expressed as a % of the radioactivity recovered
from the column.
(a) These values represent the levels of free [ l] iodide 
present in the outer culture medium at the beginning of 
each experiment and are included for comparison.
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differ to some extent. This can be explained by considering
medium at the beginning of each experiment (see column 4,
proportion of the total radioactivity present. Consequently, 
the proportion of radiolabelled polymer present appears to be 
less than that reported when using G-25 (Table 5.2). The 
radiolabelled copolymer preparations used in earlier 
experiments utilizing G-25 chromatography did not contain so 
much free |^25lj iodide since they had not been stored for long 
periods at 4°C (Chapter 3), and the proportion of radio- 
labelled polymer present in the serosal fluid is consequently 
higher, and probably represents a more accurate picture of the 
true cellular events. G-25 chromatography, however, gave no
tyrosine present in the serosal fluid following incubation 
with copolymer fractions. The possible routes of entry of 
the radiolabelled species to the serosal fluid is discussed 
in section 5.2.3.
5.2.3 Total Pinocvtic Uptake of Copolymer 39 Fractions by 
the Rat Jejunal Sac
The presence of [125l] iodotyrosine in the serosal fluid 
following incubation of jejunal sacs with radiolabelled 
copolymer fractions was described in section 5.2.2. This 
indicated that some degradation of copolymer had occurred 
during the 1.5h incubation period, but, in order to calculate 
the total pinocytic uptake of copolymers by this tissue, it 
is also necessary to investigate the possible release of
the quantity of free
Table 5.3). The greater the quantity of free 
present in the outer medium, the large the peak due to
fluid, giving rise to a larger
indication of the proportions of
-109-
radio label led degradation products from the tissue (following 
pinocytosis) back into the culture medium. In order to do 
this, two jejunal sacs were incubated in each flask with 
radiolabel led substrate (125 jig/ml) for 1.5h at 37°C. The 
tissue was assayed for radioactivity and protein content and 
samples (1 ml) of culture medium were applied to a Sephadex 
G-15 column and eluted with 0.02M sodium acetate in order to
1 OCdetect any I-labelled low molecular weight degradation 
products (sections 2.5 and 2.9). Fig. 5.21 shows an elution 
profile typical of all those obtained, and Table 5.4 
summarises the results of these experiments.
This particular series of experiments was carried out 
concurrently (in duplicate) with those described in the 
previous section describing column chromatography of the 
serosal fluid following incubation of jejunal sacs with 
125I-labelled copolymer 39 fractions. It can be seen from 
Table 5.4 that the lower percentage of polymer recovered from 
the column for copolymer 39b w as  due to the high level of 
free 1^25lj iodide in the pre-culture medium. Table 5.4 shows 
that very little [125lJ iodotyrosine was recovered from the 
culture medium in all cases over the 1.5h incubation period.
The highest value of 0.62* (1.26 jxl/mg protein) was observed 
for copolymer 39e, but the values obtained as a whole do not 
indicate that the extent of degradation is dependent on the 
molecular size of the substrate.
From these experiments, however, we cannot conclude that this 
low level of copolymer degradation is due to enzymatic 
hydrolysis within lysosomes following pinocytosis of copolymers 
with subsequent release of [125l] iodotyrosine from cells back
S E P H A D E X  G - 1 5  C H R O M A T O G R A P H Y  O F  C U L T U R E  M E D IU M
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into the medium, since the tissue possesses an array of 
hydrolytic enzymes on the apical membrane of its epithelial 
cells (the brush border), some of which are shed from the 
tissue into the gut lumen in vivo (Bossman & Haschen 1983).
It is therefore possible that enzymes may be shed from the 
brush border into the external culture medium by everted 
jejunal sacs.
Further experiments were carried out using 'conditioned'
medium, to examine this possibility. Two everted jejunal sacs
were incubated in each flask for 1.5h at 37 C in the absence
of radiolabelled substrate on the assumption that any enzymes
released during this period would be shed into the culture
medium. The sacs were then removed from the medium, and
labelled substrate (125 pg/ml) added and incubated for a
further 1.5h. Samples of medium (1 ml) were then applied to
the same Sephadex G—15 column and eluted with 0.02M sodium
acetate. The results of the column chromatography of this
conditioned medium are shown in Table 5.5, and when compared
with Table 5.4, it can be seen that in all cases the levels
of [125l] iodotyrosine detected in the conditioned medium are
equal to, or even slightly greater than, those obtained on
incubation of the radiolabelled copolymers with jejunal sacs.
It can be concluded therefore that if intracellular
degradation of copolymers takes place, it does not lead to
the release of degradation products back into the external
medium over a 1.5h incubation period. Since it has been
oshown that the copolymers are stable in medium at 37 C 
(Chapter 3), the low levels of [125l] iodotyrosine detected in 
the external medium must be due to extracellular degradation 
of copolymers by enzymes released by the tissue, or present
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at the cell surface during the experimental period«
The fact that £125Ij iodotyrosine is present in the external
medium following incubation of copolymers with jejunal sacs
present in the serosal fluid may have been translocated from 
the external medium across the tissue by a mechanism other 
than pinocytosis, possible by active transport or simple 
diffusion. Furthermore, the apparently high levels of free 
£l25jj ¿Qdidg ¿n the serosal fluid may have been actively 
transported across the tissue, or cleaved from radiolabelled 
molecules by an iodinase and transported, or it also may have 
diffused across the tissue.
In an attempt to establish the possible routes of entry of 
the different radiolabelled molecules into the serosal fluid, 
calculations were performed which compared the number of 
radioactive counts present in each peak present in the serosal 
fluid following incubation with the copolymer fractions, with 
the counts present in an equivalent volume of culture medium 
surrounding the jejunal sacs. For example, the total number
medium at the beginning of an experiment to determine uptake 
and transport of copolymer 39b was 73,996 cpm in 10 ml (11% 
of the total counts present). The volume of the serosal fluid 
was approximately 0.8 ml. One would therefore expect to find 
up to 5920 cpm present in the serosal fluid due to the 
diffusion of iodide. The actual number of counts recovered 
due to iodide was in fact less than this value (2402 cpm
or 36.20% of the expected value). Table 5.6 summarises the 
results of these calculations on the contents of the serosal 
fluids, and results are expressed as a percentage of the value
gives rise to the possibility that the [125l{ iodotyrosine
of radioactive counts due to
TABLE 5.6
■SKFHADEX G-15 COLUMN CHROMATOGRAPHY OF SEROSAL FLUID 
(Values expressed as % of radioactivity present in an 
equivalent volume of external culture medium)
POLYMER 
CODE NO.
% OF COUNTS 
POLYMER
PRESENT IN EQUIVALENT 
f 251] IODIDE
EXTERNAL MEDIUM 
125I-TYR
39 (un) 0.41 4.40 115.091.63 23.04 188.72
39a 1.09 23.59 137.301.52 20.75 429.08
39b 0.89 18.36 63.010.84 32.60 235.86
39c 0.67 30. 18 99.180.69 29.70 172.00
39d 1.08 25.72 229.661.26 34.21 169.70
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expected for equilibration as described above.
Table 5.6 shows that the quantity of iodide present in the 
serosal fluid in all cases is less than that present in an 
equivalent volume of external culture medium (4-34%). This 
observation suggests that the mechanism of transport is 
probably diffusion. This finding in conjunction with Table
5 .3  illustrates the need to check the levels of contaminating 
[125l] iodide in radiolabelled preparations prior to use when 
stored for periods longer than one month (Chapter 3).
From Table 5.6 it can be seen that, in all cases, the 
concentration of polymer in the serosal fluid represents < 2%
of the concentration in the outer medium. These values are
il25
•]I iodide and [1 2 5 4 ‘much lower than those observed for 
tyrosine. The only possible routes which could account for 
this movement are leakage and vesicular transport, since it
iodo-
raay safely be assumed that macromolecules are too large to 
diffuse across the tissue (Chapter 1). Leakage through the 
tied ends of the sacs was investigated by Bridges (section 5.1), 
and subsequent experiments (section 5.2.6) in the present 
study support the finding that everted jejunal sacs do not 
leak. It is therefore reasonable to conclude that macro­
molecules are transported across the mucosa by pinocytosis 
followed by exocytosis, and subsequently move across the 
tissue either intracellularly (by pinocytosis) or inter­
cellularly.
It is apparent from Table 5.6 that [125l] iodotyrosine is 
present (in all but one case) at a greater concentration in 
the serosal fluid than in the outside medium following 
incubation with jejunal sacs for 1.5h. Since the
-113-
¿odotyrosine in the outer medium cam be accounted for by 
extracellular or brush border enzymatic cleavage, it seems 
likely that the levels detected in the serosal fluid are 
transported across the tissue following copolymer degradation 
within the tissue. If the [125l} iodotyrosine present in the 
serosal fluid was the result of active transport of free 
J^^lj iodotyrosine generated by extracellular or brush border 
enzyme activity, one would expect the levels in the outer 
medium to be less than those observed on using conditioned 
medium.
Further experiments using G-15 column chromatography of 
serosal fluids following incubation with freshly labelled 
copolymer preparations were not carried out, since the 
Sephadex G-15 chromatography using small columns proved both 
difficult and time-consuming. Sephadex G-25 column 
chromatography (see earlier) was carried out using fresh 
preparations, and the results obtained for transport of 
macromolecules were therefore a more accurate representation 
of the true levels transported, since a low concentration of 
[125l] iodide was present in the radiolabelled copolymer 
preparat ions.
Given the assumptions discussed above, the total pinocytic 
uptake of copolymers by jejunal sacs over the experimental 
period is given by the sum of the tissue and serosal 
accumulation of copolymer, and any degradation products 
released following lysosomal hydrolysis of copolymer. Since 
it is probable that the only intracellular degradation that 
takes place results in the accumulation of [125lJ iodotyrosine 
in the serosal fluid, pinocytic uptake is taken to be the sum
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of the accumulation of radiolabelled substrate in the jejunal 
tissue« and that transported into the serosal fluid. On 
making this assumption« it must be noted that values given 
for the serosal accumulation of radioactivity include those 
counts due to the presence of iodide. The calculations 
necessary to correct for this error are complicated and hardly 
significant in terms of the possible differences which would 
be observed in total pinocytic uptake values where the 
majority of the pinocytosed substrate is present in the tissue 
after a l.5h incubation period.
125Table 5.7 shows the pinocytic uptake of I-labelled copolymer 
39 fractions by the jejunal sac, and the values obtained for 
125I-PVP control experiments. The results of all experiments 
were subjected to a linear regression analysis and Table 5.8 
indicates the correlation coefficient and the slope of the 
regression line (the rate of uptake) for each substrate. The 
sum of the rate of uptake from the incubation medium by the 
tissue and the rate of appearance of substrate in the serosal 
fluid is also shown for each substrate in Table 5.7, and it 
can be seen that because the rates of accumulation of 
substrate in the serosal fluid are low, the total rates of 
pinocytic uptake of copolymer 39 by this tissue resemble 
those given for tissue accumulation alone. There is an 
increase in the rate of pinocytosis with increasing molecular 
size by everted rat jejunal sacs.
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5.2.4 The Effect of Temperature on the Pinocytic Uptake of 
Copolymer 39 Fractions by the Jejunal Sac
Pinocytic uptake experiments using copolymer fractions 39a 
and 39e were performed exactly as described in previous 
sections, but at 15°C, with control experiments using the 
same substrates at 37°C. The incubation period for all 
experiments was 1.5h. Results are expressed for each time 
point in pl/mg protein as a mean of the uptake values 
obtained from four jejunal sacs. The experimental results 
are summarised in figs. 5.22 and 5.23 and Table 5.9. From 
Table 5.9 it can be seen that at 15°C the uptake of copolymer 
39a (Mw >400,000) by the tissue is only 13% of that observed 
at 37°C for the same substrate, and that serosal accumulation 
of radioactivity is only 26% of the 37 C values. Copolymer 
39e (Mw 34,000) enters the tissue and serosal fluid at 52% 
and 33% respectively the normal rate at 15 C. These results 
show that uptake is a metabolic process which cannot proceed 
efficiently at reduced temperatures and precludes the 
possibility that the progressive accumulation of substrate 
by the tissue at 37°C is due to substrate binding to the 
surface of the tissue without subsequent internalization.
5.2.5 Pinocvtic Uptake of Copolymer 68 by the Rat Jejunal Sac
The experimental procedure to determine the pinocytic uptake 
of radiolabelled copolymer 68 (Mw 171,OOO) was exactly as 
described above. Jejunal sacs were incubated with substrate 
(125 pg/ml) for 1.5h. The experiment was performed three 
times with matched 125I-PVP controls and the result of both 
tissue and serosal accumulation of the copolymer is shown in 
fig. 5.24. The rates of uptake of radioactive substrate by 
the tissue and into the serosal fluid were 0.97 and 0.35 pl/mg/h
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FIGURE 5.22
A C C U M U L A T I O N  O F  I - L A B E L L E D  C O P O L Y M E R  
39a B Y  T H E  R A T  J E J U N A L  S AC  A T  1 ^ C  A N D  37°C
o
•  T i s s u e  a c c u m u l a t i o n  a t  15 C 
a  S er os al  a c c u m u l a t i o n  a t  1 5 ° C  
▲ T i s s u e  a c c u m u l a t i o n  at 3 7 ° C  
o  S e r o s a l  a c c u m u l a t i o n  a t  3 7  C
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FIGURE 5.23
A C C U M U L A T I O N  O F  1 2 5 I - L A B E L L E D  C OP O L Y M E R  
39e BY T H E  R A T  J E J U N A L  S A C  A T  15°C A N D  37°C
a  S e r o s a l  a c c u m u l a t i o n  a t  1 5 ° C  
a  T  i s s u e  a c c u m u l a t i o n  a t 3 7 ° C  
o  S e r o s a l  a c c u m u l a t i o n  at  3 7 ° C
TABLE 5.9
THE UPTAKE OF COPOLYMERS 39a AND 39e BY JEJUNAL SACS
POLYMER 
CODE NO.
TISSUE 0ACCUMULATION % OF 37 C 
( jil/mg/h) CONTROL
SEROSAL
ACCUMULATION
(fil/mg/h)
39a 0.42 13 0.13
AT 15°C
% OF 37°C 
CONTROL
26
39e 0.32 52 0 . 11 33
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FIGURE 5. 24
A C C U M U L A T I O N  O F 125I - L A B E L L E D  COPOLYME R 
68 B Y  T H E  R A T  J E J U N A L  S A C
•  T i s s u e  a c c u m u l a t i o n  
o  S e r o s a l  a c c u m u l a t i o n
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respect ively, giving a total rate of uptake of 1.31 pl/mg/h. 
This value is similar to the rate obtained for unfractionated 
copolymer 39 (1.82 pl/mg/h) which is of approximately the same 
average molecular weight (190,000) and polydispersity. In 
fact, the slightly larger copolymer (39) has a slightly 
higher rate of uptake which is to be expected in view of the 
substrate size effect in this tissue (section 5.2.1).
Previous experiments using the rat visceral yolk sac 
(section 4.2.5) have shown that [123i} iodotyrosine is not 
released from the copolymer backbone following pinocytic 
uptake of this substrate.
Since the radiolabelling efficiency of this copolymer was 
consistently low (section 3.3), the number of radioactive 
counts recovered from the serosal fluid was correspondingly 
low for the substrate concentration used in these experiments. 
For this reason, the substrate was dialysed to remove 
contaminating jj123!] iodide immediately before use in uptake 
experiments, and radioactive counts present in the serosal 
fluid following incubation of copolymer 68 with jejunal sacs 
were assumed to be due to radiolabelled macromolecules whose 
crosslinks may or may not have undergone cleavage during their 
transport across the tissue. Since £ l] iodotyrosine is not 
released from this substrate, and free ^ 1 2 5 l j  iodide levels, in 
theory, should be insignificant, this seemed a reasonable 
assumption to make. Both Sephadex G-15 (to detect iodide) 
and Sepharose 4B/6B (to detect changes in molecular weight 
distribution) ideally should have been carried out on serosal 
fluids, but the necessary dilution of the samples to achieve 
separation of peaks would have been too great for the radio­
active counts present to provide meaningful results.
-117-
5.2.6 Pinocvtic Uptake of Copolymer 39 by Loops of Jejunal 
Tissue
This experiment was carried out to prove that macromolecules 
actually pass across the intestine, rather than gaining 
entrance to the serosal fluid through the tied ends of the 
jejunal sacs, which remain immersed in the culture medium 
during the experimental period.
Three everted jejunal sacs were prepared as described 
previously (section 2.7), but on this occasion were of 
approximately 10 cm in length (rather than 3—4 cm). Each sac 
was placed in a culture flask containing medium as shown in 
fig. 5.25, with the tied ends of the sacs suspended by cotton 
and remaining above the culture medium throughout the 
experimental period. Each flask was then incubated for l«5h 
at 37°C with 125 fig/ml of 125I-labelled copolymer 39 
(unfractionated) exactly as described in earlier experiments.
The results were expressed in fil/mg protein giving the total 
pinocytic uptake over l#5h and are shown in Table 5*10* Also 
shown in Table 5.8 for comparison are the average results 
obtained from previous experiments on incubation of sacs with 
125I-labelled unfractionated copolymer 39.
Sephadex G-25 column chromatography of the serosal fluids 
from two loops of tissue revealed that 34.77% and 22.2% of 
the radioactivity present in the serosal fluid was attached 
to macromolecules.
It must be stressed that this experiment shows only that 
macromolecules are transported across the rat jejunum, and 
that the actual quantities given do not represent the true
SCHEMATIC R E P R E S E N T A T I O N  O F  T H E  T E C H N I Q U E  U S E D
f o r  t h e  i n c u b a t i o n  o f  « ^ - l a b e l l e d  C O P O L Y M E R  39 
W I T H  L O O P S  O F  J E J U N A L  T I S S U E __________________
FIGURE 5.25
SCHEMATIC R E P R E S E N T A T I O N  O F  T H E  T E C H N I Q U E  U S E D  
FOR T H E  I N C U B A T I O N  O F  « ^ - L A B E L L E D  C O P O L Y M E R  39 
WI T H  L O O P S  o f  J E J U N A L  T I S S U E ________________________
FIGURE 5.25
TABLE 5,10
125,
OF JEJUNAL TISSUE
JEJUNAL
TISSUE
TISSUE
ACCUMULATION
(pl/mg/l.5h)
SEROSAL
ACCUMULATION
(pl/mg/l.5h)
TOTAL UPTAKE 
(pl/mg/l.5h)
Loop 1 0.66 0.36 1.02
Loop 2 0.51 0. 18 0.68
Loop 3 0.76 0.25 1.01
Sac 1.38 - 0.16 0.45 - 0.01 1.82
I {| /
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rates of uptake, since only approximately 50% of the tissue 
was in contact with the medium containing the substrate 
during the experimental period. The results are expressed in 
terms of pl/mg protein contained in the whole sac, and are 
therefore a gross underestimate of the true uptake values.
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5.3 DISCUSSION
The rate of uptake of the crosslinked copolymer 39 by jejunal
tissue was dependent upon the size of the copolymer used.
There was an increase in the rate of tissue accumulation with
larger me am molecular weight of the copolymers. This was
clearly demonstrated in the case of copolymer 39a (Mw >400,000),
where the rate of tissue accumulation was 489% of matched
125I-PVP (Mw 40,000) control experiments (Table 5.11 and fig.
5.9 ). 125I-PVP is an accepted marker of fluid-phase
pinocytosis both in the rat jejunum and the rat visceral yolk
sac. With the exception of copolymer 39e (M* 34,000), a
slightly smaller molecule than I-PVP, it can be seen from
Table 5.11 that all copolymer fractions enter the tissue at a
higher rate than the fluid—phase substrate. This observation
is the opposite of that observed using the same substrates in
the rat visceral yolk sac system (the results of which are
also shown in Table 5.11) where all larger copolymer fractions
125enter the tissue at a lower rate than I—PVP.
Table 5.IT, however, only represents the rate of accumulation 
of substrate by the tissue during the experimental period.
It does not account for substrate which has been pinocytosed 
by the tissue and degraded by lysosomal enzymes with 
subsequent release of low molecular weight radiolabelled 
degradation products, or the transport of substrate across 
the tissue following its uptake by cells (in the case of the 
everted jejunal sacs).
Sephadex G-15 chromatography of the external culture medium 
following incubation of each of the fractions with jejunal 
sacs for 1.5h did not reveal the presence of any low molecular
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weight degradation products attributable to hydrolysis by 
lysosomal enzymes with subsequent release of [125l] iodotyrosine 
By using conditioned medium* it was discovered that the small 
amount of f1251] iodotyrosine present (1 pl/mg/l.5h or less) was 
the product of extracellular hydrolysis of susceptible bonds 
by enzymes present in the culture medium during the experiment 
This finding also excluded the possibility that brush border 
enzymes present on the apical membranes of the enterocytes 
were responsible for the degradation observed.
All the crosslinked copolymer 39 fractions were translocated 
to some extent into the serosal fluid during the 1.5h 
incubation period (fig. 5.17)» but the rate of transfer of 
radioactivity was independent of copolymer molecular weight» 
and all rates were much lower than those observed for the 
uptake into the tissue.
The total pinocytic uptake by the jejunal sac was therefore 
estimated by summing the radioactivity present in the tissue 
with that transported into the serosal fluid» or the total 
rate by summing the individual rates. Table 5.12 shows a 
summary of the total rates of uptake by the rat visceral yolk 
sac and the rat jejunum, and it can be seen that, when 
degradation by the yolk sac and serosal transfer by the 
jejunal sac has been accounted for, the patterns observed 
from the tissue levels remain the same i.e. in the yolk sac, 
the rate of pinocytosis increases with decreasing molecular 
size and in the jejunal sac the rate of pinocytosis increases 
with increasing molecular size. It is also apparent that 
125I - P V P  enters the jejunum at half the rate it enters the 
yolk sac and that copolymer 39d (Mw 110,000) is taken up at a 
similar rate by both tissues.
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The reason why the two morphologically similar absorptive 
epithelial tissues from the same species should behave in 
opposite ways remains obscuret but it is apparent that where 
the yolk sac discriminates against larger molecules, the rat 
intestine does not. The higher rates of uptake of larger 
molecules by the jejunal sac must be due to an adsorptive 
interaction between the substrate and the enterocyte membrane 
which intensifies with increasing molecular weight.
Studies by Duncan et al (1981) on the effect of molecular 
size of 125I-PVP on its pinocytosis by rat visceral yolk sacs 
and rat peritoneal macrophages showed that these two cell 
types could discriminate between molecules of the same 
substrate with different molecular weight. Macrophages 
captured the highest mean molecular weight preparation of 
125I-PVP more rapidly whereas the rate of capture by the yolk 
sac decreased with increasing molecular weight (Chapter 4).
The possibility that the differences in rates of uptake with
increasing substrate size in macrophages could be attributable
to a substrate—induced change in the rate of vesicle formation
125 —was disproved by observing the rate of I—PVP (Mw 40,000)
uptake in the presence of unlabelled preparations of various 
molecular sizes. Duncan et al postulated that the very large 
(Mw 700,000 and 7,000,000) I-PVP molecules have some
affinity for the macrophage cell surface that is not manifest 
in their smaller counterparts, and that it was possible that 
the affinity of the vinylpyrrolidone residue for the plasma 
membrane is so slight as to be ineffective until the molecule 
can provide a sufficient number of attachment sites. This 
suggestion could perhaps also explain the interaction between
certain residues present on crosslinked HPMA copolymers and 
the enterocyte membrane.
The rate of transfer of radioactivity into the serosal fluid 
is much lower than that observed for pinocytic uptake of 
substrate into the tissue. This is probably due to the fact 
that the substrate molecules do not only have to cross the 
intestinal epithelium, but also several other layers of cells 
(including two muscle layers) and basement membranes, each of 
a different nature (section 5.1). The yolk sac similarly 
consists of several layers of cells, but is by no means as 
thick as the intestinal tissue (section 4.1). Jacques (1975) 
suggested that transport is the result of several selection 
steps at different levels, each of which must be overcome 
before the molecule can reach the serosal surface. It is 
impossible, however, to extrapolate the results obtained for 
transport across the intestine to an in vivo situation, where 
endocytosed material would presumably enter the blood 
circulation or lymphatic system and be transported to remote 
organs rather than traverse the whole intestinal tissue to 
the extent observed.
Sephadex chromatography of the serosal fluid revealed that 
the radioactivity recovered was due to the presence of 
125I-labelled copolymers, [*251] iodide and [125l} iodotyrosine. 
The presence of radiolabelled copolymers indicated that some 
macromolecule transport had occurred across the intestine and 
that potentially degradable oligopeptide crosslinks or inter- 
molecular bridges within the molecules had somehow escaped 
enzymatic hydrolysis. Alternatively, hydrolysis of the 
crosslink could have taken place in one position only, 
resulting in the radiolabelled tyrosine residue remaining
attached to a polymer chain via an oligopeptide sidechain.
A further possibility is the pinocytic transport across the
enterocytes (and possibly subsequent layers of tissue) via a
non-lysosomal route (diacytosis)• This finding is consistent
with observations made by Bridges (1980) and Beahon (1981) on
125the transport of degradable I—HRP macromolecules across
everted jejunal sacs*
fluids following incubation of sacs with all copolymer 39 
fractions, in quantities greater than could be accounted for 
by simple diffusion across the tissue. This probably indicates 
that pinocytosed copolymers were degraded to some extent by 
lysosomal enzymes present in the tissue and suggests a 
unidirectional flow of degradation products away from the gut 
lumen (mucosal surface). This would make sense in 
physiological terms, when the degradation products of macro- 
molecules ingested by enterocytes might be passed on to the 
blood circulation or to other cells deeper in the tissue for 
utilization in anabolic processes. [125l]iodotyrosine is not, 
however, re-incorporated into newly synthesized proteins 
but is excreted. It is also quite possible that a 
unidirectional flow of degradation products could occur in 
the yolk sac tissue in order to supply the growing embryo with 
a source of amino acids, but it would not be possible to 
demonstrate this in the 'open' yolk sac system, where both 
surfaces of the yolk sac tissue are in contact with the same 
culture medium.
For two reasons, it was not possible to prove, or disprove, 
the occurrence of pinocytic uptake and lysosomal degradation 
of crosslinked HPMA copolymers by the rat jejunal sac by
found to be present in the serosal
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carrying out experiments which employed metabolic and
proteinase inhibitors e.g. 2,4-dinitrophenol and leupeptin
(section 4.2.4). Firstly, as discussed in section 5.1,
studies by other workers have shown that it is not possible
to totally inhibit uptake by this tissue using metabolic
inhibitors. Bridges (1980) found that various concentrations
of 2 ,4 -dinitrophenol (which abolishes pinocytosis in the rat
visceral yolk sac), sodium fluoride and sodium azide did not
125produce more than 50% inhibition of uptake of I-PVP by 
jejunal sacs. Secondly, in order to prove that degradation 
of a given substrate takes place in the lysosomes, experiments 
using e.g. the lysosomal thiol-proteinase inhibitor, leupeptin, 
are used which aim to detect a reduction in the amount of 
degradation taking place within lysosomes. The levels of 
radioactivity representing degradation product in the serosal 
fluid were, however, too low to enable significant differences 
to be observed from experiments which employed leupeptin.
The experiments carried out at low temperature (15 C) did 
show significant differences in the uptake of copolymers 39a 
and 39e when compared to those carried out at 37 C. Copolymer 
39a was taken up at 13% the rate observed at 37 C into the 
tissue and 26% of the normal rate into the serosal fluid. 
Copolymer 39e values were 52% and 33% of the 37°C values for 
the tissue and serosal accumulation. These results, together 
with figs. 5.22 and 5.23 show that the uptake values 
obtained at 37°C do not represent substrate progressively 
binding to the tissue over the incubation period, without 
membrane internalization, since this could equally well occur 
at 15°C. The reduced levels observed at 15°C, particularly 
with copolymer 39a, clearly demonstrate that the mechanism
-125
responsible for the uptake and transport of macromolecules 
by the intestine is a temperature-dependent metabolic process.
The pinocytosis of copolymer 68 (Mw 171,000) by the jejunal 
sac gave a total rate of uptake of 1.31 jil/mg/h. This value 
was similar to that observed for copolymers of similar average 
molecular size (Table 5.11). As discussed previously, this 
copolymer also contains potentially degradable crosslinks, 
but the radiolabel is situated close to the copolymer backbone 
and therefore is an indicator of the presence of the copolymer 
chain rather than of crosslink presence/cleavage, which is the 
case in copolymer 3 9. It was assumed, therefore, that radio­
activity present in the serosal fluid following incubation of 
copolymer 68 with jejunal sacs, was due to the presence of 
macromolecules, since iodotyrosine is not released from
this copolymer (Chapters 3 and 4), and the copolymer 
preparation used was essentially free of contaminating
The transport of macromolecules across the jejunal tissue was 
demonstrated using loops of intestine. This experiment 
disproved the possibility that all macromolecules entered the 
serosal fluid through the cut ends of the sacs which are tied 
off with cotton. The experiment did not aim to give accurate 
quantitative measures of translocation rates, since 
approximately 50% of the tissue, though included in the tissue 
protein determination, was not in contact with the substrate. 
Three separate experiments, however, indicated transfer of 
radioactivity into the serosal fluid, and Sephadex G—25 
chromatography carried out on two of the samples indicated 
that 34.77% and 22.2% of the radioactivity was due to the
presence of macromolecules» the rest being due to iodide
and [125lJ iodotyrosine.
In summary, the data obtained from the experiments performed 
using the rat everted jejunal sac have shown that I-labelled 
crosslinked HPMA copolymers are taken up by the tissue at a 
rate that is dependent on the mean molecular weight of the 
copolymer used. The lowest molecular weight fraction 
(Mw 34,000) is taken up at a rate consistent with fluid-phase 
pinocytosis, and increasing molecular size results in 
adsorption to the cell membrane with resulting increase in 
uptake with high molecular weight fractions. Uptake of HPMA 
copolymers is by a mechanism dependent upon metabolic energy 
and/or membrane fluidity and is most probably by pinocytosis 
(rather than intercellular transport). HMPA copolymers move 
across the intestine into the serosal fluid at a lower rate 
which is independent of molecular size. A small amount of 
degradation of all copolymer 39 fractions is observed, some 
of which takes place extracellularly. The degradation products 
observed in the serosal fluid are probably the result of 
intracellular lysosomal degradation with subsequent release 
of degradation products across the baso-lateral membrane of 
the enterocytes, resulting in the eventual appearance on the 
serosal side of the tissue.
From the experiments performed using everted jejunal sacs, 
and rat visceral yolk sacs (Chapter 4, section 3), it was not 
possible to prove conclusively that crosslink cleavage took 
place to yield copolymer chains of lower mean molecular
weight
CHAPTER 6
BLOOD CLEARANCE AND ORGAN DEPOSITION OF 
125I-LABELLED HPMA COPOLYMERS FOLLOWING 
INTRAVENOUS ADMINISTRATION TO RATS
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6.1 INTRODUCTION
The in vitro experiments reported in previous chapters have 
demonstrated that soluble crosslinked HPMA copolymers are 
pinocytosed by cells and that the crosslinks are degraded to 
some extent by lysosomal enzymes present within the tissues.
An effect of size of the polymer on its rate of uptake by cells 
has also been observed. In the yolk sac. pinocytic uptake of 
the substrate is seen to increase with decreasing molecular 
weight, and the jejunal sac shows a preferential uptake of 
higher molecular weight fractions. From these results, it is 
apparent that morphologically similar cell types do not behave 
in a similar fashion.
In order to study the pinocytic uptake of crosslinked HPMA 
copolymers of differing average molecular weights by different 
tissues within the body, in vivo experiments were subsequently 
undertaken. This chapter reports the blood clearance and 
organ deposition of 125I-labelled crosslinked copolymer 
fractions of different molecular weights following intravenous 
injection to rats. The possibility of targeting crosslinked 
polymers to hepatocytes by the incorporation of galactosamine 
residues into the polymer structure is also investigated (see 
Chapter 1).
The clearance from the bloodstream of any macromolecule, 
particularly one with little affinity for cell membranes such 
as the HPMA copolymers described so far, is governed to a large 
extent by its size (Kooistra et al 1980). Molecules of less 
than approximately Mw 40,000 are removed rapidly from the 
bloodstream by glomerular filtration. The exact renal 
threshold value is dependent on the shape and charge of the
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molecule, and in the case of polymers the flexibility of the 
polymer coil may also play a role in the passage across the 
glomerular barrier (Rypacek et al 1982).
Rogoeczi (1976) demonstrated an essentially biphasic pattern 
of clearance of 125I-PVP (Mw 50,000) from the bloodstream of 
rabbits, with an initial rapid clearance of the polymer due to 
the ultrafiltration of smaller molecules by the kidney 
followed by a slower rate of clearance due to tissue uptake of 
the larger molecules.
125Rogoeczi (1976) also demonstrated that I-PVP possessed no 
affinity for plasma proteins* he incubated it with human plasma 
and compared the dispersity of the preparation before and after 
incubation, using gel permeation chromatography. Similar 
studies have been carried out on crosslinked HPMA copolymers 
(section 3.7) using rat plasma, and the results demonstrate 
that this polymer, too, has no affinity for plasma proteins.
In vivo experiments using 125I-PVP (M^ r 33,000) as a marker for 
fluid-phase pinocytosis have been carried out by Munniksma et 
al (1980) in order to determine rate constants of fluid—phase 
pinocytosis of liver, spleen, parenchymal and sinusoidal liver 
cells (hepatocytes and Kupffer cells). Rate constants of 1.2 
and 1.8 ml of plasma per gram of tissue weight per day were 
calculated for liver and spleen respectively, and Kupffer cells 
were observed to pinocytose about nine times as much PVP as 
parenchymal cells. Subcellular fractionation of liver showed 
that PVP is mainly localized in the lysosomes following 
pinocytic uptake.
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The effect of molecular size on blood clearance and organ 
deposition has been studied by a number of workers. Kooistra 
et al (1980) found that rat sinusoidal liver cells (Kupffer 
cells - of the reticuloendothelial system) demonstrated 
preferential uptake of large basic proteins following in vivo 
studies using lysozyme, ribonucléase and lactic dehydrogenase. 
Ilium et al (1982) studied the effect of particle size on the 
blood clearance and organ deposition of intravenously 
administered colloidal particles and showed that small (1.27 pm 
diameter) polystyrene microspheres were taken up by sinusoidal 
cells of the liver, while large polystyrene particles (15.8 pm 
diameter) were mechanically deposited in the capillary beds of 
the lungs.
14The elimination and retention of C-labelled non-degradable 
Poly N-(2-hydroxypropyl)methacrylamide (Duxon - see Chapter 1) 
by rabbits following intravenous administration was investigated 
by Sprincl et al (1976). Five polymer fractions (Mw 11,000, 
28,000, 33,000, 63,000 and 91,000) of Gaussian molecular weight 
distribution were used in the study and it was found that 
polymers of lower molecular weights (11,000 and 28,000) were 
eliminated from the body via the kidney. The higher molecular 
weight polymers were found to be deposited in the organs of 
the reticuloendothelial system, particularly the spleen and 
lymph nodes.
Rypàcek et al (1982) also investigated the blood clearance and 
renal excretion of another ’inert' synthetic polymer, 
N(2-hydroxyethyl)aspartamide (PHEA) in rabbits and mice.
Polymer fractions (fiir 11,000-32,000) were injected intravenously 
into rabbits and demonstrated increased renal excretion with
decreasing average molecular weight of the polymer.
The in vivo studies described above (Sprincl 1976, Rypacek 1982) 
have employed soluble synthetic polymers ranging from Mw 11,000 
to Mw 91,000. The HPMA copolymer 39 fractions (crosslink 
structure p-Gly-Gly-Phe-Tyr-HMDA-Tyr-Phe-Gly-Gly-P) described 
in previous chapters are of Mw 34,000->400,000, and have a 
narrow polydispersity. In order to observe the effect of 
polymer size on its clearance from the bloodstream and to 
examine the possibility of different patterns of organ 
deposition on administration of polymers of different sizes, 
radiolabelled copolymer 39 fractions and copolymer 74 (the 
aminolysed polymeric precursor of copolymer 39) were injected 
intravenously to rats and their subsequent fate examined. 
^ ^ I - P V P , a known in vitro and in vivo marker of fluid-phase 
pinocytosis, was used as a control substrate.
It has been shown previously (Chapters 4 and 5) that 
experiments performed in vitro using copolymers 39 and 74 
demonstrate hydrolysis of susceptible bonds following uptake 
of copolymer by cells, with resultant liberation of radio- 
labelled low molecular weight degradation products. Detection 
of these 125I-labelled degradation products was achieved 
following Sephadex G—15 column chromatography (section 2.5) of 
culture medium after each experiment. It is not possible, 
however, to determine the possible degradation of crosslinks 
or sidechains from small blood samples (50 pi) following 
administration of 125I-labelled copolymers 39 and 74 in vivo.
Radiolabelled copolymer 68 (Mw 171,000, crosslink structure 
P-Gly-Gly-Phe-HMDA—Phe-Gly—Gly-P) contains a radioiodinated 
tyrosine residue attached to the copolymer backbone which is
not susceptible to hydrolysis by enzymes (Chapter 4). This 
copolymer was also administered intravenously to rats for 
comparison with the unfractionated copolymer 39 (Mw 190,000).
If the blood clearance patterns and organ deposition of the 
two copolymers proved similar, this would probably indicate 
that the radiolabel was still attached to the copolymer in both 
cases, and that degradation of oligopeptide sequences present 
in copolymer 39 had not taken place to any significant extent. 
Alternatively, if extensive degradation of copolymer 39 did 
take place over the proposed experimental period, one might 
expect a different rate of blood clearance and pattern of organ 
deposition due to a more rapid cellular uptake of smaller 
radiolabelled copolymer degradation products.
The role of carbohydrates in the recognition and uptake of 
glycoproteins from the blood circulation has been the subject 
of a number of studies (Ashwell and Morrell 1974, Schlesinger 
et al 1980, Jourdian et al 1981, Pitha et al 1981, Shepherd 
et al 1983), and has been discussed in Chapter 1. One such 
recognition system is the uptake of galactose-exposing proteins 
by mammalian hepatocytes. The incorporation of galactosamine 
into sidechains of 125I-labelled tyrosine-containing HPMA 
copolymers (Mw 25,000) has been shown to enhance the pinocytic 
uptake of the polymer from the bloodstream into the liver in 
the rat (Duncan et al 1983). With a control HPMA copolymer 
bearing l-aminopropan-2-ol in place of the galactosamine,
10.11% of the recovered radioactivity was present in the liver 
after lh, whereas 68.95% of the recovered radioactivity was 
found in the liver following intravenous administration of 
the copolymer bearing galactosamine after lh. This finding is 
presumably due to the receptor-mediated pinocytosis of
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galactose-bearing macromolecules by liver hepatocytes (Chapter 1)<| 
For both copolymers approximately 20% of the recovered radio­
activity was found in the kidneys.
Copolymers 78 and 79 are crosslinked copolymers prepared from 
the same polymeric precursor (Mw 21,500) and contain the same 
crosslink structure (P-Gly-Gly-Phe-HMDA-Phe-Gly-Gly-P) with 
tyrosineamide attached to the polymer backbone to enable 
radioiodination of the copolymer. Both are of similar Mw 
(copolymer 78 73,800 and copolymer 79 64,300) and polydispersity 
(3.05 and 2.74 respectively). Copolymer 78 contains 
galactosamine (2 mol %) attached to the copolymer backbone via 
a diglycyl spacer, and copolymer 79 contains 1—aminopropan—2—ol 
in place of galactosamine.
These polymers were prepared (section 3.2), radiolabelled 
(section 2.3) and administered intravenously to rats in order 
to observe the effect of the galactosamine moiety on the 
pinocytic uptake of crosslinked copolymers i.e. polymers of Mw 
higher than the renal threshold, by the liver. Since copolymer 
79 is similar to copolymer 78 in all respects except for the 
absence of galactosamine, any differences observed in the blood 
clearance and organ deposition of the two polymers must be 
attributable to the presence of the sugar moiety.
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6.2 RESULTS
6.2.1 Blood Clearance and Organ Deposition of Copolymer 39 
Fractions and Copolymer 74 in the Rat Following 
Intravenous Administration» The Effect of Size
Following injection of radiolabelled copolymers (125 )ig in 
0.1 ml phosphate buffer pH 8.0) into the femoral vein, 
duplicate 50 pi blood samples were taken at various time 
intervals over a period of one hour and assayed for radio­
activity. At the end of each experiment, the animals were 
sacrificed and the liver, lungs, kidneys and spleen removed 
and assayed for radioactivity (section 2.11.6). Experiments 
using each substrate were repeated at least twice.
Figures 6.1-6.6 show the blood clearance of the different
fractions and of the unfractionated copolymer 39. Figure 6.7
combines figures 6.1—6.6. Figure 6.8 shows the clearance of
the polymeric precursor (copolymer 74) from the rat bloodstream
IPSand fig 6.9 that of the I-PVP control. Results are 
expressed as a percentage of the value obtained two minutes 
following intravenous administration, since it was not possible 
in practice to obtain a value for t=0. Furthermore, to express 
the results as a percentage of the dose administered requires 
a value for the total blood volume and also must assume that 
10056 of the dose enters the circulation.
From these results it can be seen that the clearance of radio- 
labelled copolymer from the bloodstream is related to the 
average molecular weight of the preparation. Blood levels of 
the three largest fractions (39a, b and c Mw >400,000, 400,000 
and 150,000) after one hour were in excess of 90% of the
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2 min value, indicating a very slow rate of clearance.
Copolymer 39d, Mw 110,000, demonstrates a more rapid clearance 
over the first five minutes following administration, after 
which there is little further clearance over the rest of the 
experimental period with 77.5% of the 2 min value remaining in 
the bloodstream after one hour. This observation is consistent 
with the removal of smaller polymers contained within the 
preparation by glomerular filtration. Copolymer 39e (Mw 34,000) 
and the unfractionated copolymer 39 (which contains a large 
proportion of low molecular weight fractions) show a more 
pronounced clearance over the first ten minutes of the 
experimental period, followed by a gradual decrease in radio­
activity present in the bloodstream resulting in 47.2% (for 
39e) and 62.4% (for the unfractionated copolymer) of the initial 
values still present in the bloodstream after one hour.
This pattern of more rapid clearance with decreasing molecular 
weight is apparent again on administration of copolymer 74 
(Mw 31,000) which is cleared quickly with only 40% of the 
initial value present in the bloodstream at the end of the 
experiment (fig 6.8). Finally, 125I-PVP (Mw 40,000) (fig 6.9) 
is cleared at a rate consistent with its average molecular 
weight, showing similar, but slightly higher levels than 
copolymer 39e (Mw 34,000).
Table 6.1 summarises the amounts of radioactivity recovered 
from the tissues one hour after intravenous administration of 
the various fractions. The total in the blood was calculated 
by multiplying the concentration of radioactivity in the blood 
by the blood volume, estimated by the formula of Everett et al 
(1956), i.e. 55.6 pi blood per gram body weight. Dose 
recoveries were calculated by expressing the total radioactivity
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recover ed from the experiment as a percentage of the dose 
administered and were almost always in excess of 90%. It can 
be seen that the unfractionated copolymer 39, fraction 39e, 
copolymer 74 and 125I-PVP are all found in a higher percentage 
in the kidneys. This is presumably due to ultrafiltration, 
since all contain a significant number of small molecules, and 
are cleared from the bloodstream rapidly. Table 6.1 also shows 
that between 4 and 8% of the radioactivity recovered is found 
in the liver, and between 1 and 3% in the lung.
In order to establish whether the values presented in Table 6.1 
were the consequence of tissue uptake of copolymers by the 
various organs or were due to the presence of residual blood 
which contained the copolymers, control experiments were 
performed (once only) to estimate the body distribution of 
radiolabelled copolymers 2 minutes following intravenous 
administration, on the assumption that uptake into the various 
organs would be less after 2 minutes than one hour. Table 6.2 
shows the results of these experiments, from which it can be 
seen that similar levels of radioactivity are recovered from 
the lungs, liver and spleen 2 minutes and 1 hour following 
intravenous administration. This finding suggests that the 
levels of radioactivity shown in Table 6.1 for those organs are 
largely due to the presence of residual blood.
The levels of radioactivity present in the kidney after 2 
minutes do however increase with decreasing average molecular 
weight and this finding is more pronounced after 1 hour. This 
indicates a very rapid clearance of small molecules in the 
first few minutes following intravenous administration. The 
percentage of the unfractionated copolymer in the kidney after 
2 minutes is higher than that noted after 1 hour. This could
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indicate the rapid passage of smaller molecules into the kidney 
following introduction of the copolymer into the bloodstream, 
with subsequent passage into the bladder during the experimental 
period. This would result in a lower level of radioactivity in 
the kidney at the end of the 1 hour experiment. The contents 
of the bladder were not assayed for radioactivity. It must be 
noted, however, that the 2 minute experiment was performed once 
only and that this observation was noted only on administration 
of the unfractionated copolymer. All fractions derived from 
this copolymer, including the smallest copolymer, 39e (Mw 34,000) 
showed a higher percentage of recovered radioactivity in the 
kidney after 1 hour than after 2 minutes.
Everett et al (1956) proposed a method for estimating organ 
blood volumes. Using their values, the data of Table 6.1 were 
revised to subtract blood-borne radioactivity. The result is 
shown in Table 6.3 and indicates virtually no accumulation of 
radioactivity in the liver, lungs and spleen. This confirms 
the earlier surmise that the levels of radioactivity shown in 
Table 6.1 for those organs are largely due to residual blood.
The levels of radioactivity recovered from the kidney (after 
correcting for blood) do, however, indicate that smaller 
polymer molecules are being filtered out of the blood by the 
organ.
6.2.2 Blood Clearance and Organ Deposition of Copolymer 68 
in the Rat Following Intravenous Administration
The quantitation of blood clearance and body distribution of 
copolymer 68 over a 1 hour experimental period following 
intravenous administration to rats was carried out exactly as 
described in the previous section. The blood clearance
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(fig 6.10) shows the mean * S.E. of four experiments and the 
organ distribution of recovered radioactivity is shown in 
Table 6.4. From these results it is apparent that this 
unfractionated copolymer enters the kidney, with little 
accumulation elsewhere. Again, this is most probably due to 
the ultrafiltration of smaller molecules present in the 
polydisperse preparation. The clearance of copolymer 68 from 
the bloodstream is, however, slightly slower than that 
observed for unfractionated copolymer 39. The reason for this 
is not known, but one possibility is that copolymer 68, a more 
densely crosslinked copolymer, could contain a smaller 
proportion of lower molecular weight fractions than copolymer 
39, resulting in a less rapid initial loss of copolymer from 
the bloodstream (figs 6.6 and 6.10). Sepharose 4B/6B elution 
profiles of the two copolymers (section 3.4, figs 4 and 11) 
appear to support this suggestion.
6.2.3 Blood Clearance and Organ Deposition of Copolymers 78 
and 79 Following Intravenous Administration to Ratsi 
Targeting to the Liver
Copolymers 78 and 79 were administered to rats as described 
previously and blood levels monitored for 1 hour. The body 
distribution of radioactivity was estimated after 1 hour and 
the results of triplicate experiments are shown in fig 6.11 
and Table 6.5. Fig 6.11 shows that the copolymer containing 
galactosamine residues (copolymer 78) is cleared more rapidly 
from the bloodstream than the control copolymer (79). From 
Table 6.5 it is clear that the radiolabelled copolymer 78 has 
been efficiently captured by the liver, where 60.42% of the 
recovered radioactivity is found to be present 1 hour following 
intravenous administration, in contrast with only 7.48% with 
the control polymer. Little accumulation of copolymers 78 and
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79 is seen in the lungs and spleen. Both copolymers are 
present in the kidneys, but a greater amount (12.35%) is 
present following administration of copolymer 79, than 
copolymer 78 (3.76%). The reason for this is probably the 
ultrafiltration of smaller molecules, and although both 
preparations contain approximately the same proportion of lower 
molecular weight fractions, it is likely that smaller copolymer 
78 molecules will contain galactosamine residues which could be 
removed from the circulation by the liver (through receptor- 
mediated pinocytosis by hepatocytes) even before encountering 
the kidney glomerulus. This suggestion is supported by the 
values shown in Table 6.6 for the organ deposition of 
copolymers 78 and 79 2 minutes following intravenous 
administration, where it can be seen that 21.55% of the 
recovered radioactivity is found in the liver in the case of 
copolymer 78, and only 8.29% (not correcting for blood) in the 
case of copolymer 79. The smaller molecules present in the 
copolymer 79 preparation, which contain no galactosamine 
residues and therefore have little or no affinity for cell 
membranes, would be filtered out in the normal way and be 
present in the kidneys in greater quantity.
Table 6.5 also shows the results of the same experiments after 
correcting for radioactivity present in residual blood within 
the organs. Again, it is apparent that the radioactivity 
present in the liver 1 hour following intravenous administration 
of the control copolymer 79 (7.48%) is largely due to residual 
blood, whereas, in the case of the galactosamine containing 
copolymer 78, almost 60% of the recovered radioactivity is 
still found to be present in the liver after correcting for
blood content.
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TABLE 6.6
BODY DISTRIBUTION OF 125I-LABELLED COPOLYMERS 78 AND 79 
2 MINUTES FOLLOWING INTRAVENOUS ADMINISTRATION TO RATS
POLYMER % RADIOACTIVITY RECOVERED IN
CODE NO. LIVER LUNG KIDNEY SPLEEN BLOOD
78
79
21.55 5.92 7.88
8.29 2.99 4.86
0.27 64.39
0.46 83.40
-139-
6.3 DISCUSSION
The rate of clearance of radiolabelled copolymer 39 fractions 
from the rat bloodstream following intravenous administration 
was dependent upon the average molecular weight of the 
preparation used. The unfractionated copolymer 39 and 
copolymers of an average molecular weight of less than 150,000 
were cleared from the bloodstream to a greater extent than the 
larger fractions over the one hour experimental period.
This finding is consistent with results published previously 
by other workers using soluble synthetic polymers of different 
average molecular weights (Sprincl 1976 and Rypkcek 1982), and 
also confirms that low molecular weight fractions do not bind 
to plasma proteins (which would effectively increase their 
molecular weight and give rise to a different pattern of blood 
clearance). The rapid initial clearance of smaller molecules 
can be explained by filtration through the kidney glomerulus 
(Tables 6.1 and 6.3) and the subsequent slower clearance rate 
is presumably due to endocytosis of different sizes of 
copolymer by a range of cell types and/or movement of the 
radiolabelled molecules from the circulation into intercellular 
spaces. The clearance after the first 20 minutes or so is very 
slow in all cases (figs 6.1-6.10), and hardly apparent in the 
three largest fractions.
It is possible that very large molecules contained within the 
preparations would ultimately be phagocytosed by cells of the 
reticuloendothelial system (e.g. Kupffer cells), although the 
largest copolymer fractions 39a and b, show little or no 
accumulation in organs containing cells of the RE system (liver, 
lungs, spleen) over the experimental period. It cannot be
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assumed, however, that prolonged experiments would show 
similar results.
|l25jj_jodotyrosine is not released from radiolabelled copolymer 
68 following pinocytic uptake by cells (section 4.2.5). The 
copolymer backbone therefore retains its radiolabel throughout 
the experimental period, whether or not the unlabelled cross­
links contained within the molecule are degraded. The radio­
activity levels recorded from the bloodstream and tissues must 
therefore denote the presence of macroraolecules at all times. 
The blood clearance and body distribution of radioactivity 
following intravenous administration of I-labelled copolymer 
68 was very similar to that observed for the unfractionated 
copolymer 39 over the same experimental period. Had copolymer 
39 been degraded extensively, with resultant release of radio- 
labelled low molecular weight degradation products from the 
degraded crosslinks, the pattern of radioactivity recovered 
from the blood and tissues would probably be different (section 
6.1). Since the observations for the two unfractionated 
copolymers are similar, it appears that little degradation of 
copolymer 39 occurs during the 1 hour experimental period.
125The blood clearance and organ deposition of I-labelled 
copolymer 78 following intravenous administration to rats was 
markedly different from all other copolymers used in this study 
including its control (copolymer 79), showing rapid blood 
clearance and copolymer deposition in the liver. This can be 
attributed to the incorporation of galactosamine residues into 
the copolymer, leading to the receptor-mediated pinocytosis of 
the copolymer by rat liver cells as described by Duncan et al 
(¿983Ï.
CHAPTER 7
ORGAN DEPOSITION OF 1251-LABELLED HPMA 
COPOLYMERS FOLLOWING INTRAPERITONEAL, 
SUBCUTANEOUS AND ORAL ADMINISTRATION TO RATS
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7. 1 INTRODUCTION
125The blood clearance and organ deposition of I-labelled 
crosslinked HPMA copolymers following intravenous administration 
to rats was reported in Chapter 6. This chapter investigates 
the fate of soluble crosslinked HPMA copolymers following 
different routes of administration to rats (intraperitoneal, 
subcutaneous and oral). The specific questions asked arei-
1. How long does it take for soluble crosslinked HPMA 
copolymers to migrate from the various sites of 
administration?
2. Is it still possible to target crosslinked copolymers to 
the liver using routes of administration other than the 
intravenous one? (Chapter 6)
3. Does the route of administration of crosslinked copolymers 
affect the organ distribution of radioactivity?
4. Can crosslinked copolymers be cleared from the body?
The possible movements of polymers within the body are depicted 
schematically, using a compartmental model, in fig 7.1. Also 
included in the figure are the points of entry of copolymer 
following the different routes of administration used in this 
study. It can be seen from fig 7.1 that the proposed routes 
of administration result in the introduction of polymer into 
different body compartments.
The intravenous route (used in experiments described in Chapter 
6) involves the entry of polymer directly into the blood 
circulation, resulting in the rapid transport of molecules to 
all vascularized areas of the body. Molecules of a molecular 
weight below that of the renal threshold are filtered from the 
plasma by the kidney glomerulus and excreted in the urine.
Those molecules that are retained in the circulation may either
Intraperitoneal
EXCRETION
FIGURE 7.1
The Possible Fates of Synthetic Polymers In Vivo
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undergo passage across cells of the blood vessels»contained 
within membrane bounded vesicles (diacytosis), or they may 
pass between the cells, depending on the permeability of the 
vascular tissue in question. Clearance of polymers from the 
blood circulation into interstitial fluid across capillary 
walls takes place by diacytosis, since capillary endothelial 
cells are joined together by relatively impermeable cell 
junctions (Simionescu et al 1975). Transendothelial passage 
or passage between cells may, however, take place in 
capillaries of the sinusoidal type where gaps are found 
between endothelial cells,and these intercellular spaces allow 
free communication with the interstitial fluid. Such 
sinusoidal capillaries are found in the liver, spleen, bone 
marrow and lymph nodes (Drobnik and Rypacek 1984). The 
vascular system of the brain, on the other hand, is relatively 
impermeable to macromolecules, diacytosis is reduced, and 
endothelial cells are tightly joined together (Rapoport 1980).
Subcut au» eou s administration of copolymer results in the 
deposition of copolymer into the interstitial fluid (fig 7.1) 
and consequently, migration of polymer from the site of 
injection is less rapid than following intravenous administration 
When present in the interstitial fluid, macromolecules may be 
pinocytosed by adjacent cells or be drained from this 
compartment either into venous capillaries (where pores are 
present) and hence be transported to all vascularized areas, 
or pass through the lymphatic system. Larger molecules are 
believed to be drained preferentially via the lymphatic system 
(Szabo et al 1973). The lymphatic vessels gradually converge 
into two large trunks which empty into the large veins near to 
the heart, thus transporting the polymer into the blood
The distribution of the polymer then proceeds ascirculation.
described above.
Intraperitoneal administration deposits the copolymer into the 
peritoneal cavity. Movement of macromolecules from this 
compartment is hindered by the serose, which lines the inner 
surface of the cavity, and is reported to be slow and take 
place mainly in the lymphatic capillaries (Noronha-Blob 1977) 
which are more permeable than blood capillaries to large 
molecules (Drobnik and Rypàcek 1984). Movement into the 
interstitial fluid can also take place. Ultimately, molecules 
may be transported into the blood circulation and distributed 
throughout the body.
It has been reported that polymers are not transported across 
the intestine into the blood circulation in significant 
quantities (Pitha 1981, Weishenker 1978, Drobnik and Rypàcek 
1984). Oral administration of copolymers was, nevertheless, 
undertaken in view of the previous finding that soluble cross- 
linked HPMA copolymers are transported across the rat jejunum 
in vitro in small quantities (Chapter 5).
The crosslinked HPMA copolymers used in this study were 
polydisperse preparations 39 (crosslink structure 
P-Gly-Gly-Phe-Tyr-HMDA-Tyr-Phe-Gly-Gly-P), 78 and 79 (both of
crosslink structure p—Gly—Gly—Phe—HMDA—Phe-Gly—Gly-P)• The 
characteristics of these copolymers are shown in section 3.4. 
All three copolymers have been shown to be stable in rat 
plasma over 1-24 h (section 3.7).
125I-Labelled copolymer 39 enters cells by fluid-phase 
pinocytosis i.e. with little or no interaction with cell 
membranes. It contains a radiolabelled tyrosine residue within 
its degradable crosslinks. Copolymer 79 also enters cells by
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fluid-phase pinocytosis but contains the radiolabelled 
tyrosine residue attached directly to the copolymer backbone, 
not in its potentially degradable crosslink. The organ 
distribution of radioactivity following administration of 
copolymer 79 will therefore denote the presence of copolymer 
chains, whereas that of copolymer 39 will denote the presence 
of either crosslinks or crosslink degradation products 
(section 4.2.1).
Copolymer 78 is of a similar structure to copolymer 79 but 
contains galactosamine, and has been shown to accumulate 
rapidly in the liver following intravenous administration to
rats (section 6.2.3). Because it interacts with specific cell 
membranes, it shows a different body distribution of copolymer 
from that of its control (copolymer 79). The administration 
of copolymer directly into the blood circulation does, however, 
allow easy access of copolymer to all vascularized areas, and 
the liver contains more blood at any time than any other organ 
in the body. It was of interest, therefore, to observe whether 
copolymer 78 was still able to accumulate in the liver 
following administration to other, more remote, sites of the 
body.
Body distributions of radioactivity were studied following 
administration of these three substrates via the different 
routes over periods up to 24 h. Preliminary experiments 
(employing intraperitoneal administration) were also carried 
out to observe whether or not crosslinked copolymers 78 and 79
could eventually be totally eliminated from the body following 
uptake of the polymers by cells and intralysosomal cleavage of 
crosslinks to produce copolymer chains small enough to be 
excreted from the body. (The importance of body clearance of 
copolymer following its administration was discussed in Chapter 1)
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7.2 RESULTS
7,2.1 Organ Deposition of 125I-labelled Copolymers Following 
Intraperitoneal Administration to Rats
Male Wistar rats (250-350g) were injected intraperitoneally with 
125 pg of 125I-labelled copolymer (39, 78 or 79) in PBS as 
described in section 2.11.2 and placed, if necessary, into 
metabolic cages. After 2 minutes, lh, 2.5h or 24h, animals 
were anaesthetized and duplicate 50 pi blood samples were 
taken and assayed for radioactivity (section 2.11.5). The 
animals were then sacrificed and the peritoneal cavity washed 
with 10 ml of normal saline, as described in section 2.11.6, 
in order to recover copolymer remaining in the cavity. Organs 
were removed, homogenised, and assayed for radioactivity. 
Experiments for each time point, for each substrate, were 
carried out in triplicate. Table 7.1 shows the percentage of 
the administered dose that was recovered at the end of each 
experiment. Results from each experiment are expressed as a 
percentage of the recovered radioactivity.
The organ distribution of radioactivity following intraperitoneal 
injection of copolymer 39 is shown in Table 7.2 and fig 7.2.
It can be seen that over the 24h experimental period, the 
radioactivity recovered from the peritoneal washings declined 
quite rapidly, with only 1.54% of the total recovered radio­
activity remaining after 24h. Over 50% of the radioactivity 
recovered was found in the urine after 24h, with levels in the 
kidney first rising over 2.5h to 3.48% and at some point 
declining to give a value of 1.68% after 24h. Blood levels of 
radioactivity, and levels associated with the liver rose over 
the first 2.5h and then reamined constant.
TABLE 7.1
TNTRAPERITONEAL a d m i n i s t r a t i o n, dose rec over ies (%)
SUBSTRATE 2 min lh 2. 5h 24h
39 117.00 86.09 99.60 59.35
64.00 54.49 76.03 79.68
73.71 21.16 40.66 71.97
78 130.00 108.00 81.43 73.74
66.91 108.00 100.40 68.19
64.93 48.43 32.24 60.03
79 103.00 58.24 38.00 46.07
63.37 51.88 33.90 40.43
78.29 66.77 73.03 45.53
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In order to ascertain the nature of the radioactivity recovered 
from the urine following intraperitoneal injection of copolymer
column and eluted as described previously (section 2.5).
A typical elution profile is shown in fig 7.3 and calculated 
data are presented at the end of this section, along with 
further discussion. Figure 7.3 shows that approximately one 
half of the recovered radioactivity co-elutes with copolymer, 
and the other half is present in the second peak, which co-
Xhe organ deposition of copolymer 79 following intraperitoneal 
administration (Table 7.3 and fig 7.4) shows a very similar 
pattern to that observed for copolymer 39, the only notable 
differences are that blood levels are slightly lower and urine 
levels are slightly higher. A typical elution profile 
following Sepharose 4B/6B chromatography of urine recovered 
from rats injected with 125I-labelled copolymer 79 is shown in 
fig 7.5. It can be seen that two peaks of radioactivity are 
again present, the first co-eluting with copolymer and the 
second with [125l] iodide. This figure shows that the radio­
activity present in the urine is largely attached to the 
copolymer.
The experimental results following intraperitoneal 
administration of the galactosamine containing copolymer 78 to 
rats are shown in Table 7.4 and fig 7.6. It can be seen that 
the copolymer is cleared from the peritoneal cavity at about 
the same rate as copolymers 39 and 79 and that, despite 
administration by the intraperitoneal route, the copolymer is 
still able to accumulate progressively in the liver, with
39, 1 ml samples of urine were applied to a Sepharose 4B/6B
elutes with both iodide and
co
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almost 52% of the recovered radioactivity present in the organ 
24h following injection. This value is approximately the same 
as that observed to accumulate in the liver lh following 
intravenous administration of the copolymer. Presumably, the 
copolymer is cleared rapidly by receptor-mediated pinocytosis 
by liver cells following entry into the blood circulation.
This would result in low blood levels, as observed throughout 
the experimental period.
Although this experiment illustrates the progressive 
accumulation of copolymer 78 in the liver, a single experiment 
was performed to try to ascertain whether the accumulation of 
copolymer took place following transport into the bloodstream, 
or whether it was possible that the copolymer was binding to 
receptors present on the outside of the liver, thereby gaining 
access to the organ from the peritoneal cavity.
An intact liver was removed from a rat following ligation of 
major blood vessels, and was incubated in medium 199 containing 
12-*I-labelled copolymer 78 at 37°C for lh. Following 
incubation, the liver was washed three times in ice cold saline, 
blotted, homogenised, and samples of homogenate assayed for 
radioactivity. It was found that only 0.3% of the polymer in 
the solution was associated with the tissue at the end of the 
experiment. It was therefore concluded that copolymer 
accumulation in the liver, following intraperitoneal injection, 
took place following transport into the blood and removal from 
the circulation by liver cells.
From Table 7.4 it is apparent that copolymer 78 does not 
accumulate significantly in any of the other organs investigated. 
40% of the recovered radioactivity was found in the urine after
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24h. An elution profile of a urine sample is shown in fig 7.7 
which shows the presence of copolymer and a small amount of
Table 7.5 summarises the results of chromatography of all the 
urine samples and shows that, in all cases, the majority of the 
radioactivity present in the urine represents radiolabelled 
copolymer rather than low molecular weight [125i] iodide
counts recovered in the low molecular weight peak is much
level of radioactivity present in the second peak from urine
administration.
The copolymer present in the urine following intraperitoneal 
administration of all radiolabelled preparations could 
represent the filtration of low molecular weight polymer 
fractions present in the dose administered, or filtration of 
partially degraded molecules which have at some point undergone 
pinocytosis, intralysosomal digestion and exocytosis with 
transport back into the bloodstream. It is probable that a 
combination of these two possibilities has taken place, 
particularly in the case of copolymer 39, which, when degraded, 
releases [125l] iodotyrosine. The elution profile obtained from 
the urine sample following administration of copolymer 39 
indicates the presence of such degradation products. In view
free iodide.
or [12 5 lJ iodotyrosine. It can be seen that on administration 
of 125l-labelled copolymer 39, the percentage of the total
greater than that which could be expected from fre 
alone, and must therefore represent a mixture of
and f1 2 5 l]  iodotyrosine crosslink degradation products. The high
containing 125I-labelled copolymer 79 reflects the high level 
of free l125II iodide present in the copolymer preparation on
of this finding, it is not possible to determine whether the
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observed organ distribution of radioactivity on administration 
of 125i-labelled copolymer 39 represents the presence of 
1 2 5 copolymer or ^^^I-labelled crosslink degradation 
products. Extensive degradation of copolymer 39 seems unlikely, 
however, over the experimental period, in view of the 
similarity between the body distributions of copolymer 39 and 
copolymer 79, which contains radiolabelled polymer chains. The 
most likely explanation for the slight differences observed in 
the body distribution of copolymers 39 and 79 24h following 
intraperitoneal administration, is the difference in average 
molecular weight of the two copolymers (39 Mw 190,000 » 79 
Mw 68,000). Copolymer 79 is of a lower average molecular weight 
and therefore contains a larger number of molecules small enough 
to pass through the kidney glomerulus. This results in a 
higher proportion of the recovered radioactivity in the urine 
and a lower proportion in the blood on administration of 
copolymer 79 than on administration of copolymer 39.
1257.2.2 Organ Deposition of____I-labelled Copolymers Following
Subcutaneous Administration to Rats
Male Wistar rats (200-250g) were injected subcutaneously with 
125 pg of 125I-labelled copolymer (39, 78 or 79) in PBS as 
described in section 2.11.3. Following periods of lh, 5h and 
24h, animals were anaesthetized, blood samples taken and then 
the animals were sacrificed as described in sections 2.11.5 and 
2.11.6. Organs were removed, homogenised and assayed for 
radioactivity. Again, all experiments were carried out in 
triplicate. The percentage of the administered dose recovered 
at the end of each experiment was calculated and the results 
are shown in Table 7.6. From this table, it can be seen that 
although dose recoveries obtained at each time point were 
variable, there was an increase in dose recovery with time.
TABLE 7.6
SUBCUTANEOUS INJECTION - DOSE RECOVERIES (%)
SUBSTRATE lh 5h 24h
39 7.19 38.51 62.90
9.33 24.88 71.21
11.91 17.47 66.76
78 14.28 40.32 42.50
9.43 39.81 63.84
14.24 32.93 56.76
79 14.68 29.10 36.27
29.4726.63 65.98
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The reason for this is that the organs sampled in the case of 
subcutaneous injection did not include the injection site, 
unlike previous routes of administration (peritoneal cavity and 
bloodstream). The dose recoveries indicate that migration of 
the copolymer from the site of injections is relatively slow, 
but after 24h dose recoveries approach those obtained following 
intraperitoneal injection of copolymers. Because of the low 
recoveries obtained following short experimental periods (1 and 
5h), the data presented will include typical results expressed 
as a percentage of the dose administered, in addition to the 
usual format i.e. percentage of the recovered dose.
The body distribution of radioactivity following subcutaneous 
administration of 125I-labelled copolymer 39 is shown in Table
7.7 and fig 7.8. It can be seen that the radioactivity 
recovered after lh is largely confined to the blood, kidney and 
urine. After 24h the recovered radioactivity is found largely 
in the blood, urine and faeces, as on intraperitoneal 
administration of this copolymer, but a greater proportion of 
the recovered radiolabelled material is excreted within 24h 
following subcutaneous administration. Similarly, subcutaneous 
administration of 125I-labelled copolymer 79 (Table 7.8 and 
fig 7.9) results in the recovery of radioactivity largely from 
the blood, kidney and urin,e within lh, with the majority of 
recovered radioactivity excreted by the kidney after 24h.
Again, more of the recovered radioactivity is excreted with 24h 
following subcutaneous injection of I-labelled copolymer 
than following intraperitoneal administration of the same 
copolymer.
Table 7.9 and fig 7.10 show the results following subcutaneous
1 2 5administration of I—labelled copolymer 78 to rats. As
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observed with copolymers 39 and 79, the radioactivity recovered 
after lh is present in the blood, kidney and urine in measurable 
quantities. In addition, 18.58% of the recovered radioactivity 
is again associated with the liver. The percentage of 
recovered radioactivity in the liver is seen to rise very 
slowly over the 24h period (fig 7.10), but when results are 
expressed as a percentage of the dose administered (Table 7.9), 
it is apparent that because the dose recoveries are increasing 
with time, the actual quantity of polymer accumulating in the 
liver is increasing quite rapidly with time.
A further interesting feature in Table 7.9 is that in excess of 
16% of the recovered radioactivity is present in the faeces 24h 
after subcutaneous injection of copolymer 78. This value is 
somewhat higher than that observed 24h following intraperitoneal 
administration of the same copolymer (4.69%) and also higher 
than that observed for copolymer 79 by either route (4.77% 
intraperitoneal and 7.95% subcutaneous).
The pattern of organ deposition and excretion of copolymers 
following subcutaneous administration is different from that 
observed following intraperitoneal administration of the 
copolymers in that more of the recovered radioactivity is found 
in the urine following subcutaneous injection in all cases.
This is best illustrated after 24h where dose recoveries 
following both routes of administration are similar. This 
indicates that a greater proportion of smaller molecular weight 
copolymer fractions is eliminated from the body following 
subcutaneous injection than following intraperitoneal injection 
after 24h. This, in turn, could indicate either that there is 
a preferential movement of smaller molecules away from the site 
of injection following subcutaneous injection, but not (at
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least not so pronounced) following intraperitoneal injection, 
or that copolymers undergo more degradation of crosslinks en 
route to the circulation following subcutaneous administration 
than following intraperitoneal administration.
1257,2.3 Organ Deposition of____ I-labelled Copolymers Following
Oral Administration to Rats
l^I-Labelled copolymers (125 jig in PBS) were administered into 
the stomachs of Male Wistar rats (200-250g body weight) as 
described in section 2.11.4. Duplicate blood samples (50 pi) 
were taken lh, 5h or 24h following administration of copolymer 
(section 2.11.5), after which the animals were sacrificed.
Organs were removed, washed and assayed for radioactivity as 
described in section 2.11.6. Dose recoveries were calculated 
following each experiment, the results of which are shown in 
Table 7.10. The percentage of the dose recovered at the end of 
each experiment was variable, but no obvious trend with time 
was apparent.
The organ distribution of radioactivity recovered following 
oral administration of 125I-labelled copolymer 39 is shown in 
Table 7.11 and fig 7.11. A very high proportion (42.44%) of 
the recovered radioactivity was associated with the small 
intestine lh following administration of the copolymer. 45.34% 
of the recovered radioactivity was found in the caecum 
(+ contents) but it was not possible to determine whether this 
radioactivity was associated with the tissue or the material 
contained within it. Results presented in section 5.2.1 
demonstrated the preferential uptake of high molecular weight 
copolymer 39 (fraction a, Mw >400,000) by rat intestine in vitro 
The rate of uptake of this fraction was approximately five times 
that of the smallest fraction 39e (Mw 34,000) and the fluid-
TABLE 7. 10
ORAL ADMINISTRATION - DOSE RECOVERIES (%)
SUBSTRATE lh 5h 24h
39 55.12 114.55 76.83
81.73 105.59 97.99
63.96 111.70 76.28
78 83.72 76.04 78.80
54.98 86.06 57.21
67.89 80.76 66.67
79 53.79 74.00 45.00
45.70 83.00 64.11
62.52 64.72 56.40
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phase marker 125I-PVP (Mw 40,000). However, the crosslink 
contained in copolymer 39 (P-Gly-Gly-Phe-Tyr-HMDA-Tyr-Phe-Gly- 
Gly-P) has been shown to be rapidly hydrolysed by chymotrypsin 
(49% crosslink cleavage in 5 min) (section 1.4), which is 
secreted into the lumen of the small intestine. In view of 
this, the most likely explanation for a large proportion of 
this tissue-associated radioactivity seems not to be the 
pinocytic uptake of copolymer by the small intestine, but the 
rapid uptake of free [125l] iodotyrosine following its release 
on degradation of copolymer by chymotrypsin present in the gut 
lumen. Results after 5h show that the intestinal tissue level 
had dropped to less than 4%, blood levels had risen from 0.11% 
to 4.68% and 10.69% of the recovered radioactivity had been 
excreted in the urine. Within 24h virtually all of the radio­
activity recovered was present in the urine (32.77%) and 
faeces (64.01%).
In order to try to establish whether or not significant 
¿[©gradation of copolymer had taken place on its passage through 
the small intestine, a 1 ml sample of caecum homogenate (which 
included the contents) was precipitated with 20% trichloroacetic 
acid (TCA) to remove protein, centrifuged (2,OOOg for 20 min) 
and the supernatant applied to a Sepharose 4B/6B column 
(section 2.5). Material from the caecum was chosen after a 5h 
experimental period, rather than washings from the small 
intestine, because of the comparatively high level of radio­
activity present in the tissue with its contents at that time 
(45.34%). The elution profile obtained is shown in fig 7.12» 
similar levels of radioactivity elute in two peaks, one of 
which co-elutes with I—labelled copolymer* and the other
with [125l] iodide and [125l] iodotyrosine. This shows that the 
copolymer has been degraded, since the polymer peak present
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co-elutes with the lower molecular weight fractions in 
copolymer preparation, and a greater proportion of radioactivity 
is present in the second peak than in the copolymer preparation, 
indicating the presence of radiolabelled degradation products. 
Although these results do not indicate whether copolymer or 
^25l] iodotyrosine, or both, are taken up by intestinal tissue, 
they do show that [125l] iodotyrosine was released in the gut 
lumen.
The body distribution of radioactivity following oral 
administration of copolymer 79 is shown in Table 7.12 and fig 
7.13. Since the radiolabel is attached to the copolymer chain 
and is not removed by enzymes, the observed 7% of the recovered 
radioactivity observed in the bloodstream after lh may 
represent some translocation of macromolecules across the small 
intestine into the circulation. The possibility that this 
radioactivity represents free [125l] iodide, at least in part, 
cannot, however, be discounted. Over 2% of the radioactivity 
was recovered from the liver after lh, but the remainder of 
the copolymer was largely confined to the stomach (6.94%) the 
small intestine (7.46%) and their contents. After 5h, blood 
levels drop to 1.9% and the polymer can be seen to have moved 
further down the intestinal tract, located mainly in the caecum 
and colon contents. Within 24h virtually all the radioactivity 
has been eliminated from the body, although only approximately 
half the amount of radioactivity is recovered in the urine 
(18%) than on administration of copolymer 39 (33%).
Sepharose 4B/6B column chromatography of TCA-precipitated 
caecum homogenate (fig 7.14) was carried out in order to 
observe any change in the molecular weight distribution of the 
radiolabelled copolymer. The elution profile indicates that
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------Copolymer 79 recovered from the
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some copolymer crosslink degradation has occurred during the 
passage of the copolymer through the small intestine and into 
the caecum, since the resultant polymer peak appears to co-elute 
with the smaller molecular weight fractions present in the 
original copolymer preparation.
The organ distribution of I-labelled copolymer 78 following 
its oral administration to rats is shown in Table 7.13 and fig 
7.15. It can be seen that, like copolymer 39, a large 
proportion of the recovered radioactivity (65.81%) is 
associated with the tissue of the small intestine lh following 
administration. A major difference between the two copolymer 
structures, however, is the position of the radiolabelled 
tyrosine residue, which is present in the degradable crosslink 
of copolymer 39, but is attached to the polymer chain of 
copolymer 78. After 5h however, the body distributions of 
copolymers 39 and 78 are very different. Unlike the 
distribution of radiolabel on using copolymer 39, copolymer 78 
is still largely confined to the intestinal tract, with very 
little elsewhere, and the level of radioactivity associated 
with the small intestine has dropped to just over 1% of the 
recovered radioactivity. Within 24h, in excess of 80% of the 
recovered radioactivity is found in the faeces, and only 7% in 
the urine. These findings demonstrate that the copolymer could 
not have been pinocytosed by the small intestine, despite the 
levels noted lh following oral administration, since one would 
expect to find significant levels of radioactivity in the blood, 
kidney, urine and perhaps the liver following the passage of 
copolymer across the intestine. Instead, the distribution of 
radioactivity recovered 24h following oral administration of 
copolymer 78 is similar to that observed for the control 
copolymer (79) which does not contain galactosamine, and is not
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FIGURE 7.15
BODY DISTRIBUTION OF 125I-LABELLED COPOLYMER 78 FOLLOWING 
ORAL ADMINISTRATION TO RATS
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associated with the small intestine following oral 
administration.
These results cam be explained by the hypothesis that the 
galactose-containing copolymer bound to receptors present on 
the surface of cells of the small intestine, but that 
subsequent internalization of copolymer did not take place to 
any significant extent. Either copolymer was displaced by 
galactose, or similar moieties, present in the food subsequently 
eaten by the animals, or enzymes present on the microvillous 
brush border of the enterocytes (section 5.1) or the gut lumen, 
were able to hydrolyse a bond present in the linkage of the 
galactose to the polymer (P-Gly-Gly-galactosamine). Each of 
these possibilities would result in the body distribution 
pattern observed i.e. a temporary association of copolymer with 
cells of the small intestine, after which the radiolabelled 
copolymer continues its passage through the alimentary tract.
Sepharose 4B/6B column chromatography of TCA-precipitated 
caecum homogenate was carried out following oral administration 
of 125i-labelled copolymer 78 as described previously and the 
elution profile (fig 7.16) shows results very similar to those 
observed using copolymer 79. Copolymer recovered from the 
caecum appears to be of a lower molecular weight than the 
preparation administered, indicating some degree of crosslink 
cleavage by enzymes present in the gut lumen.
It is clear from results presented that significant 
translocation of copolymer across the intestine does not take 
place, and that it is not possible to target copolymer 78 to 
the liver following oral adininis'tra'tion#
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7,2.4 Uptake of ^2~*I-labelled Copolymers 78 and 79 by Rat 
Jeiunal Sacs In Vitro
In view of the finding that 125I-labelled copolymer 78 interacts 
with intestinal cell membranes lh following its oral 
administration to rats, this copolymer and control copolymer 79 
(which contains no galactosamine) were studied using the 
everted rat intestinal sacs exactly as described in Chapter 5 
to see whether this observation could be reproduced in vitro. 
Since it was suspected that copolymer 78 bound to the tissue 
through the galactosamine moiety but was not pinocytosed, the 
experiment was carried out at both 37 C and 15 C. If copolymer
78 bound to cells, one would expect a high association of the 
copolymer with the tissue at low temperature, but little, if 
any, interaction between copolymer 79 and the cell membranes 
under the same conditions. If the copolymers were pinocytosed 
by the tissue at 37°C, one would expect a greater uptake of 
copolymer 78 by receptor-mediated pinocytosis than copolymer
79 which should enter the tissue in the fluid-phase at a rate 
proportional to the molecular size of the copolymer (Mw 63,800). 
The results of the experiments are shown in figs 7.17, 7.18
and Table 7.14.
Clearly, the in vitro experiments do not confirm the
observations in vivo. No significant difference in uptake
o oor binding of the two substrates is apparent at 37 C or 15 C. 
The results support previous findings (section 5.2.4) that 
values at 15°C are lower than those noted at 37°C. Neither 
copolymer shows affinity for the enterocyte cell membrane, and 
uptake values at 37°C are similar to those observed for lower 
molecular weight copolymer 39 fractions (section 5.2.1). 
Copolymer 79, which does not contain galactosamine, appears
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FIGURE 7.18
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TABLE 7.14
UPTAKE OF 125I-LABF-LLED COPOLYMERS 78 AND 79 BY RAT 
JEJUNAL SACS IN VITRO AT 15°C AND 37°C
POLYMER 
CODE NO.
RATE OF TISSUE ACCUMULATION 
(jil/mg protein/h)
RATE OF SEROSAL 
ACCUMULATION 
(pl/rag protein/h)
T + S 
(pl/mg/h)
78 (15°C) 0*339 0* 180 0*519
78 (37°C) 0*452 0* 214 0*666
79 (15°C) 0*034 0* 184 0*218
79 (37°C) 0*880 0*265 1*145
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to enter the tissue at a slightly higher rate than copolymer 
78, the exact opposite to the expected result. Although the 
experiment was performed once only, using two jejunal sacs for 
each time point, it can be safely concluded that copolymer 78 
does not bind significantly to the tissue.
It is possible that the galactosamine receptors may be present 
in a different region of the small intestine and not in the 
jejunum. Other possible explanations for this finding are that 
the receptors were damaged or their conformations altered 
during preparation of the tissue e.g. through disturbing the 
mucus layer which coats the intestinal epithelium or under 
the experimental conditions e.g. pH. If either of the two 
explanations are responsible for the observed differences 
between the in vivo and in vitro experiments performed using 
these substrates, the experimental results reported in Chapter 
5 may not represent the findings one would make on repeating 
those experiments in vivo.
7.2.5 Body Clearance of 125I-labelled Copolymers 78 and 79 
Following Intraperitoneal Administration to Rats
Two male Wistar rats (each weighing 250g) were used for this 
preliminary experiment. Each was injected intraperitoneally 
with 125I-labelled copolymer 78 or 79 (125 fig) as described in 
section 2.11.2 and placed into a metabolic cage. Urine and 
faeces were collected regularly and assayed for radioactivity. 
After 32 days, the animals were sacrificed exactly as 
described in section 2.11.6 following collection of blood 
samples (section 2.11.5). The organ distributions of radio­
activity are shown in Table 7.15 and the recoveries of radio­
activity from the urine and faeces are shown in figs 7.19 and
7.20 .
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The percentage of the dose recovered from the animal injected 
with copolymer 78 was 100.60% with 96.27% of the dose 
recovered in the urine and faeces. 2.29% of the recovered 
radioactivity was still present in the blood and only 1.11% 
remained in the liver.
Following injection of control copolymer 79, 95.5% of the dose 
was recovered at the end of the experiment and 96.35% of the 
recovered radioactivity was present in the urine and faeces.
The blood contained 2.65% of the recovered radioactivity and 
0.35% was found in the liver. On correction of liver values 
for blood-borne radioactivity (section 6.2), 0.76% of the 
recovered radioactivity was present in the liver following 
administration of copolymer 78, and none was present in the 
liver following administration of copolymer 79.
These results clearly show that crosslinked copolymers can be 
excreted from the body following pinocytic uptake and crosslink 
cleavage of larger polymers to release smaller molecules of a 
size below the renal threshold.
Total body clearance was not observed in either case, but this 
could well be achieved on extending the experimental period.
The copolymers still present in the body in both cases could 
represent molecules too large to permit filtration by the 
kidney, which cannot be degraded further. This could occur if 
the copolymer precursor (Mw 21,500) contains a few copolymer 
chains of a size above that of the renal threshold.
An interesting feature of figs 7.19 and 7.20 is the difference 
in the patterns of excretion between the two copolymers. 
Copolymer 79 (shown in fig 7.19) is excreted largely by the 
kidney, with approximately 63% of the dose recovered in the
-160-
urine in the first 24h. This level rises to 75% after 4 days 
after which the rate of excretion by the kidney slows down 
considerably with 82% of the dose recovered in the urine after 
32 days. The rate of dose recovery from the faeces shows a 
similar pattern with 8% of the dose recovered in the first 4 
days, rising to 10% after 32 days.
Copolymer 78, however, shows a slower rate of excretion of 
copolymer after the first 24h, with 56% of the dose recovered 
in the urine after lO days rising to 63% after 32 days. 
Recovery from the faeces amounts to 28% after 10 days, rising 
to 34% after 32 days. This indicates a slower clearance of 
the galactose-containing copolymer from the liver, with some 
of the accumulated copolymer released back into the blood 
circulation to be excreted by the kidneys and some being 
released into the bile and ultimately excreted in the faeces.
-161-
7.3 DISCUSSION
Intraperitoneal administration of copolymers results in the 
deposition of the dose into a body cavity with a large surface 
area surrounded by a membrane through which the polymer must 
pass. Movement of polymers from the peritoneal cavity has been 
reported to be protracted and delayed (Noronha-Blob 1977) with 
large molecules remaining in the cavity for several days 
(Punonen and Viinamaki 1982). The results presented here, 
however, indicate that all three copolymers used in the study 
are largely cleared (approximately 99% of the recovered radio­
activity) from the peritoneal cavity within 24h.
Subcutaneous injection of copolymers gives rise to a bolus of 
material in the interstitial fluid at the site of injection. 
Although movement of copolymer into the circulation possibly 
occurs at a similar rate to that following intraperitoneal 
administration, it was not practicable to attempt to recover 
any of the dose still present at the site of the injection at 
the end of each experiment and so determine the quantity of 
copolymer remaining. Dose recoveries 24h following 
subcutaneous administration approached those obtained 24h 
following intraperitoneal administration.
1 2 5Oral administration of I-labelled copolymers resulted m  
the elimination of a larger proportion of the dose after 24h 
than on administration of copolymers via parenteral routes.
Dose recoveries of copolymers were, in most cases, in the 
region of 60% 24h following administration by intraperitoneal 
and subcutaneous routes, and 70% 24h following oral 
administration. These values are only approximate, however, 
since they are calculated from data which include total blood
162-
levels of radioactivity, which in turn is calculated from an 
estimate of rat blood volume. Such estimates of blood volumes 
are dependent on rat body weight, age and sex of the animals, 
and different values for blood volume per gram rat body weight 
have been reported in the literature (Millard 1979, Everett 
1956). For this reason, and also the difficulty in the 
recovery of all metabolic waste from the animal, it is 
difficult to determine precisely the proportion of the dose 
actually remaining in the body, or excreted, at the end of the 
24h experimental period. A more detailed analysis of the 
whole carcass to estimate residual radioactivity would help to 
establish the location of copolymer, and so assess the 
accuracy of the methods employed, but such a procedure is 
beyond the scope of the current study. It is possible that 
the proportion of the dose not accounted for may be present in 
low levels in many different tissues which were not examined, 
or may have accumulated in one or a few tissues which were not 
examined, or have been retained at the site of injection in 
the case of parenteral administration. Alternatively, the 
calculated blood (or urine) values could have been under­
estimated. In order to compare the data from the experiments, 
it is assumed that the distribution of the radioactivity 
recovered from the experiments represents the distribution of 
the whole dose.
Clearance of galactose-containing glycoproteins by the liver 
following intravenous administration has been reported by a 
number of workers (Regoeczi et al 1978, Schlesinger et al 1980, 
Quintart et al 1984 and Schiff et al 1984). Clearance of 
liposomes bearing surface galactose residues by rat liver 
hepatocytes has also been reported (Ghosh et al 1982).
Evidence for the clearance of galactose-containing copolymers 
by the liver following intravenous administration to rats has 
also been described by Duncan et al (1983) and Chapter 6 of 
this thesis. The work presented here shows that it is also 
possible to target galactose-containing HPMA copolymers to the 
liver following alternative routes of parenteral administration, 
namely by the intraperitoneal and subcutaneous routes.
Intraperitoneal administration of copolymer 78 results in 
51.90% of the recovered radioactivity present in the liver 
after 24h, while subcutaneous administration results in 23.58% 
in the liver after 24h with a greater proportion of the 
recovered radioactivity present in the urine. Two hypotheses 
might be put forward to explain this difference in the 
quantity accumulated by the liver on using the two routes. 
Firstly, it must be noted that each copolymer chain present in 
this crosslinked copolymer (which contains 2 mol % 
galactosamine) may not necessarily contain both a galactosamine 
residue and a radiolabelled tyrosine residue, and that the 
likelihood that both these residues are present on each 
copolymer will decrease with decreasing molecular weight of 
the copolymer. This would result in the presence of some low 
molecular weight fractions containing either galactosamine and 
no radiolabel (which cannot be traced) or a radiolabel, but no 
galactosamine residue (which would not accumulate in the liver). 
It is therefore possible that either preferential transport of 
low molecular weight copolymer 78 fractions (some of which do 
not contain galactosamine) took place from the site of 
subcutaneous injection, but not following intraperitoneal 
injection, or that some degradation of copolymer 78 crosslinks 
took place en route to the liver following subcutaneous
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injection, but not following intraperitoneal injection. Both 
possible explanations would result in the body distributions 
of copolymer observed, that is, less accumulation of radiolabel 
in the liver following subcutaneous administration of copolymer, 
with smaller copolymer fractions which do not contain 
galactosamine residues being filtered from the circulation by 
the kidney. There is no significant accumulation of radio- 
labelled copolymer 78 in any organ other than the liver 
following administration by any of the parenteral routes, thus 
indicating specific receptor-mediated uptake of this copolymer 
by liver cells.
It was not possible to target copolymer 78 to the liver
following its oral administration to rats, since uptake of
significant quantities of copolymer by the gut was not observed.
The galactose-containing polymer, however, transiently bound to
cells of the small intestine. This tissue association did not
125occur on oral administration of I-labelled copolymer 79, 
which is similar to copolymer 78 in size and structure but 
does not contain galactosamine. This suggests that there is a 
receptor present in the small intestine of the rat which 
recognises galactosamine. This observation was also noted by 
Anderson et al (1980) who reported an interaction of 
Escherichia Coli K88 Antigen with porcine intestinal brush 
border membranes. The formation of such complexes was found 
to be inhibited by glycoproteins with terminal N-acetylgalactos- 
amine and N-acetylglucosamine, and therefore denotes the 
presence of carbohydrate receptors on the brush border of the 
small intestine of pigs. There is no reason to suppose that 
rats may not also possess such receptors on the brush border 
of enterocytes of the small intestine.
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This finding could not be reproduced in vitro, however, on 
125incubation of I-labelled copolymer 78 with everted rat 
jejunal sacs (section 7.2.4).
Copolymer 79 does not significantly accumulate in the liver, 
or any of the organs examined during the 24h experimental 
period whatever route of administration is employed. Radio­
activity is largely confined to the blood, kidney and urine 
following parenteral administration, indicating the removal of 
low molecular weight copolymer fractions following their 
appearance in the circulation. Presumably, larger molecules 
remain in the circulation until pinocytosed by cells, after 
which digestion of crosslinks and release of lower molecular 
weight fractions would occur. A greater proportion of radio­
activity is again recovered in the urine following subcutaneous 
administration than following intraperitoneal administration 
of the copolymer. The possible reasons for this observation 
have already been discussed i.e. preferential movement of low 
molecular weight fractions from the site of subcutaneous, but 
not intraperitoneal injection,or more extensive degradation of 
copolymer en route to the circulation following subcutaneous 
than intraperitoneal administration. Oral administration of 
this copolymer resulted in a small percentage of radioactivity 
in the stomach, small intestine and blood after lh, followed 
by the appearance of radioactivity in the urine. This indicates 
the transport of some copolymer and/or free (125iJ iodide 
across the gut into the circulation with ultimate removal by 
the kidney. The fact that a greater proportion of the 
recovered radioactivity was found in the bloodstream lh after 
oral administration of copolymer 79 (7• 38%) than on oral 
administration of copolymer 78 (0*64%)$ which is of similar
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size and structure but contained less free iodide
(section 7.2.1), suggests that free [*25i] iodide could be 
largely responsible for this observation.
The body distributions of copolymer 79 following the various 
routes of administration show that this copolymer has little 
affinity for cell membranes, giving similar body distributions 
of radioactivity to those observed on administration of 
125I-PVP (of similar Mw), which has been described as a fluid- 
phase marker for in vivo studies (Munniksma et al 1980, 
Kooistra et al 1979, Ose et al 1979). Copolymer 79 does not 
accumulate in cells of the reticuloendothelial system (i.e. 
cells present in the liver, spleen and lungs) over a 24h 
experimental period, and does not appear to enter cells by 
adsorptive pinocytosis.
Very little difference in body distributions of radioactivity
125is observed on parenteral administration of I-labelled 
copolymer 79 and 125I-labelled copolymer 39. This indicates 
that the difference in average molecular weight of the two 
copolymers (section 7.1) has little effect on their ultimate 
fates in vivo, and therefore that both copolymers can be 
considered to be * fluid—phase® substrates (if little or no 
degradation of radiolabelled copolymer 39 crosslinks takes 
place).
The extent of copolymer 39 degradation following intra­
peritoneal and subcutaneous routes is not known, and it is not 
possible to determine from the results what proportion of the 
recovered radioactivity is due to radiolabelled crosslink 
degradation products. Drobnik and Rypacek (1984) state that 
movement of polymers from the site of subcutaneous injection
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takes place by size-dependent transport via venous or 
lymphatic capillaries. In view of this, the finding that the 
body distributions of the two copolymers (39 and 79) are 
similar following the same routes of administration might be 
interpreted that crosslinks are not extensively degraded in 
transit to the circulation and therefore that there is 
preferential movement of smaller copolymer fractions from the 
injection site following subcutaneous injection rather than 
the alternative explanation of degradation of crosslinks to 
give rise to smaller polymer chains.
125On oral administration of I-labelled copolymer 39, the 
radiolabelled crosslinks appear to be degraded substantially 
by enzymes present in the gut lumen, with subsequent uptake of 
j^ 25lj iodotyrosine degradation product by cells of the small 
intestine. These degradation products appear to enter the 
circulation and are eventually excreted by the kidney.
125I_Labelled copolymers 78 and 79 contain crosslinks which 
also appear to be hydrolysed in the gut lumen giving rise to 
smaller molecular weight fractions in the lower regions of the 
gut.
Extended experiments following intraperitoneal injection of 
125X-labelled copolymers 78 and 79 largely confirmed that it is 
possible to clear crosslinked HPMA copolymers from the body 
following their pinocytic uptake by cells. Although total body 
clearance was not observed using either copolymer in this 
preliminary experiment (which lasted 32 days) 92.04% of the 
copolymer administered was recovered in the urine and faeces 
in the case of copolymer 79, and 96.27% in the case of 
copolymer 78. On correcting for blood-borne radioactivity
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it was found that less than 1% of the dose administered was 
still present in the liver. Extension of the experimental 
period for a further few days would probably have resulted in 
complete body clearance of copolymers.
More than three times as much copolymer was excreted in the 
faeces following administration of galactose-containing 
copolymer 78 (34.15%) than the control copolymer 79 (10.62%).
I OC #The excretion of I-PVP from the bloodstream into the 
intestine following intravenous administration is reported by 
Drobnik and Rypàcek (1984). They suggest that the fraction 
excreted by the intestinal pathway is less dependent on the 
polymer molecular weight than that excreted by the kidney, and 
that intestinal excretion may be a way in which large 
molecules that cannot be degraded or excreted by the kidney can 
escape from the body. The authors also suggest that some 
of the copolymer excreted in the faeces may be transported into 
the intestinal lumen with the bile, which is produced by liver 
hepatocytes, the rest being excreted by vesicle transport 
across the intestine into the lumen.
The results shown here strongly support this latter proposal 
by Drobnik and Rypàcek, since the copolymer containing 
galactose (78) is rapidly accumulated by liver cells and is 
excreted in the faeces to a much greater extent than copolymer 
79, which is not taken up significantly by the liver.
Since bile is produced by hepatocytes, this result also 
suggests that a significant proportion of the galactose- 
containing copolymer is endocytosed by hepatocytes, rather than 
kupffer cells of the liver which are also reported to express 
galactose receptors (Kolb et al 1981).
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An upper limit of between Mw 6,000 and 10,000 was suggested by 
Roze (1971) for biliary elimination of PVP. This limit is much 
lower than that observed for HPMA copolymers, since the average 
molecular weight of the polymeric precursor i.e. the molecular 
weight of the crosslinked copolymer (78 or 79) following 100% 
cleavage by enzymes, is Mw 21,500.
Studies by Schiff et al (1984) have demonstrated that all 
immunoglobulin A (IgA) which enters liver cells by receptor- 
mediated pinocytosis and 1-4% of injected asialoglycoprotein 
(ASG) i.e. galactose-bearing protein, are transported from 
blood to bile intact, although a major fraction of the ASG is 
degraded in hepatic lysosomes. The authors propose that 
proteins pinocytosed by hepatocytes can be processed in one of 
three ways* they can be transported to bile, returned to the 
blood, or transferred intracellularly to lysosomes. They 
suggest that receptor-mediated pinocytosis of IgA and ASG 
involves two distinct intracellular routes. IgA is contained 
within vesicles which are transported to the bile canaliculi 
without fusion with lysosomes, whereas ASG is transported in 
vesicles which are destined to fuse with lysosomes and is 
therefore largely degraded. It is proposed that the distinct 
receptors for the two proteins are not normally present in 
juxtaposition on the plasma membrane and that the occasional 
missorting of receptor—ligand complexes gives rise to a small 
percentage of transcellular passage of ASG into the bile. 
Similarly, Limet et al (1982) have proposed different 
transcellular routes which escape fusion with lysosomes for 
the transport of intact IgA into the bile following its 
binding and receptor—mediated uptake by hepatocytes. From 
figures 7.19 and 7.20 it can be seen that the levels of
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radioactivity recovered from both the urine and the faeces 
rise more slowly following administration of copolymer 78 than 
on administration of copolymer 79. This suggests that 
copolymer 78 is released from cells (probably the liver) both 
into the blood (followed by filtration by the kidney) and into 
the bile (followed by excretion in the faeces). It is not 
possible to determine whether that proportion released into 
the intestine is of a larger molecular weight (degraded or not) 
than that filtered by the kidney, which has probably been 
partially degraded within hépatocyte lysosomes. The 
transcellular route into the bile therefore cannot be 
identified conclusively.
The cellular events taking place within hepatocytes following 
receptor-mediated pinocytosis of copolymer 78 probably 
include the fusion of pinocytic vesicles containing copolymer 
with acidic endosomes (prelysosomal vesicular compartments 
section 1.3), resulting in receptor-ligand dissociation 
(Wolkoff et al 1984) and return of the receptors to the cell 
surface. Copolymer may then either be transported across the 
cell intact via specialised vesicles and released at the 
biliary membrane, or transported to lysosomes. Fusion of the 
copolymer-containing vesicle with lysosomes probably results 
in the degradation of copolymer crosslinks and eventual 
exocytosis of lower molecular weight fractions either back 
into the blood or into the bile canaliculi.
CHAPTER 8
CROSSLINK CLEAVAGE OF 125I-LABELLED 
HPMA COPOLYMERS BY LYSOSOMAL ENZYMES
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8.1 INTRODUCTION
The work reported thus far in this thesis has involved the 
administration of radiolabelled copolymers to tissues in vitro, 
or to animals in vivo, in order to monitor the uptake of the 
copolymers into cells and the resultant release of radio- 
labelled degradation products from cells following enzymic 
hydrolysis within lysosomes. This chapter describes the study 
of the direct interaction between radiolabelled copolymers and 
lysosomal enzymes in vitro. An attempt is made to quantitate 
the extent of cleavage of the crosslinks contained within the 
copolymers used throughout this study by comparison of 
copolymer molecular weights before and following incubation 
with the enzymes.
Several techniques have been employed to isolate intact 
lysosomes from cells derived from various organs (Dean 1977).
The technique employed here involves decreasing the lysosomal 
density using the non-lytic detergent Triton WR-1339. The 
detergent is administered intraperitoneally to rats and 
eventually accumulates in liver lysosomes following endocytic 
uptake. Separation of the detergent laden 'tritosomes' is 
achieved by initial differential centrifugation of liver 
homogenate in 0.25M sucrose followed by sucrose density 
(discontinuous gradient) centrifugation at high speed, 
resulting in an interfacial band of lysosomes (Trouet et al 
X974)» The lysosomal membranes may subsequently be ruptured 
by the addition of Triton X-100, to release the lysosomal 
enzymes.
Lysosomes are known to contain at least sixty acid hydrolases, 
including various lipases, phosphatases, nucleases, sulphatases,
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glycosidases, exopeptidases and endopeptidases (Barrett and 
Heath 1977, Bainton 1981). Collectively, they are capable of 
hydrolysing almost all classes of natural macromolecules, the 
breakdown products of which are usually available for 
metabolic re-use.
The enzymes of particular interest to this study i.e. those 
able to hydrolyse the oligopeptide sequences contained within 
crosslinks are the proteinases, comprising endopeptidases 
(hydrolases cleaving peptide bonds away from the ends of 
polypeptides), and exopeptidases (hydrolases cleaving peptide 
bonds near the end of polypeptides).
As discussed previously (Chapter 1.4), the extent of crosslink 
cleavage by various purified enzymes has been shown to be 
dependent upon both the length of the oligopeptide sequence 
present in the crosslink, and upon the amino acid sequence 
itself, which must conform to the specificity of a given 
enzyme to promote efficient hydrolysis. It has been shown 
(Kopecek 1961, Ulbrich et al 1980, 1981, Rejraanova et al 1981) 
that the extension of the oligopeptide sequence by one amino 
acid residue (from tripeptide to tetrapeptide) leads to a 
pronounced increase in the rate of degradation of the 
oligopeptide crosslinks in HPMA copolymers. Previous studies 
on HPMA copolymer crosslink cleavage have been carried out in 
Prague using the purified enzymes chymotrypsin, trypsin and 
papain (Ulbrich et al 1980, 1981, Rejmanova et al 1981). 
Incubation of a copolymer containing the same crosslink 
structure as that of copolymer 39 (P-Gly-Gly-Phe-Tyr-HMDA-Tyr- 
Phe-Gly-Gly-P - a tetrapeptide) with chymotrypsin showed that 
45% of the crosslinks were cleaved after 5 minutes, 88% after 
30 minutes, and 100% after 48 hours. Similar studies using
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the crosslink structure P-Gly-Gly-Phe-HMDA-Phe-Gly-Gly-P, a 
tripeptide showed 22% crosslink cleavage after 48h incubation 
with Chymotrypsin. This crosslink structure is contained 
within copolymers 68, 78 and 79.
The polydisperse crosslinked copolymers 39, 68, 78 and 79 were 
used in this study. Characteristics of the copolymers are 
given in Chapter 3.4, and details relevant to this study are 
repeated in Table 8.1.
Radiolabelied copolymer 39 contains a tetrapeptide sequence 
(which includes [125l] iodotyrosine) known to be hydrolysed 
completely by Chymotrypsin within 48h, and partially by 
enzymes of the yolk sac lysosomes (Chapter 4). Radiolabelled 
copolymers 68, 78 and 79 contain the same tripeptide sequence 
within their crosslinks. Degradation of this sequence could 
not be detected in previous experiments since the radiolabelled 
tyrosine residue is attached to the copolymer backbone. This 
feature, however, enables detection of radiolabelled copolymer 
chains following crosslink cleavage. It is therefore possible, 
using gel permeation chromatography, to estimate the average 
molecular weight of each of the copolymers both before and 
following incubation of crosslinked polymers with lysosomal 
enzymes and hence estimate the extent of crosslink cleavage.
Copolymers 78 and 79 are of similar average molecular weight 
(*''70,000) and crosslink density (see Table 8.1), their only 
difference being the incorporation of galactosamine in 
copolymer 78. Copolymer 6 8, on the other hand, is larger 
(Mw 171,000) and contains a greater density of crosslinks.
Each of the four radiolabelled crosslinked copolymers were 
incubated with rat liver lysosomal enzymes for up to 72h in
TABLE 8.1
CHARACTERISTICS OF CROSSLINKED COPOLYMERS
POLYMER 
CODE NO. Mw Mw . - /Mn f (xlO-3)
%
CROSSLINKED 
SIDECHAINS
Mw
PRECURSOR
39 190,000 6.80 0.518 3.885 14.7 32,100
68 171,000 5.80 0.669 6. lOO 14.9 21,500
78 73,800 3.05 0.541 4.940 12.0 21,500
79 64,300 2.74 0.509 4.640 11.3 21,500
denotes the crosslinking index i.e. the number of 
crosslinked units per primary chain.
denotes the network density i.e. the molar fraction 
of crosslinked units.
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order to see whether these crosslinks were cleaved.
Experiments reported in Chapter 4 described the pinocytic 
uptake and intracellular degradation of copolymer 39 fractions. 
Studies on the degradation of copolymer included the use of 
leupeptin, a lysosomal thiol-proteinase inhibitor, and results 
demonstrated a reduced degradation of the copolymer. This 
finding suggested the involvement of one or more lysosomal 
thiol-proteinases in the degradation process. To allow the 
full activity of these thiol-dependent enzymes to be expressed 
in the experiments described in this in vitro study, reduced 
glutathione was included in the incubation medium.
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8.2 RESULTS
Rat liver 'tritosomes' in sucrose were prepared according to 
the method of Trouet (1974) (see Chapter 2). Approximately 
30-fold purification of a representative lysosomal enzyme 
(aryl sulphatase) over the initial homogenate was achieved.
Radiolabelled copolymers (125 pg in 0.1 ml phosphate buffer 
pH 8.0) were added to 0.6 ml of 0.2M potassium phosphate buffer 
pH 5.5 containing 0.2% Triton X-lOO, 5 m M reduced glutathione 
and 2 mM EDTA. At the beginning of the experiment 0.3 ml of 
undiluted tritosomes (approx. 2 mg protein/ml) was added to 
each experimental tube. The pH of the resultant mixture was 
found to be 5.7. Incubation took place at 37°C in stoppered 
tubes for periods of 0, 24, 48 and 72h for each substrate. 
Control experiments were carried out concurrently, in which 
tubes contained copolymers buffer and GSH only. The 
experiment was performed once only.
Following incubation, proteins were precipitated using TCA as 
described previously (section 4.2.5). Supernatants were 
stored at -20°C prior to column chromatography. I-Labelled
copolymer preparations, following TCA precipitation, and 
samples of supernatants following incubation of each copolymer 
with tritosomes for 24h (and copolymer 39 following 48h and 
72h incubation periods) were applied to a Sephadex G-15 column 
(bed height 16 cm, I.D. 8 mm, flow rate 14 ml/h). Figure 8.1 
and Table 8.2 show that after 24h incubation, approximately 
30% of the radioactivity present in the supernatants recovered 
following incubation of copolymer 39 with tritosomes co—elutes 
with |125l] iodotyrosine. A similar percentage was found when
incubations were extended to 48 or 72h
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FIGURE 8 .1
S E P H A D E X  G - 1 5  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  39 F O L L O W I N G  
I N C U B A T I O N  W I T H  R A T  L I V E R  T R I T O S O M E S
C O P O L Y M E R  < 1 2 5 I >  < 1 2 5 I - I O D O T Y R O S 1 N E >
TABLE 8.2
SEPHADEX G—15 COLUMN CHROMATOGRAPHY FOR THE DETECTION OF
P^25ll IOPOTYROSINE f o l l o w i n g i n c u b a t i o n o f  r ad iola belle d
COPOLYMERS WITH TRITOSOMES
% RADIOACTIVITY CO-ELUTING 
WITHfi25l! IODOTYROSINE AFTER
POLYMER 
CODE NO.
(t=0 )
PREPARATION 24h 48h 72h
39 0 30.03 29.80 31.89
68 0 0 - -
78 0 0 - -
79 O O
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Copolymers 68, 78 and 79, however, showed no release of 
1^25l] iodotyrosine after 24h incubation with tritosomes (Table 
8.2). Figure 8.2 shows typical elution profiles obtained from 
these experiments. These results support those reported in 
previous chapters, i.e. that lysosomal enzymes are unable to 
liberate [125l] iodotyrosine when the residue is attached 
directly adjacent to the copolymer chain.
This experiment indicates the release of radiolabelled low 
molecular weight degradation products following incubation of 
copolymer 39 with lysosomal enzymes, but does not indicate 
whether the [125l}-iodotyrosine is released from crosslinks 
which connect copolymer chains together, or from the hydrolysis 
of intramolecular cycles (Chapter 3.2). If crosslink cleavage 
had taken place, one would expect a lowering of the average 
molecular weight of the copolymer, but this would not be 
expected if hydrolysis was confined to intramolecular cycles.
To assess the extent of crosslink cleavage, supernatants 
derived from the experiment described above were applied to 
previously calibrated Sepharose 4B/6B columns, the details of 
which are shown in Table 8.3 and fig 8.3, and eluted with 
0.2M Tris/HCl buffer pH 8.0 containing 0.5M NaCl. The HPMA 
polymers used for the calibration of the columns were all of 
low polydispersity (Mw/Mn 1.2).
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S E P H A D E X  G - 1 5  C O L U M N  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  78 B E F O R E  A N D  
F O L L O W I N G  2 4 H  I N C U B A T I O N  W I T H  R A T  L I V E R  
T R I T O S O M E S
FIGURE 8.2
TABLE 8.3
DETAILS OF SEPHAROSE 4B/6B COLUMNS USED FOR DETERMINATION 
OF AVERAGE MOLECULAR WEIGHTS OF COPOLYMERS
COLUMN A COLUMN B
length 60 cm 65 cm
I.D. 16 mm 16 mm
flow rate 20 ml/h 20 ml/h
void volume 44 ml 50 ml
maximum peak_height
for 22,000 Mw polymer Fraction 47 Fraction 51
» 78,000 " " t t 38 I f 42
" 143,000 " " •1 34 II 38
" 297,000 " " II 29 II 33
regression analysis: 
constant a (intercept) 7.2903 7.5416
" b (slope) -0.06283 -0.06283
correlation coeff. .999 .999
column used for 
Mw determination 39,78 68,79of copolymers
FIGURE 8.3
S E P H A R O S E  4 B / 6 B  C O L U M N  C A L I B R A T I O N  U S I N G
125 I - L A B E L L E D  P O L Y M E R S  O F  K N O W N  M E A N  
M O L E C U L A R  W E I G H T
F R A C T I O N  N U M B E R  
( S H O W I N G  M A X I M U M  P E A K  H E I G H T )
• ——•  Col umn A  
• ------•  C o l u m n  B
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The radioactive counts recovered from each fraction were 
recorded and the average molecular weight of each copolymer 
was calculated for each time point using the computer programme 
shown in Appendix 2.
The extent of crosslink cleavage was then calculated from the 
average molecular weight values for the copolymer precursor, 
the crosslinked copolymer and the copolymer following enzymatic 
cleavage using the formula described by Bohdanecky (1974)
(section 2.13) i.e.
Mw aminolvsed precursor
The % of cleaved bonds = 100 - ^w cleaved polymer ^ ^_ flw aminolvsed precursor 
* — fflw crosslinked polymer
The results, shown in figs 8.4—8.7 and Table 8.4, indicate 
that, in all cases, there is a decrease in the average molecular 
weight of copolymer following incubation with tritosomes, 
indicating some hydrolysis of all crosslinks by lysosomal 
enzymes. The values obtained in control experiments (in which 
copolymers were incubated for 24h in the absence of tritosomes) 
were taken to represent the initial average molecular weight 
of the preparations.
It can be seen from Table 8.4 that the values calculated for 
these control experiments are higher than the average molecular 
weights estimated in Prague for the copolymer preparations, 
with the exception of copolymer 39. The most likely 
explanation for these higher values is that different column 
dimensions and flow rate were employed in Prague. The Czech 
column was 90 cm in length and an approximate flow rate of 
10-12 ml/h was used. This longer column and lower flow rate 
would lead to a better resolution of peaks and consequently a
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FIGURE 8.4
S E P H A R O S E  4 B / 6 B  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  39 O N  I N C U B A T I O N  
W I T H  R A T  L I V E R  T R I T O S O M E S
—  t = 0
------ A f t e r  7 2 h  incubation
w i t h  tritosomes
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FIGURE 8.5
S E P H A R O S E  4B /6 B  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  6 8  ON I N C U B A T I O N  
W I T H  R A T L I V E R  T R I T O S O M E S
-  t  = 0
------A f t e r  7 2 h incubation
with tritosomes
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FIGURE 8 .6
S E P H A R O S E  4 B / 6 B  C H R O M A T O G R A P H Y  O F  
125I - L A B E L L E D  C O P O L Y M E R  78  O N  I N C U B A T I O N  
W I T H  R A T  L I V E R  T R I T O S O M E S
—  t = 0
— After 72h incubation 
with tritosomes
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FIGURE 8.7
S E P H A R O S E  ¿ B / 6 B  C H R O M A T O G R A P H Y  O F
125I - L A B E L L E D  C O P O L Y M E R  79 O N  I N C U B A T I O N  
W I T H  R A T  L I V E R  T R I T O S O M E S
.... t = 0
—  A f t e r  72h incubation 
with tr it o so me s
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more accurate column calibration and molecular weight 
determination. For the purpose of the present study i.e. to 
detect differences in average molecular weights of copolymers 
following incubation with lysosomal enzymes, the columns 
employed were adequate.
It must be noted however, that the values for the average 
molecular weight of the polymeric precursors used in the 
calculation of crosslink cleavage (32,000 for copolymer 39 and 
21,500 for copolymers 68, 78 and 79) were estimated using 
detection by differential refractometry in Prague, since it was 
not possible to evaluate radiolabelled precursors in the current 
study. In view of the fact that differences in calculated 
molecular weight averages occur using the different columns, it 
can be assumed that different (probably higher) values for the 
same polymeric precursor would be estimated using the shorter 
columns. The values presented for % crosslink cleavage 
(Table 8.5) must be interpreted as approximate, but they do 
allow comparisons between values to be made.
Each value in Table 8.5 is expressed in comparison with the 
appropriate control experiment, but a value for copolymer 39 at 
t=0 was not obtained, since the average molecular weight 
calculated for that copolymer at t=0 was higher than that 
obtained for its control (a 24h incubation of copolymer 39 in 
the absence of tritosomes). The difference in chromatography 
system would not account for the difference in average 
molecular weight of the copolymer 39 control which gives a 
value smaller, rather than larger, than the Prague value 
(Table 8.4). The reason for this is not known. All other 
samples taken at t=0 were lower than those calculated in
TABLE 8.5
THE PERCENTAGE CLEAVAGE OF ORIGINAL CROSSLINKS FOLLOWING 
INCUBATION WITH TRITOSOMES (EXPRESSED AS % CONTROL)
POLYMER 
CODE NO. t 0
INCUBATION
24h
PERIOD 
48 h 72h
39 - 35.95 36.82 38.56
68 2.56 4.78 6.67 18.46
78 2 .02 4.17 17.30 24.12
79 2.94 5.12 11.52 14.98
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control experiments. This finding could be attributable to 
either entrapment of larger molecules in the pellet following 
TCA precipitation of protein with subsequent centrifugation, or 
extremely rapid degradation taking place between the addition 
of tritosomes and the addition of precipitating protein and 
TCA which took place directly afterwards.
Table 8.5 shows that approximately 37% of the crosslinks 
contained within copolymer 39 are cleaved within the first 24h 
on incubation with tritosomes, and this value does not increase 
significantly on further incubation. However, in the case of 
this particular polymer, this figure of 37% does not represent 
total crosslink cleavage, since it has already been shown that 
30-32% of the total radioactivity present in the copolymer is 
released in the form of [125l] iodotyrosine degradation product. 
The values shown for copolymer 39 in Tables 8.4 and 8.5 
represent the average molecular weight (and crosslink cleavage) 
of the copolymer that retains some (125i] iodotyrosine i.e. that 
which has not lost the radiolabel following liberation of the 
j^125l] iodotyrosine residue from the completely hydrolysed 
crosslink.
A number of cleavage events could possibly result in the 
observed recovery of lower molecular weight copolymer 39 
polymer chains still containing radiolabelled tyrosine residues.
requires the hydrolysis of two peptide bonds. Such cleavage 
events could include the following possibilities*
Firstly, it must be noted that
from crosslinks or intramolecular cycles (section 4.2.1)
1 Crosslink cleavage by enzymes, with no hydrolysis of 
intramolecular cycles, thereby retaining radioactive
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tyrosine residues within intramolecular cycles.
2. Preferential cleavage of crosslinks in larger copolymer 
fractions, leaving a greater proportion of smaller radio- 
labelled copolymer fractions.
3. Cleavage of one peptide bond contained within the crosslink 
resulting in a lower average molecular weight of the 
copolymer, but £125l] iodotyrosine would still be attached
to an oligopeptide sidechain. Such single cleavage events 
could occur at one of two points in the sequence i.e.
(i) P-Gly-Gly-Phe Tyr*-HMDA-Tyr-Phe-Gly-Gly-P
(ii) P-Gly-Gly-Phe-Tyr* HMDA-Tyr-Phe-Gly-Gly-P
(assuming one radiolabelled tyrosine residue per crosslink).
4. A combination of these possible events.
It is apparent that the total crosslink cleavage of copolymer 
39 shown in Table 8.5 is an underestimate, since it does not 
take into consideration the |^ 2 l^j iodotyrosine released during 
the experiment. Although it is not possible to accurately 
assess the extent of crosslink cleavage for this copolymer, it 
can be stated that maximum cleavage appears to have taken place 
within the first 24h.
Interpretation of the results shown in Tables 8.4 and 8.5 for 
copolymers 6 8, 78 and 79 is more straight forward, since 
£125l} iodotyrosine release does not take place during 
incubation of these substrates with tritosomes. As the 
copolymer backbone is radiolabelled, one can follow the 
average molecular weight of the whole preparation throughout 
the experiment. The crosslinks of each of the three copolymers 
was cleaved to a small, but similar, extent after a 24h 
incubation with tritosoraes (Table 8.5). Further cleavage of
-181-
each polymer was observed throughout the experimental period.
Copolymer 68 is a more densely crosslinked preparation than 
copolymers 78 and 79 and this is reflected in the finding that 
only 6.67% of the crosslinks were cleaved in the first 48h.
At the end of the experimental period (72h), however, copolymer 
68 has been degraded to a similar extent (18.46%) as copolymer 
79 (14.98%). Copolymer 78 is slightly larger than copolymer 
79, but contains the same density of crosslinks, is degraded 
slightly more than copolymer 79 with 24.12% of the original 
crosslinks cleaved after 72h incubation with tritosomes.
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8.3 DISCUSSION
The crosslinked copolymers used in this study are all 
hydrolysed to some extent by lysosomal enzymes. The results 
support previous reports that crosslinks containing tetra- 
peptide sequences are cleaved more readily than those 
containing tripeptide sequences, since the % of cleavage of 
the copolymer 39 crosslinks was greater than that achieved 
with copolymers 6 8, 78 and 79.
The maximum rate of cleavage of crosslinks contained in 
copolymer 39 by lysosomal enzymes was observed within the first 
24h. However, it was not possible to estimate the total 
cleavage of crosslinks contained within copolymer 39, since the 
required calculation is dependent on the average molecular 
weights of both the initial preparation and the resultant 
hydrolysed copolymer. It was impossible to estimate the latter 
figure, since a proportion of the preparation lost its radio­
label following cleavage of iodotyrosine from crosslinks
and/or intramolecular cycles. However, the incubation of 
crosslinked copolymer 39 fraction c (Mw 150,000) with the 
lysosomal thiol-proteinase Cathepsin B has recently demonstrated 
64% cleavage of crosslinks within 72h (Cartlidge, Rejmanovà et 
al, in press). This experiment did not involve radiolabelled 
polymer, but was made possible by the detection of copolymer in 
the chromatography eluant using differential refractometry.
Crosslinks of copolymers 68, 78 and 79 were hydrolysed to a 
lesser extent and in all cases the values observed indicate 
that cleavage was still continuing after 72h incubation (Table
8.5), with a maximum value of 24% for copolymer 78 after 72h.
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None of the polymers underwent complete crosslink cleavage 
during the 72h incubation period, however, and the results 
obtained from this study show that although a significant 
increase in the rate of cleavage is observed using the tetra- 
peptide crosslink (presumably at least partly due to easier 
access and a 'better fit' of the substrate in the enzyme 
active site - see Chapter 1.4), the specificity of the amino 
acid sequences for lysosomal proteinases is not optimal.
Recent work of Duncan et al (1983) has described the design of 
oligopeptide side—chains in HPMA copolymers to promote 
efficient degradation by lysosomal enzymes. HPMA copolymer 
side-chains were synthesized to match the known specificities 
of two lysosomal thiol-proteinases, Cathepsins D and L. 
Cathepsin D is known to cleave bonds between hydrophobic 
residues (Barrett 1977) and Cathepsin L has been shown to 
cleave bonds where hydrophobic residues occupy the P2 and P3 
positions (Kargel et al 1980) (terminology according to 
Schechter and Berger 1967). A series of different copolymers 
were incubated with lysosomal enzymes and it was found that 
sidechains of composition P-Gly-Phe-Leu-Gly-Phe-NAp and 
P-Gly-Gly-Phe-Leu-Gly-Phe-NAp demonstrated (respectively) > 52% 
and > 40% release of p-nitroaniline after 5h incubation. Both 
sidechains also released Phe-NAp, demonstrating the importance 
of hydrophobic amino acids in the P3 and P2 positions 
relative to the cleaved bond.
An extension of this work was carried out by Rejmanova et al 
(1983), who incubated copolymers containing both sidechains 
and crosslinks with bovine spleen Cathepsin B. From the series 
of sidechain structures examined, the maximum cleavage of
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p-nitroaniline (-NAp) was 83%, achieved after a 48h incubation 
of the sidechain P-Gly-Phe-Leu—Gly-NAp with Cathepsin B. This 
observation was in agreement with data reported by Duncan (1983) 
using mixed lysosomal enzymes, and demonstrates the importance 
of hydrophobic residues in the P3 and P2 position relative to 
the cleaved bond on using Cathepsin B, in addition to Cathepsin 
L. Crosslinked copolymers used by Rejmanova (1983) were 
symmetrical (as in the present study) and maximum crosslink 
cleavage was achieved using the crosslink structure P-Gly-Phe-
Tyr-Ala-Ala-UMDA..... P where 100% cleavage was observed after
24h incubation of the substrate with Cathepsin B. The 
structurally similar tetrapeptide copolymer P-Gly-Phe-Tyr-Ala-
HMDA..... P, on the other hand, demonstrated 71% cleavage
under the same experimental conditions. The initial bond 
cleaved by the enzyme in the pentapeptide copolymer was between 
the two alanine residues, and that in the tetrapeptide copolymer 
between alanine and HMDA i.e. in both cases with the two hydro- 
phobic residues in positions P3 and P2» From these results, it 
is also apparent that the interaction of the amino acid present 
in the P-l1 position i.e. Ala v HMDA (on the leaving group side) 
with the enzyme active site also plays a role in the relation­
ship between structure and the rate of degradation of substrate.
From these recent studies by Duncan and Rejmanova, it is clear 
that the presence of hydrophobic residues in the P3 and P2 
positions, relative to the bond to be cleaved, are important 
in order to promote efficient crosslink and sidechain cleavage 
by lysosomal enzymes, particularly Cathepsins B and L. The 
structure present in the P ^  position has also been shown to 
be important, and the extension of the amino acid sequence 
from tetrapeptide to pentapeptide would probably maximise 
crosslink cleavage by suitable lysosomal enzymes.
These recent findings indicate that the crosslinks contained 
in copolymers 39, 6 8, 78 and 79, are not the ideal structures 
for lysosomal hydrolysis, and therefore not the most 
favourable for incorporation into a drug carrier to promote 
maximum rate of cleavage within lysosomes. There may be 
circumstances, however, where the maximum rate of drug release 
or crosslink cleavage is not required. Since oligopeptide 
sidechains present on the polymer precursor are used to 
synthesize both crosslinks and drug linkages, it would be 
possible to control the rate of release of the drug by 
altering the length and sequence of the oligopeptide.
Provided that 100% cleavage of both active drug and crosslinks 
is eventually achieved (see Chapter 7), both therapeutic 
efficiency and elimination of copolymer from the body would be 
possible.
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A number of lysosomotropic polymeric drug carriers have been 
proposed which include polyphosphazenes, derivatives of 
poly(methacrylic acid), synthetic poly(amino acids), polyvinyl 
analogs of nucleic acids, copolymers of vinylpyrrolidone and 
others (Duncan and Kopecek 1984).
The advantages of such systems have been discussed previously 
(sections 1.3 and 1.4) and include ease of fabrication and the 
ability to design polymeric carriers to meet specific require­
ments. It is also possible to attach a number of moieties to 
the polymer backbone, thereby enabling a much higher drug 
loading than can be achieved with other lysosomotropic systems. 
Polymeric drug delivery systems, like other systems, also have 
their disadvantages.
One possible disadvantage of synthetic polymeric drug carriers 
is that of poor biocompatibility, since synthetic polymers are 
•foreign' molecules in biological systems. Incompatible 
polymers can cause inflammatory and/or immune responses by the 
host, or result in adverse chemical modification of the polymer 
or its degradation products by the host tissues (Black 1984).
The homopolymer hydroxypropyl(methacrylamide) has been shown 
to be non—toxic, apyrogenic and generally shows good 
biocompatibility (Kopecek et al 1973, Kopecek 1981, 1984).
Recent studies on the immunogenicity of hydroxypropyl(meth­
acrylamide) copolymers and the homopolymer of HPMA using 5 
different inbred strains of mice have shown that the homopolymer
HPMA is non-immunogenic and that HPMA copolymers containing
* / ;oligopeptide side chains are only weakly immunogenic (Rihova 
et al 1985). The factors influencing the immune response to 
HPMA copolymers are the structure of the oligopeptide side
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chains, the dose of polymer administered, its average molecular 
weight and the presence/absence of drug models. The HPMA 
copolymer containing the oligopeptide side chain sequence 
P-Gly-Gly-OH caused a greater immune response than sequences 
P-Acap-Leu-HMDA, P-Acap-Phe-OH or P-Gly-Phe-Tyr-OH in all 5 
strains of mice. The immune reaction was also dependent upon 
the size of the copolymer, with a preparation of copolymer of 
Mw 150-200,000 resulting in a 2-5 increase of antibody 
producing cells in the spleen over that observed on 
administration of a preparation of Mw 5,000. The incorporation 
of drug models (haptens) into the HPMA copolymer with side 
chain composition P—Acap-Leu—HMDA also increases the originally 
weak immunogenicity of the copolymer. The content of side 
chains (1-8 .4 mol %) in the copolymer does not affect the 
immunological response.
These findings reported by Rihova et al (1985) indicate that 
small changes in polymer structure can result in large 
differences in the immune response of the immunized organism. 
Nevertheless, it was concluded from the paper that HPMA 
copolymers can be considered as possible drug carriers in a 
targetable drug delivery system.
Clearly, it would be necessary to undertake immunological 
studies on each proposed polymeric drug-carrier conjugate, 
taking polymer Mw and side chain/crosslink structure into 
consideration, in addition to the drug and any targeting 
moiety incorporated into the final structure. This procedure 
is a necessary prerequisite in any system since antibody 
formation is possible even when natural molecules are modified 
and employed as drug carriers (Gregoriadis 1979, 1980). For
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example, desialylated fetuin has been shown to be strongly 
immunogenic, whereas lactosaminated homologous albumin appears 
less likely to induce significant antibody formation (Fiume et 
al 1983). It should be noted, however, that if a drug-carrier 
conjugate is rapidly cleared from the bloodstream by receptor- 
mediated uptake by target cells, its duration in the 
circulation is short, and the possibility of any immune 
response is thereby reduced.
Two other problems encountered when considering the use of 
synthetic polymers as drug carriers are those of the poly- 
dispersity and degradability of the polymer. These problems, 
with respect to HPMA copolymers, have been considered in the 
present study.
Synthetic polymers are polydisperse by nature. If a poly- 
disperse preparation of polymer is used as a drug carrier, the 
fate of the conjugate will depend, at least in part, on the 
effect of size of the different molecular weight fractions 
contained within the preparation on their rate of uptake by 
cells, and also on the renal threshold of the organism 
employed. However, the ability to synthesize and isolate 
different sizes of the same polymer can be an advantage, if 
there is an effect of size of the proposed carrier on its rate 
of uptake by specific cell types.
The work presented in this thesis clearly indicates the 
importance of size (and low polydispersity) of the proposed 
polymeric carrier. From the results presented in Chapters 4 
and 5 it is evident that the fractions derived from poly­
disperse copolymer 39 are taken up by cells at very different 
rates than the unfractionated copolymer.
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The uptake of copolymer 39 fractions by the rat yolk sac 
epithelium was by fluid-phase pinocytosis i.e. with no inter­
action with the cell membrane, and this tissue showed 
preferential uptake of lower molecular weight copolymer 
fractions (copolymer 39e Mw 34,000). Uptake of copolymer 39 
fraction e by everted rat jejunal sacs was also at a rate 
consistent with that observed for I-PVP (Mw 40,000) which 
is reported to enter this tissue by fluid-phase pinocytosis, 
but larger fractions (Mw >400,000) were pinocytosed 3-4 times 
faster. This indicates that some degree of adsorption of 
larger copolymer 39 fractions to the cell membrane occurs prior 
to pinocytic uptake. The results suggest that it might be 
possible to enhance cellular uptake by certain tissues by the 
manipulation of copolymer size alone.
If a drug is to be targeted to a particular tissue by the 
attachment of an antibody or other targeting moiety to the 
carrier, uptake of the conjugate will take place by receptor- 
mediated pinocytosis following the binding of the conjugate to 
receptors on the cell surface. The size of the carrier may 
still be important, however, since results presented in 
Chapter 4 show that very large molecules are hardly pinocytosed 
at all by yolk sac epithelial cells. It is possible that the 
sheer bulk of a molecule may preclude, or reduce, its entry 
into certain cell types, despite the attachment of targeting 
moieties. It is therefore advisable to use molecular sizes 
known to be taken up readily by cells by fluid-phase pinocytosis 
when targeting moieties are to be attached to a drug carrier, 
since the rate of uptake of the conjugate by target cells will 
then be governed solely by cell surface receptor interaction 
with the conjugate, and non-specific uptake of conjugates by
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non-target tissue will be minimal.
The blood clearance and body distribution of copolymer 39 
fractions over lh following intravenous administration, 
confirms previous reports that smaller copolymer fractions are 
rapidly filtered from the blood circulation by the kidney 
glomerulus. The renal threshold for such copolymers will 
therefore largely dictate the minimum size of a drug carrier 
which is designed to be retained in the circulation for any 
significant period of time.
It would appear from these studies on the effect of copolymer 
size that when uptake is to be by cells other than those of 
the reticuloendothelial system (which accumulate large 
molecules), a drug-carrier conjugate of molecular weight in 
the region of 100-150,000 would enable pinocytic uptake by 
most cell types, whilst preventing rapid glomerular filtration. 
The use of HPMA copolymers of a larger size than this could 
induce a greater immune response that that reported for 
molecules of Mw 150—200,000 (Rihova et al 1985). Also, since 
copolymer size has been shown to be of such importance, it is 
necessary to ensure that the polydispersity of the polymer 
carrier is kept to a minimum in order to achieve the desired 
response.
The design of the proposed crosslinked HPMA copolymers 
incorporates oligopeptide sequences which it was hoped would 
confer limited biodegradability in biological systems. Although 
total degradation of the polymer would be desirable, this is 
not essential providing that the polymer is not allowed to 
accumulate within, and subsequently damage, cells. It must 
therefore be eventually eliminated from the body. In vitro
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experiments performed in Chapters 4 and 5 demonstrated that 
oligopeptide sequences are hydrolysed by lysosomal enzymes with 
resultant release of low molecular weight degradation products, 
and results presented in Chapter 8 show that at least some of 
this degradation results in the cleavage of crosslinks (rather 
than inter-molecular cycles) by lysosomal enzymes. The long 
term in vivo experiment described in Chapter 7 shows that the 
resultant lower molecular weight copolymer chains are virtually 
cleared from rats within 32 days following intraperitoneal 
injection of 0.5 fig/g body weight of crosslinked HPMA copolymers 
78 and 79. These results confirm that the oligopeptide cross­
links used in the study are degraded in vivo and that the 
problem of polymer accumulation in the body can be overcome 
using the proposed crosslinked carrier concept.
It is quite possible that copolymers could be cleared more 
rapidly if crosslinks of an optimum structure for specific 
lysosomal enzymes were incorporated into the carrier (Chapter 
8). Unfortunately, the copolymers used throughout the study 
contained crosslinks which were of optimal structure for 
cleavage by chymotrypsin, although at the beginning of the 
study there was no reason to suppose that these structures 
could not be hydrolysed rapidly by lysosomal enzymes. The 
density and length of the crosslinks contained in the carrier 
will also determine the rate of crosslink cleavage. Rapid 
cleavage will be achieved using the minimum number of longer 
crosslinks (e.g. tetrapeptide sequences) of optimal structure
for a given enzyme.
To ensure efficient uptake of drug-carrier conjugate by cells 
and elimination from the body, it is also important that the
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polydispersity of not only the crosslinked copolymer 
preparation is kept to a minimum, but also that of the polymeric 
precursor. This will ensure that the crosslinked molecules 
introduced into the body are retained in the circulation (i.e. 
are of a size above that of the renal threshold) and that the 
resultant hydrolysed copolymer chains can be excreted from the 
body (i.e. are of a size below that of the renal threshold).
Targeting of soluble crosslinked HPMA copolymers to the liver 
by the incorporation of galactosamine into the structure has 
been achieved following intravenous, intraperitoneal and 
subcutaneous administration. The galactosamine—containing 
copolymer was also transiently associated with the brush border 
of the small intestine following oral administration - a 
finding which could, perhaps, be exploited in some useful way 
(delivering drugs active in the small intestine). These 
results show that it may be possible to administer HPMA-drug 
conjugates via routes other than the intravenous one. Since 
the appearance of copolymer is protracted and delayed following 
subcutaneous and intraperitoneal administration, this feature 
may also allow further control over the rate of drug delivery 
to target cells.
The polydispersity of copolymers 39, 78 and 79 led to difficulty 
in interpretation of some of the data obtained from in vivo 
experiments employing intraperitoneal and subcutaneous 
administration of these copolymers. Because the preparations 
contained molecules of various sizes it was not possible to 
determine whether lower molecular weight fractions excreted in 
the urine were non-degraded molecules which were present in the 
initial preparation, or fragments of copolymers which had been
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partially degraded within cells. In addition, it was not 
possible to determine whether molecules of a particular size 
preferentially migrated from one body compartment to another.
The use of radiotracers such as |^ 25lJ iodide are invaluable in 
allowing the detection of very small quantities of copolymer 
(and degradation products) throughout the body. Iodination of 
copolymers results in only very small changes in the polymer 
properties (Drobnik and Rypa<*ek 1984), and therefore radio- 
labelled copolymers will be likely to record the true fate of 
the unlabelled drug carrier. Radiotracers can, however, also 
lead to complications in interpretation of data. It cannot be 
proven, for example, that the radiolabel monitored throughout 
the experiment is attached to the copolymer (or its degradation
products). A known (usually small) quantity of free [125l]iodide 
was present in radiolabelled copolymer preparations on 
administration to rats, and this must affect the body 
distribution of radioactivity to some extent. Also, it is 
possible that some free [125l]iodide might be released from the 
copolymer during the experimental period, for example, through
the action of deiodinases present in certain tissues.
Correction for radioactive decay is another problem encountered
125during long term experiments using I-labelled preparations. 
Since urine and faeces samples were collected and assayed 
regularly throughout the long term experiment, and the majority 
of the radioactivity was recovered in the first few days, 
corrections for decay were not made during this experiment.
Despite these, and other problems encountered during in vivo 
studies (Chapter 7), the results reported in Chapter 7 were 
remarkably reproducible and therefore do allow some 
conclusions to be drawn from the work undertaken, especially
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where large proportions (> 10%) of the recovered radioactivity 
are found in tissues and excreta. Such studies, though time 
consuming and fraught with potential sources of error, are 
essential in order to gain a basic understanding of the 
ultimate fate of the copolymers in the body.
In summary, the work presented in this thesis proves that the 
theoretical concept of soluble crosslinked copolymers as drug 
carriers (section 1.4) does work in practice. Crosslinked 
HPMA copolymers are stable in rat plasma and are pinocytosed 
by a number of different cell types. Crosslinks (and drug 
linkages - Duncan et al 1981) are degraded intracellularly and 
resultant lower molecular weight copolymer chains can be 
eliminated from the body. It is possible to target crosslinked 
copolymers to the liver by the incorporation of galactosamine 
into the copolymer structure.
In addition, the study has shown the importance of size of the 
drug carrier on its rate of cellular uptake and the ability to 
target the carrier to the liver following different routes of 
administration.
The results reported will help in the design of polymers for 
use in future studies in that further consideration will be 
given to the size, polydispersity and crosslink structure of 
copolymers, in addition to those of drug linkages and other 
targeting moieties.
As a consequence of the work presented in this study, further 
in vivo experiments are planned to study the effect of size of 
HPMA copolymers on body distribution following different routes 
of administration to rats. Also, following the work of Duncan
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et al (1983) and the current study on the effect of attachment 
of galactosamine to copolymers, the effect of the incorporation 
of other sugar groups into HPMA copolymers on biological 
systems is currently being studied by other workers in the 
group. Other studies recently undertaken include the testing 
of biocompatibility of HPMA copolymers using macrophages, 
evaluation of the toxicity of HPMA-drug conjugates using human 
hepatoma cells, and the use of antibody-copolymer conjugates. 
Last, but not least, in vivo studies on mice inoculated with 
L1210 leukaemia cells using daunomycin attached to single 
chain HPMA copolymers via oligopeptide sequences have commenced 
and preliminary results show a significant increase in 
survival time over free drug (Duncan 1985 - personal 
communication).
Collectively, these results show that the use of HPMA copolymers 
as drug carriers in a lysosomotropic drug delivery system is 
indeed a feasible proposition.
To date, the primary aim of this project, and many other 
proposed lysosomotropic drug delivery systems, has been to 
improve the treatment of malignant disorders by delivering 
existing anti-tumour drugs to the required tissues in optimum 
concentrations and thereby reduce damage to normal tissues 
(Monsigny et al 1980, Trouet et al 1982, 1983, Baurain et al 
1982). There is no reason to restrict the use of lysosomotropic 
drug delivery systems to this one medical application, however. 
Recent work on liposomes, for example, has opened up new 
possibilities in their use as drug carriers (Gregoriadis 1981). 
The stability of liposomes in plasma (Hunt 1982) and simulated 
intestinal environments (Rowland and Woodley 1982) has been 
shown to be dependent on lipid composition and much recent work
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in the field has therefore been concerned with the stability 
of liposomes of different compositions in biological 
environments. As a result, liposomes can now be synthesized 
which are stable in the circulation, non-toxic and can also 
contain surface targeting moieties (Ghosh et al 1982).
However, because of their size, targeting of liposomes to cells 
other than those of the reticulo-endothelial system has been 
difficult to achieve (Poste et al 1982, 1983). This feature of 
liposomes nevertheless can allow their targeting to macrophages, 
which avidly phagocytose liposomes. Drugs can be contained 
within the liposomes which activate the macrophages, rendering 
them tumouricidal (Poste et al 1982, 1983). Alternatively, 
liposomes could be used to carry drugs for treating infectious 
diseases involving macrophages e.g. leishmaniasis, leprosy, 
tuberculosis (Alving 1979, 1983).
The limitations imposed by size (discussed above) are also 
often apparent on using other vesicular carriers such as 
erythrocyte ghosts (Pitt et al 1983) and microspheres (Ilium 
and Davies 1982). Similarly, treatment of diseases involving 
cells of the reticulo-endothelial system could be improved by 
the use of drug carriers such as these.
T h e  m a n i p u l a t i o n  o f  c o p o l y m e r  s i z e  o r  t h e  a t t a c h m e n t  o f  s p e c i f i c  
t a r g e t i n g  m o i e t i e s  t o  m a c r o p h a g e  r e c e p t o r s  c o u l d  a l s o  e n a b l e  
c r o s s l i n k e d  HPMA c o p o l y m e r s  t o  b e  u s e d  a s  t a r g e t a b l e  c a r r i e r s  
f o r  a n t i b i o t i c s ,  w i t h  t h e  a d d e d  a d v a n t a g e s  o f  c o v a l e n t  d r u g  
l i n k a g e s  a n d  c o m p a r a t i v e  e a s e  o f  f a b r i c a t i o n .  S i n g l e  c h a i n  
HPMA c o p o l y m e r s  c o n t a i n i n g  a n t i b i o t i c s  a t t a c h e d  b y  o l i g o p e p t i d e  
s i d e  c h a i n s  p - G l y - G l y - a m p i c i l l i n ,  P - G l y - P h e - a m p i c i l l i n  a n d  
P - G l y - V a l - P h e - a m p i c i l l i n  a n d  o t h e r s  c o n t a i n i n g  6 - a m i n o -
penicillanic acid have already been synthesized avid shown to 
inhibit the growth of Staphylococcus aureus 209 P (Solovskij 
et al 1983).
It would also be possible to use smaller, single chain 
copolymers as molecular bridges between drug and antibody 
carriers. Natural macromolecules dextran and human serum 
albumin, when used as intermediate carriers between drug and 
antibody, have demonstrated improved drug toxicity over direct 
coupling of drug to antibody on incubation with tumour cells 
in vitro (Tuskada et al 1982, Garnett et al 1983). The use of 
an HPMA 'bridge' would also allow increased drug loading in 
such a system.
Other applications of the crosslinked HPMA copolymer include 
that of a blood plasma expander (section 1.4) and as a carrier 
for replacement enzymes in the treatment of lysosomal storage 
diseases.
Clearly, the potential applications of HPMA copolymers in drug 
delivery systems are diverse and numerous.
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Methods

COMPUTER PROGRAMME TO CALCULATE THE UPTAKE OF NON-DIGESTIBLE 
SUBSTRATES
5 REM KEW 125I-PVP PROGRAME,MODIFIED NOV.,1974 
10 DIM H(15),I(15),L(15),R(15)
12 IF W=1 THEN 84
13 LET W— 116 PRINT '• NON-DIGEST IBLE PROG. ENTERED"
17 PRINT "EXPT.NO. (DIGITS ONLY) = "t
18 INPUT Z19 PRINT " BACKGROUND IN CPM = "|
20 INPUT A35 PRINT " COUNTING TIME FOR EACH ML OF MEDIUM, SECS = j 
40 INPUT C45 PRINT "COUNTING TIME FOR EACH ML OF YS SOLUTION, SECS = |
50 INPUT D75 PRINT " NO. OF POINTS IN PLOT = "j
80 INPUT G
82 STOP
84 LET W = O
95 FOR X = 1 TO G
98 INPUT H(X),I(X) ,K(X),L(X)
99 NEXT X
100 FOR X =1 TO G
101 LET M = (I(X)*60/C) -A
135 LET Q = ( (K(X)*60/D) - A)*5
136 LET N = M + Q/20140 LET R(X) = (Q*1000)/N*L(X) )
145 PRINT FRE (5) | H(X), FRE(6)jR(X)
150 NEXT X
153 PRINT FRE(5) j -1, FRE(6) } Z 
155 DRSPEC TO OWN
157 PRINT " "
158 PRINT " "160 PRINT " INCUBATION TIME (HOURS) ",
" PROTEIN IN YS "," UPTAKE "
165 PRINT
190 FOR X = 1 TO G195 PRINT " ", FRE(5)jH(X), FRE(6);L(X), FRE(6)|R(X)
200 NEXT X 
205 STOP
Input Data
H(X) Duration of yolk sac incubation period (h)
I(X) Mean radioactivity count per 30s for 1.0ml of incubation 
medium
K(X) Mean radioactivity count per 5min for 1.0ml of yolk sac 
solution
L(X) Total protein content of the yolk sac (mg)
COMPUTER PROGRAMME TO CALCULATE THE AVERAGE MOLECULAR WEIGHT 
OF COPOLYMERS
OOÌOPRINT"PRAGUE PROGRAMME" 
0O20DIMA(90,2)
0O30PRINT"ENTER CONSTANTS"
0O40PRINT"’a'="
0050INPUTA 
0060PRINT"'b'="
0070INPUTB
0O80PRINT"ENTER FIRST PEAK COUNT-'C'" 
0O90INPUTC1
OlOOPRINT"ENTER NO. OF COUNTS"
0110INPUTC
0120MATA=ZER ( C , 2 )
0130PRINT"ENTER PEAK HEIGHTS"
0140X=C1-1
0150FORI=1TOC
0160X=X+1
0170A(1,1)=X
0180PRINT"COUNT"» X
0190INPUTA(1,2)
0200NEXTI
0210H1=0
0220D1=0
0230P1=0
0240F0RI=1T0C
0250H1=H1+A(1,2)
0260S1=A+(B*A(I,1))
0270S2=10TS1 
0280D1=D1+(A(1,2)/S2) 
0290P1=P1+(S2*A(1,2))
0300NEXTI 
0310W=Pl/Hl 
O320N=Hl/Dl 
O330U=W/N
0340PRINT"PEAK PARAMETERS i"
0350PRINT"COUNT VALUES","HEIGHTS"
0360MATPRINTA
0370PRINT
O380PRINT"'a'="}A
0390PRINT"'b' = "J B
O400PRINT"MW="j W
0410PRINT"MN="}N
0420PRINT"U ="jU
0430END
APPENDIX II
TABLE 3.1
COPOLYMER CROSSLINK/SIDECHAIN STRUCTURES
POLYMER CODE NO. STRUCTURE
39
1 i 1 1P-Gly-Gly-Phe-Tyr-HMDA-Tyr-Phe-Gly-Gly-P
74 iP-Gly-Gly-Phe-TyrNH2
68
/TyrNH
Px 2 1 | /Gly-Gly-Phe-HMDA-Phe-Gly-Gly'
78
/ yrNH2 | 1 P-Gly-Gly-Phe-HMDA-Phe-Gly-Gly-P
^Gly-Gly-galactosamine
79
/ y rNH2 ! iP-Gly-Gly-Phe-HMDA-Phe-Gly-Gly-P
'\3iy-Gly-amin0pr0pan0l
denotes the bonds probably hydrolysed by lysosomal enzymes
